<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Benzodiazepines for psychosis‐induced aggression or agitation - Zaman, H - 2017 | Cochrane Library</title> <meta content="Benzodiazepines for psychosis‐induced aggression or agitation - Zaman, H - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003079.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Benzodiazepines for psychosis‐induced aggression or agitation - Zaman, H - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003079.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003079.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Benzodiazepines for psychosis‐induced aggression or agitation" name="citation_title"/> <meta content="Hadar Zaman" name="citation_author"/> <meta content="University of Bradford" name="citation_author_institution"/> <meta content="hzaman4@bradford.ac.uk" name="citation_author_email"/> <meta content="Stephanie J Sampson" name="citation_author"/> <meta content="University of York" name="citation_author_institution"/> <meta content="Alison LS Beck" name="citation_author"/> <meta content="South London and Maudsley NHS Foundation Trust" name="citation_author_institution"/> <meta content="Tarang Sharma" name="citation_author"/> <meta content="Nordic Cochrane Centre" name="citation_author_institution"/> <meta content="Fiona J Clay" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Styliani Spyridi" name="citation_author"/> <meta content="Cyprus University of Technology" name="citation_author_institution"/> <meta content="Sai Zhao" name="citation_author"/> <meta content="The Ingenuity Centre, The University of Nottingham" name="citation_author_institution"/> <meta content="Donna Gillies" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD003079.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/12/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003079.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003079.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003079.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Aggression [drug effects]; Anti-Dyskinesia Agents [therapeutic use]; Antipsychotic Agents [*therapeutic use]; Benzodiazepines [*therapeutic use]; Drug Therapy, Combination [methods]; Emergency Treatment [methods]; Haloperidol [therapeutic use]; Lorazepam [therapeutic use]; Olanzapine; Psychomotor Agitation [drug therapy]; Psychotic Disorders [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003079.pub4&amp;doi=10.1002/14651858.CD003079.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003079\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003079\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","hr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003079.pub4",title:"Benzodiazepines for psychosis\\u2010induced aggression or agitation",firstPublishedDate:"Dec 8, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003079.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003079.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003079.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003079.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003079.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003079.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003079.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003079.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003079.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003079.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7460 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003079.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-sec-0184"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-sec-0077"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-sec-0162"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/appendices#CD003079-sec-0200"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/supinfo/CD003079StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/supinfo/CD003079StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Benzodiazepines for psychosis‐induced aggression or agitation</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#CD003079-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Hadar Zaman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#CD003079-cr-0005">Stephanie J Sampson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#CD003079-cr-0006">Alison LS Beck</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#CD003079-cr-0007">Tarang Sharma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#CD003079-cr-0008">Fiona J Clay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#CD003079-cr-0009">Styliani Spyridi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#CD003079-cr-0010">Sai Zhao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information#CD003079-cr-0011">Donna Gillies</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information/en#CD003079-sec-0215">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 December 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003079.pub4">https://doi.org/10.1002/14651858.CD003079.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003079-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003079-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003079-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003079-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003079-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003079-abs-0001" lang="en"> <section id="CD003079-sec-0001"> <h3 class="title" id="CD003079-sec-0001">Background</h3> <p>Acute psychotic illness, especially when associated with agitated or violent behaviour, can require urgent pharmacological tranquillisation or sedation. In several countries, clinicians often use benzodiazepines (either alone or in combination with antipsychotics) for this outcome. </p> </section> <section id="CD003079-sec-0002"> <h3 class="title" id="CD003079-sec-0002">Objectives</h3> <p>To examine whether benzodiazepines, alone or in combination with other pharmacological agents, is an effective treatment for psychosis‐induced aggression or agitation when compared with placebo, other pharmacological agents (alone or in combination) or non‐pharmacological approaches. </p> </section> <section id="CD003079-sec-0003"> <h3 class="title" id="CD003079-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's register (January 2012, 20 August 2015 and 3 August 2016), inspected reference lists of included and excluded studies, and contacted authors of relevant studies. </p> </section> <section id="CD003079-sec-0004"> <h3 class="title" id="CD003079-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) comparing benzodiazepines alone or in combination with any antipsychotics, versus antipsychotics alone or in combination with any other antipsychotics, benzodiazepines or antihistamines, for people who were aggressive or agitated due to psychosis. </p> </section> <section id="CD003079-sec-0005"> <h3 class="title" id="CD003079-sec-0005">Data collection and analysis</h3> <p>We reliably selected studies, quality assessed them and extracted data. For binary outcomes, we calculated standard estimates of risk ratio (RR) and their 95% confidence intervals (CI) using a fixed‐effect model. For continuous outcomes, we calculated the mean difference (MD) between groups. If there was heterogeneity, this was explored using a random‐effects model. We assessed risk of bias and created a 'Summary of findings' table using GRADE. </p> </section> <section id="CD003079-sec-0006"> <h3 class="title" id="CD003079-sec-0006">Main results</h3> <p>Twenty trials including 695 participants are now included in the review. The trials compared benzodiazepines or benzodiazepines plus an antipsychotic with placebo, antipsychotics, antihistamines, or a combination of these. The quality of evidence for the main outcomes was low or very low due to very small sample size of included studies and serious risk of bias (randomisation, allocation concealment and blinding were not well conducted in the included trials, 30% of trials (six out of 20) were supported by pharmaceutical institutes). There was no clear effect for most outcomes. </p> <p>Benzodiazepines versus placebo</p> <p>One trial compared benzodiazepines with placebo. There was no difference in the number of participants sedated at 24 hours (<i>very low quality evidence</i> ). However, for the outcome of global state, clearly more people receiving placebo showed no improvement in the medium term (one to 48 hours) (n = 102, 1 RCT, RR 0.62, 95% CI 0.40 to 0.97, <i>very low quality evidence</i>).<br/>Benzodiazepines versus antipsychotics </p> <p>For the outcome of sedation by 16 hours, there was no difference between haloperidol and benzodiazepine (n = 434, 8 RCTs, RR 1.13, 95% CI 0.83 to 1.54, low quality evidence). There was no difference in the number of participants who had not improved in the medium term (n = 188, 5 RCTs, RR 0.89, 95% CI 0.71 to 1.11, <i>low quality evidence</i> ). However, one small study found fewer participants improved when receiving benzodiazepines compared with olanzapine (n = 150, 1 RCT, RR 1.84, 95% CI 1.06 to 3.18, <i>very low quality evidence</i> ). People receiving benzodiazepines were less likely to experience extrapyramidal effects in the medium term compared to people receiving haloperidol (n = 233, 6 RCTs, RR 0.13, 95% CI 0.04 to 0.41<i>, low quality evidence</i>). </p> <p>Benzodiazepines versus combined antipsychotics/antihistamines</p> <p>When benzodiazepine was compared with combined antipsychotics/antihistamines (haloperidol plus promethazine), there was a higher risk of no improvement in people receiving benzodiazepines in the medium term (n = 200, 1 RCT, RR 2.17, 95% CI 1.16 to 4.05, <i>low quality evidence</i> ). However, for sedation, the results were controversial between two groups: lorazepam may lead to lower risk of sedation than combined antipsychotics/antihistamines (n = 200, 1 RCT, RR 0.91, 95% CI 0.84 to 0.98, <i>low quality evidence</i> ); while, midazolam may lead to higher risk of sedation than combined antipsychotics/antihistamines (n = 200, 1 RCT, RR 1.13, 95% CI 1.04 to 1.23, <i>low quality evidence</i>). </p> <p>Other combinations</p> <p>Data comparing benzodiazepines plus antipsychotics versus benzodiazepines alone did not yield any results with clear differences; all were very low quality evidence. When comparing combined benzodiazepines/antipsychotics (all studies compared haloperidol) with the same antipsychotics alone (haloperidol), there was no difference between groups in improvement in the medium term (n = 185, 4 RCTs, RR 1.17, 95% CI 0.93 to 1.46, <i>low quality evidence</i> ), but sedation was more likely in people who received the combination therapy (n = 172, 3 RCTs, RR 1.75, 95% CI 1.14 to 2.67, <i>very low quality evidence</i> ). Only one study compared combined benzodiazepine/antipsychotics with antipsychotics; however, this study did not report our primary outcomes. One small study compared combined benzodiazepines/antipsychotics with combined antihistamines/antipsychotics. Results showed a higher risk of no clinical improvement (n = 60, 1 RCT, RR 25.00, 95% CI 1.55 to 403.99, <i>very low quality evidence</i> ) and sedation status (n = 60, 1 RCT, RR 12.00, 95% CI 1.66 to 86.59, <i>very low quality evidence)</i> in the combined benzodiazepines/antipsychotics group. </p> </section> <section id="CD003079-sec-0007"> <h3 class="title" id="CD003079-sec-0007">Authors' conclusions</h3> <p>The evidence from RCTs for the use of benzodiazepines alone is not good. There were relatively few good data. Most trials were too small to highlight differences in either positive or negative effects. Adding a benzodiazepine to other drugs does not seem to confer clear advantage and has potential for adding unnecessary adverse effects. Sole use of older antipsychotics unaccompanied by anticholinergic drugs seems difficult to justify. Much more high‐quality research is still needed in this area. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003079-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003079-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003079-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003079-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003079-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003079-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003079-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003079-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003079-abs-0002" lang="en"> <h3>Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis</h3> <p><b>Review question</b> </p> <p>The aim of this review was to compare the tranquillising (calming) or sedative (sleepiness) effects of benzodiazepines, given alone or combined with other drugs compared with the effect of placebo (a pretend treatment), other drugs or non‐drug treatments for people who are aggressive or agitated because they are experiencing psychoses. </p> <p><b>Background</b> </p> <p>Acute psychosis is a rapid worsening of a person’s mental state where touch with reality is often lost. People may experience frightening delusions or hallucinations which are distressing and may cause agitated or aggressive behaviour. In urgent cases, this agitation or aggression may cause harm to the person experiencing the psychoses or others around them. To avoid such harm, rapid tranquillisation or sedation with medicines may be required. The most common medicines used to achieve a state of calmness or sedation are benzodiazepines and these can be given either alone or in combination with antipsychotics. </p> <p><b>Searching</b> </p> <p>The original search for this review was carried out in January 2012 and subsequently two further update searches were run in August 2015 and August 2016. In total, these searches found 2497 records, which the review authors checked for inclusion or exclusion from the review. Authors included records only if they were randomised trials (clinical studies where people are randomly put into one of two or more treatment groups) that allocated people with acute psychosis who presented with agitation, violence aggressive behaviour (or a combination of these) to receive benzodiazepines either given alone or combined with any antipsychotics, versus placebo, antipsychotics alone or in combination with other antipsychotics/benzodiazepines/antihistamines or non‐drug treatments. </p> <p><b>Evidence found</b> </p> <p>In total, 20 trials were included. Overall, the quality of evidence was low or very low due to serious risk of bias and very small size of included trials. There was no clear difference in improvement between benzodiazepines and placebo, benzodiazepines and antipsychotics or benzodiazepines plus antipsychotics and benzodiazepines alone or antipsychotic alone. When benzodiazepines were compared with combined antipsychotics/antihistamines, there was a higher risk of no improvement in people receiving benzodiazepine alone but the evidence was of low quality. Only one study showed lower effect of combined benzodiazepines/antipsychotics versus combined antihistamines/antipsychotics. However, the evidence was of very low quality. In terms of side effects, people receiving benzodiazepines compared to antipsychotics had lower risk of presenting with symptoms such as shaking, tremors and slurred speech whereas the results for the sedation caused were unclear. </p> <p><b>Conclusions</b> </p> <p>The existing trials are not informative enough to support or refute the use of benzodiazepines alone or in additional to other medicines when urgent tranquillisation or sedation with medicines is required. Although benzodiazepines alone may cause fewer side effects compared to older antipsychotics, when they are added on to other medicines this may lead to unnecessary side effects. Further studies are needed to provide good‐quality evidence with robust conclusions to inform clinical practice and policies around rapid tranquillisation for people with psychoses who are aggressive or agitated. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003079-sec-0184" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003079-sec-0184"></div> <h3 class="title" id="CD003079-sec-0185">Implications for practice</h3> <section id="CD003079-sec-0185"> <section id="CD003079-sec-0186"> <h5 class="title">1. For people with agitation/aggression due to schizophrenia or schizophrenia‐like illnesses </h5> <p>The intervention selected must be a reasonable and proportionate response to the risk posed by the person at that particular time. The aim of rapid tranquillisation is to achieve a state of calm sufficient to minimise the risk posed to patients or others. To achieve this state of calmness, various interventions can be used ranging from de‐escalation to pharmacological. Benzodiazepines are a viable option for care in acute aggression though secondary to psychotic illness, but much of the data on which practice is based are poor (although there are exceptions). Many recommendations for treatment are based on clinician's experience, expert consensus or local prescribing practice rather than data from high‐quality trials or well‐considered consumer feedback. We think that the situation is changing but certainly more well‐designed, conducted and reported trials are needed. </p> </section> <section id="CD003079-sec-0187"> <h5 class="title">2. For clinicians</h5> <p>The data suggest that there is no difference between benzodiazepines and antipsychotics in particular relation to sedation but data are limited and not of high quality. Moreover, low‐quality evidence of differences between benzodiazepine and olanzapine exists even if not for every outcome. Using a combined benzodiazepine/antipsychotic does not seem to confer any advantage over use of either drug alone. There is some evidence that newer antipsychotics may be more beneficial than benzodiazepines but data are very limited. </p> </section> <section id="CD003079-sec-0188"> <h5 class="title">3. For managers or policy‐makers</h5> <p>Lack of high‐quality evidence leaves managers and policy makers with difficult decisions to make. There is currently insufficient clinical evidence to suggest that the benzodiazepine group of drugs (alone or in combination with antipsychotics) is clearly superior to antipsychotics in reducing acute psychotic behaviour. </p> </section> </section> <h3 class="title" id="CD003079-sec-0189">Implications for research</h3> <section id="CD003079-sec-0189"> <section id="CD003079-sec-0190"> <h5 class="title">1. General</h5> <p>Adherence to the <a href="http://www.consortstatement.org" target="_blank">CONSORT</a> statement would probably have resulted in this review being more conclusive (<a href="./references#CD003079-bbs2-0107" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA2001;285(15):1987-91.">Moher 2001</a>). Clear descriptions of randomisation would have reassured users of these trials that selection bias had been minimised and well‐described and blinded outcome measurement could have encouraged greater confidence in the control of performance and detection bias. The use of validated binary outcomes should take preference over continuous results because they are easier to interpret and better reporting of validated rating scales would have provided more usable data. The reporting of outcomes with their means and standard deviations, again, would have provided more usable data and facilitated synthesis of findings. When presenting data in a graph, the exact numbers and standard deviations should also be reported. </p> </section> <section id="CD003079-sec-0191"> <h5 class="title">2. Specific</h5> <section id="CD003079-sec-0192"> <h6 class="title">2.1. Reviews</h6> <p>Although our original protocol specified a focus on rapid tranquillisation for acute psychosis, but by restricting our analyses up to 48 hours, other potential serious adverse effects may have been overlooked. For further reviews on this topic, or the update of this review in the future, we recommend a less rigid time restriction on long‐term effects of benzodiazepines to attain a more accurate consideration of the outcomes and other adverse effects (see <a href="#CD003079-tbl-0012">Table 5</a>). </p> </section> <section id="CD003079-sec-0193"> <h6 class="title">2.2. Research</h6> <section id="CD003079-sec-0194"> <p><b>2.2.1. Methods</b></p> <p>There is a need for better evidence regarding the relative effectiveness of benzodiazepines and antipsychotics, particularly regarding the reporting of both short‐term and long‐term adverse effects. We did identify large, well‐designed and clearly reported trials in this area (<a href="./references#CD003079-bbs2-0119" title="AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9.">TREC Vellore</a>; <a href="./references#CD003079-bbs2-0120" title="TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [EMBASE: 2003210869]">TREC‐II Brazil</a>). </p> </section> <section id="CD003079-sec-0195"> <p><b>2.2.2. Interventions</b></p> <p>More trials comparing the atypical antipsychotics, such as IM clozapine or olanzapine, with benzodiazepines are needed. Additional trials that compare combined benzodiazepines/antipsychotics with either drug alone are still needed, particularly where the newer antipsychotics are used. Because dosages could be adjusted on an as‐needed basis in the majority of trials, it is difficult to make conclusions about what doses of which drugs are most suitable for managing psychosis‐induced aggression or agitation. As the ability to adjust doses would seem to be the only ethical option in longer‐term trials, these data also need to be reported in future trials. </p> </section> <section id="CD003079-sec-0196"> <p><b>2.2.3. Outcomes</b></p> <p>Standardised, validated scales that are acceptable to recipients of this care, clinicians working in the field, researchers and people working with regulatory authorities are needed to measure outcomes in future trials. Possible outcome measures should include measures of violence, degree of sedation, acceptability of the medication and adverse effects, all recorded over a suitable timescale to match the pharmacokinetic properties of the drugs. This will mean selective reporting biases are more likely to be eliminated and better‐quality meta‐analyses possible. One way to address this fundamental issue would be to develop and employ a standardised set of outcome measurements, or 'core outcome sets.' This may be achieved through the COMET (Core Outcome Measures in Effectiveness Trials; <a href="http://www.comet-initiative.org/" target="_blank">www.comet-initiative.org/</a>) Initiative that seeks to identify a standardised set of outcomes, with consensus on how these are to be defined and measured. </p> </section> <section id="CD003079-sec-0197"> <p><b>2.2.4. Suggested design of trial</b></p> <p>We realise that design of suitable trials takes time and a great deal of care but we have spent some considerable period studying the relevant existing trials and, therefore, suggest an outline of a suitable trial design (<a href="#CD003079-tbl-0013">Table 6</a>). </p> </section> </section> </section> </section> <div class="table" id="CD003079-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Suggested design of future reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Methods</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully described in terms of methods of randomisation and allocation concealment. </p> <p>Blinding: double/single blind, with methods of maintenance of blinding fully described.</p> <p>Setting: psychiatric emergency settings/hospital.</p> <p>Duration: immediate term (0‐15 minutes); short term (15 minutes to 1 hour); medium term (1‐48 hours); long term (≥ 48 hours). </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Participants</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: primary diagnosis of schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder with psychosis‐induced aggression or agitation. </p> <p>Subgroups: dual diagnoses or drug/alcohol use, or both.</p> <p>Age: adults, with age specified in trial.</p> <p>Sex: both.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparisons</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>a. Benzodiazepines ‐ given alone.</b> </p> <p>Including: alprazolam, bretazenil, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clotiazepam, cloxazolam, delorazepam, diazepam, estazolam, flunitrazepam, halazepam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam or triazolam. </p> <p>Any dose, any means of administration.</p> <p>Compared with:</p> <p>1. Other benzodiazepine ‐ given alone.</p> <p>Any dose, any means of administration.</p> <p>2. Antipsychotics.</p> <p>First generation/typical, including: chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, droperidol, flupentixol/flupenthixol, fluphenazine, haloperidol, levomepromazine, loxapine, mesoridazine, molindone, periciazine, perphenazine, pimozide, prochlorperazine, promazine, promethazine, thioridazine, thiothixene, trifluoperazine, triflupromazine or zuclopenthixol. </p> <p>Second generation/atypical, including: amisulpride, aripiprazole, asenapine, clozapine, clothiapine, clotiapine, iloperidone, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, risperidone, sertindole, sulpiride, ziprasidone or zotepine. </p> <p>Any dose, any means of administration.</p> <p>3. Other combinations of drugs.</p> <p>3.1. Benzodiazepines + antipsychotics.</p> <p>3.2. Antipsychotics + antihistamine/anticholinergic drugs.</p> <p>Antihistamines include: azelastine<i>,</i> brompheniramine<i>,</i> buclizine<i>,</i> bromodiphenhydramine<i>,</i> carbinoxamine<i>,</i> cetirizine<i>,</i> cyclizine<i>,</i> chlorpheniramine<i>,</i> chlorodiphenhydramine<i>,</i> clemastine<i>,</i> cyproheptadine<i>,</i> desloratadine<i>,</i> dexbrompheniramine<i>,</i> deschlorpheniramine<i>,</i> dexchlorpheniramine<i>,</i> dimenhydrinate<i>,</i> dimethindene<i>,</i> diphenhydramine<i>,</i> doxylamine<i>,</i> ebastine<i>,</i> embramine<i>,</i> fexofenadine<i>,</i> levocetirizine<i>,</i> loratadine<i>,</i> meclozine<i>,</i> olopatadine<i>,</i> orphenadrine<i>,</i> phenindamine<i>,</i> pheniramine<i>,</i> phenyltoloxamine<i>,</i> promethazine<i>,</i> pyrilamine<i>,</i> rupatadine<i>,</i> tripelennamine or triprolidine. </p> <p>Any dose, any means of administration.</p> <p>4. Non‐pharmacological approaches.</p> <p><b>b. Benzodiazepines plus antipsychotics.</b> </p> <p>Compared with:</p> <p>1. Placebo.</p> <p>2. Antipsychotics.</p> <p>Any dose, any means of administration.</p> <p>3. Other combinations.</p> <p>3.1. Benzodiazepines plus antipsychotics.</p> <p>3.2. Antipsychotics plus antihistamines.</p> <p>4. Non‐pharmacological approaches.</p> <p><b>c. Benzodiazepines (specific named drug) ‐ given alone.</b> </p> <p>1. High dose (as defined by each study).</p> <p>2. Low or standard dose (as defined by each study).</p> <p><b>d. Benzodiazepines (specific named drug) ‐ given alone.</b> </p> <p>1. Oral.</p> <p>2. Intramuscular or intravenous.</p> <p><b>e. Benzodiazepines (specific named drug) ‐ given alone.</b> </p> <p>1. Low frequency (as defined by each study).</p> <p>2. High frequency (as defined by each study).</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes measures</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary outcomes.</b> </p> <p>1. Global impression.</p> <p>1.1. Specific.</p> <p>1.1.1. No improvement: as defined by each study. If more than 1 measure of improvement was reported, then improvement in behaviour is used, followed by improvement in mental state, and then improvement in symptoms. </p> <p>1.1.2. Tranquillisation (feeling of calmness or calm, non‐sedated behaviour (or both)).</p> <p><b>Secondary outcomes.</b> </p> <p>2. Global impression ‐ CGI.</p> <p>2.1. General.</p> <p>2.1.1. No clinically important change in general functioning.<br/>2.1.2. No change in general functioning.<br/>2.1.3. Mean endpoint change in general functioning.<br/>2.1.4. Mean change in general functioning. </p> <p>2.2. Specific.</p> <p>2.2.1. Aggression.<br/>2.2.2. Self‐harm, including suicide.<br/>2.2.3. Injury to others.<br/>2.2.4. Improvement in self‐care or degree of improvement in self‐care.<br/>2.2.5. Sedation (sleepiness and drowsiness).<br/>2.2.6. Compulsory administrations of treatment.<br/>2.2.7. Need for additional medication.<br/>2.2.8. Decrease in medication.<br/>2.2.9. No change in medication dosage.<br/>2.2.10. Mean change/endpoint scores. </p> <p>3. Behaviour.</p> <p>3.1. General.</p> <p>3.1.1. No clinically important change in behaviour.<br/>3.1.2. Mean behaviour score. </p> <p>4. Mental state ‐ BPRS.</p> <p>4.1. General.</p> <p>4.1.1. No clinically important change in general mental state scores.<br/>4.1.2. Mean endpoint general mental state score. </p> <p>5. Adverse effects/events.</p> <p>5.1. General.</p> <p>5.1.1. Incidence of side effects, general or specific.<br/>5.1.2. Severity of symptoms.<br/>5.1.3. Measured acceptance of treatment.<br/>5.1.4. Sudden or unexpected death. </p> <p>5.2. Specific.</p> <p>5.2.1. EPS.<br/>5.2.2. Use of medication for EPS. </p> <p>6. Hospital and service outcomes.</p> <p>6.1. Hospitalisation.</p> <p>6.1.1. Time to hospitalisation.<br/>6.1.2. Hospitalisation of people in the community.<br/>6.1.3. Duration of hospital stay.<br/>6.1.4. Changes in services provided by community teams. </p> <p>6.2. Seclusion.</p> <p>6.2.1. Time in seclusion.<br/>6.2.2. Changes in hospital status (e.g. changes from voluntary to involuntary care, changes in level of observation, use of seclusion). </p> <p>7. Satisfaction with treatment.</p> <p>7.1. Specific.</p> <p>7.1.1. Consumers.<br/>7.1.2. Family and informal carers.<br/>7.1.3. Professionals/carers. </p> <p>8. Economic outcomes.</p> <p>8.1. Cost‐effectiveness.</p> <p>8.2. Direct costs.</p> <p>8.3. Indirect costs.</p> <p>9. Leaving the study early.</p> <p>9.1. For any reason.</p> <p>9.2. For reasons treatment related.</p> <p>9.3. For reasons unrelated to treatment.</p> <p>9.4. Due to relapse.</p> <p>9.5. Due to adverse effects.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression; EPS: extrapyramidal symptoms. </p> </div> </div> <div class="table" id="CD003079-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Suggested design of future studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Methods</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully described in terms of methods of randomisation and allocation concealment. </p> <p>Blinding: double/single blind, with methods of maintenance of blinding fully described.</p> <p>Setting: psychiatric emergency settings/hospital.</p> <p>Duration: follow‐up 72 hours.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: primary diagnosis of schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder with psychosis‐induced aggression or agitation. </p> <p>Subgroups: dual diagnoses or drug/alcohol use (or both)</p> <p>Number of participants &gt; 400.</p> <p>Age: adults, with age specified in trial.</p> <p>Sex: both.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interventions</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1. Benzodiazepines ‐ given alone.</b> </p> <p>Including: alprazolam, bretazenil, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clotiazepam, cloxazolam, delorazepam, diazepam, estazolam, flunitrazepam, halazepam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam or triazolam. </p> <p>Any dose, any means of administration.</p> <p>Compared with:</p> <p><b>a. Other benzodiazepine ‐ given alone.</b> </p> <p>Any dose, any means of administration.</p> <p><b>b. Antipsychotics.</b> </p> <p>First generation/typical, including: chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, droperidol, flupentixol/flupenthixol, fluphenazine, haloperidol, levomepromazine, loxapine, mesoridazine, molindone, periciazine, perphenazine, pimozide, prochlorperazine, promazine, promethazine, thioridazine, thiothixene, trifluoperazine, triflupromazine or zuclopenthixol. </p> <p>Second generation/atypical, including: amisulpride, aripiprazole, asenapine, clozapine, clothiapine, clotiapine, iloperidone, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, risperidone, sertindole, sulpiride, ziprasidone or zotepine. </p> <p>Any dose, any means of administration.</p> <p><b>c. Other combinations of drugs.</b> </p> <p>i. Benzodiazepines plus antipsychotics.</p> <p>ii. Antipsychotics plus antihistamine/anticholinergic drugs.</p> <p>Antihistamines including: azelastine<i>,</i> brompheniramine<i>,</i> buclizine<i>,</i> bromodiphenhydramine<i>,</i> carbinoxamine<i>,</i> cetirizine<i>,</i> cyclizine<i>,</i> chlorpheniramine<i>,</i> chlorodiphenhydramine<i>,</i> clemastine<i>,</i> cyproheptadine<i>,</i> desloratadine<i>,</i> dexbrompheniramine<i>,</i> deschlorpheniramine<i>,</i> dexchlorpheniramine<i>,</i> dimenhydrinate<i>,</i> dimethindene<i>,</i> diphenhydramine<i>,</i> doxylamine<i>,</i> ebastine<i>,</i> embramine<i>,</i> fexofenadine<i>,</i> levocetirizine<i>,</i> loratadine<i>,</i> meclozine<i>,</i> olopatadine<i>,</i> orphenadrine<i>,</i> phenindamine<i>,</i> pheniramine<i>,</i> phenyltoloxamine<i>,</i> promethazine<i>,</i> pyrilamine<i>,</i> rupatadine<i>,</i> tripelennamine or triprolidine. </p> <p>Any dose, any means of administration.</p> <p><b>d. Non‐pharmacological approaches.</b> </p> <p><b>2. Benzodiazepines plus antipsychotics.</b> </p> <p>Compared with:</p> <p><b>a. Placebo.</b> </p> <p><b>b. Antipsychotics.</b> </p> <p>Any dose, any means of administration.</p> <p><b>c. Other combinations.</b> </p> <p>i. Benzodiazepines plus antipsychotics.</p> <p>ii. Antipsychotics plus antihistamines.</p> <p><b>d. Non‐pharmacological approaches.</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Global impression: no improvement (as defined by each study. If more than 1 measure of improvement was reported, then improvement in behaviour was used, followed by improvement in mental state, and then improvement in symptoms). </p> <p>2. Global impression; general/specific (including tranquillisation/sedation/need for additional medication/decrease in medication/injury to others/self‐harm/aggression or agitation/compulsory administration of treatment). </p> <p>3. Behaviour: no clinically important change in behaviour.</p> <p>4. Mental state: no clinically important change in general mental state scores.</p> <p>5. Adverse effects/events (including incidence of specific adverse effects/severity of symptoms/death/EPS/use of medication for EPS). </p> <p>6. Hospital and service outcomes (including time to hospitalisation/duration of hospital stay/seclusion/time in seclusion/changes in hospital status/use of mechanical restraints). </p> <p>7. Satisfaction with treatment.</p> <p>8. Economic outcomes.</p> <p>9. Leaving the study early.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any outcomes measured using scale‐derived data should be interpreted in such a way as to make clear the real‐life relevance of changes in scale score. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EPS: extrapyramidal symptoms.</p> </div> </div> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003079-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003079-sec-0008"></div> <div class="table" id="CD003079-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benzodiazepines compared to placebo for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines compared to placebo for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> hospitals (Romania and US)<br/><b>Intervention:</b> benzodiazepines<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term</b><br/>Number of participants sedated<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b><br/>(25 to 389) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.67</b> <br/>(0.42 to 6.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>V</b> <b>ery low</b><sup>2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ medium term</b><br/>As defined in each study<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>569 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b><br/>(227 to 552) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/>(0.40 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b><br/>Number of participants requiring additional medication<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b><br/>(365 to 762) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/>(0.69 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ medium term</b><br/>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(2 to 182) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.04 to 3.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes:</b> cost‐effectiveness ‐ clinically important </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed risk: mean baseline risk presented for single study. Equates with that of control group.<br/><sup>2</sup>Risk of bias: 'very serious' ‐ 90% of trial authors and coauthors were employed by trial sponsors at the time of the study ‐ downgraded by 1.<br/><sup>3</sup>Risk of bias: 'serious' ‐ randomisation poorly described ‐ downgraded by 1.<br/><sup>4</sup>Imprecision: 'serious' ‐ small sample size ‐ downgraded by 1. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003079-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Benzodiazepines compared to antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines compared to antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> hospitals (US, Canada, Israel, China, Australia)<br/><b>Intervention:</b> benzodiazepines<br/><b>Comparison:</b> antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antipsychotics</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term vs haloperidol</b> </p> <p>Number of participants sedated<br/>Follow‐up: mean 16 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.13</b> <br/>(0.83 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>434<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> </p> <p>(83 to 154)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b><br/>(189 to 350) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>565 per 1000</b><br/>(415 to 770) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: no improvement ‐ vs haloperidol ‐ medium term</b> </p> <p>As defined in each study<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.89</b> <br/>(0.71 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>188<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> <p>(55 to 85)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>551 per 1000</b><br/>(439 to 687) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>830 per 1000</b><br/>(662 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ vs olanzapine ‐ medium term</b> </p> <p>As defined in each study<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000</p> <p>(203 to 610)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.84</b> <br/>(1.06 to 3.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>1,2,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b><br/>Number of participants requiring additional medication<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High levels of heterogeneity between included studies (Chi<sup>2</sup> = 16.41; I<sup>2</sup> = 94%) ‐ data not pooled.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ vs haloperidol ‐ medium term</b> </p> <p>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 21 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.13</b> <br/>(0.04 to 0.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>233<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b><br/>(7 to 76) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/>(20 to 205) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal care givers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: 'serious' ‐ most trials received funding from a pharmaceutical institute and there was potential risk of selection bias.<br/><sup>2</sup>Imprecision: 'serious' ‐ confidence intervals for best estimate of effect included both 'no effect' and appreciable benefit/harm. </p> <p><sup>3</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (61.9%). </p> <p><sup>4</sup>Inconsistency: 'serious' ‐ one study indicated significant favour of antipsychotics, while the other study indicated favour for benzodiazepines (non‐significant). </p> <p><sup>5</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (22.7%). </p> <p><sup>6</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (18.6%). </p> <p><sup>7</sup>Only one small study reporting data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003079-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Benzodiazepines compared to antihistamines plus antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines compared to antihistamines + antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> psychiatric hospitals (US, Canada, Israel, China, Australia)<br/><b>Intervention:</b> benzodiazepines<br/><b>Comparison:</b> antihistamines + antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antihistaimes +</b> antipsychotics </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tranquillisation or asleep: sedation ‐ medium term ‐ lorazepam vs haloperidol + promethazine</b><br/>Number of participants sedated<br/>Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>970 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>883 per 1000</b><br/>(815 to 951) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b> <br/>(0.84 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tranquillisation or asleep: sedation ‐ medium term ‐ midazolam vs haloperidol + promethazine</b><br/>Number of participants sedated<br/>Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>827 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>934 per 1000</b><br/>(860 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.13</b> <br/>(1.04 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>301<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ medium term</b><br/>As defined in each study<br/>Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b><br/>(139 to 486) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.17</b> <br/>(1.16 to 4.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b><br/>Number of participants requiring additional medication<br/>Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b><br/>(9 to 174) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b> <br/>(0.31 to 5.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ medium term</b><br/>Number of instances of extrapyramidal symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed risk: mean baseline risk presented for single study. Equates with that of control group.<br/><sup>2</sup>Risk of bias: 'serious' ‐ non‐blind, open‐label study.<br/><sup>3</sup>Imprecision: 'serious' ‐ small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003079-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Benzodiazepines + antipsychotics compared to same enzodiazepines for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines + antipsychotics compared to same benzodiazepines</b> <b>for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> hospitals (USA, China)<br/><b>Intervention:</b> benzodiazepines + antipsychotics<br/><b>Comparison:</b> same benzodiazepines </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Same</b> benzodiazepines </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Benzodiazepines<b>+</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term‐ + haloperidol ‐ medium term</b> </p> <p>Number of participants sedated<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.84</b> <br/>(0.59 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>556 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>467 per 1000</b><br/>(328 to 661) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: no improvement ‐ + haloperidol ‐ medium term</b> </p> <p>As defined in each study<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.96</b> <br/>(0.76 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>677 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>650 per 1000</b><br/>(515 to 812) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Modertate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>732 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>703 per 1000</b> </p> <p>(556 to 879)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>867 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>832 per 1000</b><br/>(659 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ lorazepam + risperidone vs lorazepam ‐ medium term</b><br/>As defined in each study<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>700 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>602 per 1000</b><br/>(315 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/>(0.45 to 1.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: need for additional medication ‐ + haloperidol ‐ medium term</b> </p> <p>Number of participants requiring additional medication<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.02</b> <br/>(0.79 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>103<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per 1000</b> </p> <p>(395 to 660)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>774 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>789 per 1000</b><br/>(611 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ + haloperidol ‐ medium term</b> </p> <p>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000<sup>6</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> <p>(4 to 483)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.94</b> </p> <p>(0.18 to 20.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: 'serious' ‐ most trials received funding from a pharmaceutical institute and there was potential risk of selection bias.<br/><sup>2</sup>Imprecision: 'serious' ‐ confidence intervals for best estimate of effect included both 'no effect' and appreciable benefit/harm. </p> <p><sup>3</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (73.2%). </p> <p><sup>4</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (50%). </p> <p><sup>5</sup>Calculated from the included studies ‐ 'moderate' risk equates with that of control group (55.6%). </p> <p><sup>6</sup>Calculated from the included studies ‐ 'moderate' risk equates with that of control group (2.4%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003079-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benzodiazepines + antipsychotics compared to same antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines + antipsychotics compared to same antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> hospitals (US, China, Brazil)<br/><b>Intervention:</b> benzodiazepines + antipsychotics<br/><b>Comparison:</b> same antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Same</b> antipsychotics </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Benzodiazepines<b>+</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term ‐ +/vs haloperidol</b> </p> <p>Number of participants sedated<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.75</b> <br/>(1.14 to 2.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>172<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b><br/>(292 to 683) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>175 per 1000</b><br/>(114 to 267) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>380 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>665 per 1000</b><br/>(433 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: no improvement ‐ +/vs haloperidol ‐ medium term</b> </p> <p>As defined in each study<br/>Follow‐up: 36 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.17</b> <br/>(0.93 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>185<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>521 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>610 per 1000</b><br/>(485 to 761) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/>(31 to 48) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/>(868 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication</b> </p> <p>Number of participants requiring additional medication<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ +/vs haloperidol ‐ medium term</b> </p> <p>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 18 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.44</b> <br/>(0.16 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b><br/>(30 to 216) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>+/vs</b> <b>:</b> with or versus; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Inconsistency: 'serious' ‐ high levels of heterogeneity.<br/><sup>2</sup>Imprecision: 'serious' ‐ confidence intervals for best estimate of effect included both 'no effect' and appreciable benefit/harm.<br/><sup>3</sup>Risk of bias: 'serious' ‐ funded by pharmaceutical institutes. </p> <p><sup>4</sup>Calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (52.1%). </p> <p><sup>5</sup>Calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (25.6%). </p> <p><sup>6</sup>Calculated from the included studies ‐ 'moderate' risk equates with that of control group (18.5%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003079-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Benzodiazepines plus antipsychotics compared to antipsychotics plus antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>B</b> <b>enzodiazepines + antipsychotics compared to antipsychotics + antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> n/a<br/><b>Intervention:</b> benzodiazepines + antipsychotics<br/><b>Comparison:</b> antipsychotics + antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Antipsychotics<b>+</b> antipsychotics </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Benzodiazepines<b>+</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003079-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Benzodiazepines plus antipsychotics compared to antihistamines plus antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>B</b> <b>enzodiazepines + antipsychotics compared to antihistamines + antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> psychiatric emergency department (Brazil)<br/><b>Intervention:</b> benzodiazepines + antipsychotics<br/><b>Comparison:</b> antihistamines + antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antihistamine +</b> antipsychotics </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Benzodiazepines<b>+</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term</b><br/>Number of participants sedated<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b><br/>(55 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 12.00</b> <br/>(1.66 to 86.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ medium term</b><br/>As defined in each study<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 25.00</b> <br/>(1.55 to 403.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b><br/>Number of participants requiring additional medication<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global impression: need for additional medication ‐ medium term in the intervention groups was<br/><b>0 higher</b><br/>(0 to 0 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed data ‐ see 'data and analysis'.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ medium term</b><br/>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(27 to 382) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> <br/>(0.16 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed risk: mean baseline risk ‐ only one trial reported with 0 events in the control group and 12 events in the intervention group.<br/><sup>2</sup>Corresponding risk: one trial reported 12 events in the intervention group (40%).<br/><sup>3</sup>Risk of bias: 'serious' ‐ study funded by pharmaceutical institutes, potential risk of selection bias, performance bias and attrition bias.<br/><sup>4</sup>Imprecision: 'very serious' ‐ only one study reported data for this outcome, data were skew.<br/><sup>5</sup>Assumed risk: mean baseline risk presented for single study. Equates with that of control group. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003079-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003079-sec-0009"></div> <section id="CD003079-sec-0010"> <h3 class="title" id="CD003079-sec-0010">Description of the condition</h3> <p>Acutely psychotic people may exhibit agitated and aggressive behaviour that can present a danger to themselves or others. To ensure a safe and therapeutic environment where the patients have their dignity and privacy respected, de‐escalation techniques should be used to calm the patient (<a href="./references#CD003079-bbs2-0109" title="National Institute for Health and Care Excellence. Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments, NG10. www.nice.org.uk/guidance/ng10 (accessed prior to 17 October 2017).">NICE 2015</a>; <a href="./references#CD003079-bbs2-0114" title="RoccaP , VillariV , BogettoF . Managing the aggressive and violent patient in the psychiatric emergency. Progress in Neuro-Psychopharmacology and Biological Psychiatry2006;30(4):586-98.">Rocca 2006</a>). Frequently, however, the behaviour may be too disturbed or agitated for these methods to be effective, and it might prove imperative that further action in the form of rapid tranquillisation is given usually as a last resort because the risk to the person or other people is too high (<a href="./references#CD003079-bbs2-0109" title="National Institute for Health and Care Excellence. Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments, NG10. www.nice.org.uk/guidance/ng10 (accessed prior to 17 October 2017).">NICE 2015</a>; <a href="./references#CD003079-bbs2-0114" title="RoccaP , VillariV , BogettoF . Managing the aggressive and violent patient in the psychiatric emergency. Progress in Neuro-Psychopharmacology and Biological Psychiatry2006;30(4):586-98.">Rocca 2006</a>). The aim of rapid tranquillisation is to achieve a state of calm that is sufficient to minimise risk of harm to the agitated person themselves, or to others around them, and allow treatment of the underlying condition (<a href="./references#CD003079-bbs2-0073" title="BattagliaJ . Pharmacological management of acute agitation. Drugs2005;65(9):1207-22.">Battaglia 2005</a>; <a href="./references#CD003079-bbs2-0109" title="National Institute for Health and Care Excellence. Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments, NG10. www.nice.org.uk/guidance/ng10 (accessed prior to 17 October 2017).">NICE 2015</a>). Rapid tranquillisation may serve as primary therapy in such instances but may also be used in conjunction with other de‐escalation methods (<a href="./references#CD003079-bbs2-0104" title="MarderSR . A review of agitation in mental illness: treatment guidelines and current therapies. Journal of Clinical Psychiatry2006;67(Suppl 10):13-21.">Marder 2006</a>; <a href="./references#CD003079-bbs2-0109" title="National Institute for Health and Care Excellence. Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments, NG10. www.nice.org.uk/guidance/ng10 (accessed prior to 17 October 2017).">NICE 2015</a>). </p> </section> <section id="CD003079-sec-0011"> <h3 class="title" id="CD003079-sec-0011">Description of the intervention</h3> <p>Rapid tranquillisation is commonly used in emergency settings in general and psychiatric hospitals worldwide (<a href="./references#CD003079-bbs2-0091" title="GoedhardLE , StolkerJJ , HeerdinkER , NijmanHL , OlivierB , EgbertsTC . Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: a systematic review. Journal of Clinical Psychiatry2006;67(7):1013-24.">Goedhard 2006</a>; <a href="./references#CD003079-bbs2-0104" title="MarderSR . A review of agitation in mental illness: treatment guidelines and current therapies. Journal of Clinical Psychiatry2006;67(Suppl 10):13-21.">Marder 2006</a>). Three major classes of drugs are used to achieve rapid tranquillisation: typical antipsychotics, benzodiazepines and, more recently, atypical antipsychotics (<a href="./references#CD003079-bbs2-0104" title="MarderSR . A review of agitation in mental illness: treatment guidelines and current therapies. Journal of Clinical Psychiatry2006;67(Suppl 10):13-21.">Marder 2006</a>). Intramuscular (IM) injections of typical antipsychotics and benzodiazepines, alone or in combination, have been the treatment of choice for several decades. One review of the research literature reported that the typical antipsychotic, haloperidol, and the benzodiazepine, lorazepam, were the most widely used drugs (<a href="./references#CD003079-bbs2-0073" title="BattagliaJ . Pharmacological management of acute agitation. Drugs2005;65(9):1207-22.">Battaglia 2005</a>). However, the drugs used for rapid tranquillisation may vary widely in different countries. One survey in Rio de Janeiro, Brazil, showed that a haloperidol/promethazine mixture was commonly used (<a href="./references#CD003079-bbs2-0096" title="HufG , da Silva Freire CoutinhoE , Fagundes HM Jr, OliveiraES , LopezJR , GewandszajderM , et al. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. BMC Psychiatry2002;2:4.">Huf 2002</a>), while one survey of African psychiatrists found that chlorpromazine and diazepam were most commonly prescribed, although the choice of drug tended to be governed by availability rather than preference (<a href="./references#CD003079-bbs2-0098" title="JamesBO . Rapid tranquillization agents for severe behavioural disturbance: a survey of African psychiatrists' prescription patterns. Tropical Doctor2011;41(1):49-50.">James 2011</a>). With the introduction of parenteral forms of the atypical antipsychotics, these are also gaining in popularity as the first‐line treatment for agitation in the psychiatric emergency setting (<a href="./references#CD003079-bbs2-0104" title="MarderSR . A review of agitation in mental illness: treatment guidelines and current therapies. Journal of Clinical Psychiatry2006;67(Suppl 10):13-21.">Marder 2006</a>; <a href="./references#CD003079-bbs2-0106" title="MintzerJE . Rapid tranquillization agents for severe behavioural disturbance: a survey of African psychiatrists' prescription patterns. Journal of Clinical Psychiatry2006;67(Suppl 10):3-5.">Mintzer 2006</a>). </p> <p>The benzodiazepine family is large (<a href="#CD003079-tbl-0008">Table 1</a>), and with different characteristics of metabolism (<a href="#CD003079-tbl-0009">Table 2</a>). </p> <div class="table" id="CD003079-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The benzodiazepine family</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Code</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Chemical name</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐3350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐bromo‐1, 3‐dihydro‐5‐(2‐pyridyl)‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Camazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SB 5833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐3‐hydroxy‐1‐methyl‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one dimethylcarbamate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlordiazepoxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐0690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐2‐methylamino‐5‐phenyl‐3H‐1, 4‐benzodiazepin‐4‐oxide</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cinolazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OX 373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐2, 3‐dihydro‐3‐hydroxy‐2‐oxo‐1H‐1, 4‐benzodiazepine‐1‐ propionitrile</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobaza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 376 H 4723 LM 2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐methyl‐5‐phenyl‐1H‐1, 5‐benzodiazepine‐2, 4‐(3H, 5H)‐dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐4023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐(o‐chlorophenyl)‐1, 3‐dihydro‐7‐nitro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clorazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4306CB A35.616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>dipotassium 7‐chloro‐2, 3‐dihydro‐2, 2‐oxo‐5‐phenyl‐1H‐1, 4‐benzodiazepine‐3‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cp 1414 S</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐amino‐7‐nitro‐5‐phenyl‐3H‐1, 5‐benzodiazepin‐4‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyprazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 3623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐2‐[(cyclopropylmethyl)amino]‐5‐phenyl‐3H‐1, 4‐benzodiazepin‐4‐oxide</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delorazepam chlordemethyldiazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1, 3‐dihydro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐2807 WY 3467 LA III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐1‐methyl‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxefazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAS 643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐3‐hydroxy‐1‐(2‐hydroxyethyl)‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elfazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SKF 72.517)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐[2‐(ethylsulfonyl)ethyl]‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethyl carfluzepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl ester of 7‐chloro‐5‐(o‐fluorophenyl)‐2, 3‐dihydro‐1‐ (methylcarbamoyl)‐2‐oxo‐1H‐1, 4‐benzodiazepine‐3‐carboxylic acid</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethyl dirazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl 7‐chloro‐5‐(o‐chlorophenyl)‐2, 3‐dihydro‐2‐oxo‐1H‐1, 4‐benzodiazepine‐3‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethyl loflazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CM 6912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl 7‐chloro‐5‐(o‐fluorophenyl)‐2, 3‐dihydro‐2‐oxo‐1H‐1, 4‐ benzodiazepine‐3‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fletazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCH 15.698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐2, 3‐dihydro‐1‐(2, 2, 2‐trifluoroethyl)‐1H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fludiazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID 540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐1 methyl‐2H‐1, 4‐benzodiazepine‐2‐0</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flunitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐4200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐(o‐fluorophenyl)‐1, 3‐dihydro‐1‐methyl‐7‐nitro‐2H‐1, 4‐ benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flurazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐6901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐[2‐(diethylamino)ethyl]‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐2H‐1, 4‐benzodiazepin‐2‐one. dihydrochloride</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flutemazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐3‐hydroxy‐1‐methyl‐2H‐1, 4‐benzodiazepine‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flutoprazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KB 509 ID 1937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐(cyclopropylmethyl)‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fosazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐[(dimethylphosphinyl)methyl]‐1, 3‐dihydro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Girisopam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GYKI 51.189 EGIS 5810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1‐(3‐chlorophenyl)‐4‐methyl‐7, 8‐dimethoxy‐5H‐2, 3‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gv 150013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(R)‐N‐[(adamantane‐1‐methyl)‐2, 4‐dioxo‐5‐phenyl‐2, 3, 4, 5‐tetrahydro‐1H‐1, 5‐benzodiazepin‐3‐yl]‐N‐phenylurea</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Halazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCH 12.041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐5‐phenyl‐1‐(2, 2, 2‐trifluoroethyl)‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iclazepam clazepam (formerly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐[2‐(cyclopropylmethoxy)ethyl]‐1, 3‐dihydro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WY 4036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1, 3‐dihydro‐3‐hydroxy‐2‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lormetazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WY 4082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1, 3‐dihydro‐3‐hydroxy‐1‐methyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M ORF8063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WE 352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1‐methyl‐5‐phenyl‐7‐(trifluoromethyl)‐1H‐1, 5‐benzodiazepine‐2, 4(3H, 5H)dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meclonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(3‐methylclonazepam) Ro 11‐3128 (meclonazepam, Roche) Ro 11‐3624 (steric antipode of meclonazepam) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(+)‐(S)‐5‐(o‐chlorophenyl)‐1, 3‐dihydro‐3‐methyl‐7‐nitro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐4556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐2, 3‐dihydro‐1‐methyl‐5‐phenyl‐1H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB 4857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐(1‐cyclohexen‐1‐yl)‐1, 3‐dihydro‐1‐methyl‐7‐nitro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metaclazepam (formerly: Brometazepam)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KC 2547 KC 3755 (normetaclazepam (active metabolite)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐bromo‐5‐(o‐chlorophenyl)‐2, 3‐dihydro‐2‐(methoxymethyl)‐1‐methyl‐1H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nimetazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>S 1530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1, 3‐dihydro‐1‐methyl‐7‐nitro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 4‐5360 Ro 5‐3059 CB 4395 (potassium salt)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1, 3‐dihydro‐7‐nitro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nordazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐2180 A 101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐3‐hydroxy‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normetrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB 4260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(1‐cyclohexen‐1‐yl)‐1, 3‐dilhydro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WY 3498 8092 CB Ro 5‐6789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐3‐hydroxy‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazepam hemisuccinate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAS 538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐2, 3‐dihydro‐3‐hydroxy‐2‐(1H)‐oxo‐5‐phenyl‐1, 4‐benzodiazepin‐3‐yl hydrogen succinate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pinazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Z 905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐5‐phenyl‐1‐(2‐propynyl)‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Potassium nitrazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB 4335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2, 3‐dihydro‐7‐nitro‐2‐oxo‐5‐phenyl‐1H‐1, 4‐benzodiazepin‐3‐carboxylic acid monopotassium salt</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 4020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐(cyclopropylmethyl)‐1, 3‐dihydro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCH 16.134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐1‐(2, 2, 2‐trifluoroethyl)‐2H‐1, 4‐benzodiazepine‐2‐thione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reclazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SC 33.963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐[7‐chloro‐5‐(o‐chlorophenyl)‐2, 3‐dihydro‐1H‐1, 4‐benzodiazepin‐1‐yl]‐2‐oxazolin‐4‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sc 32.855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1‐ (4, 5‐dihydro‐2‐oxazolyl)‐2, 3‐dihydro‐1H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W3676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐ dihydro‐1‐methyl‐5‐phenyl‐ 2H‐1, 4‐ benzodiazepin‐ 2‐thione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ER 115 Ro 5‐5345 WY 3917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐3‐hydroxy‐1‐methyl‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB 4261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(cyclohexen‐1‐yl)‐1, 3‐dihydro‐1‐methyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tofisopam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EGYT 341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐ethyl‐7‐8‐dimethoxy‐1‐(3, 4‐dimethoxyphenyl)‐4‐methyl‐5H‐2, 3‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uldazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 31.920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐[(allyloxy)amino]‐7‐chloro‐5‐(o‐chlorophenyl)‐3H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Tricyclic benzodiazepines</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐Hydroxytriazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine‐1‐methanol</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adinazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 41.123 F (mesylate) U 41.123 (base)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐1‐[(dimethylamino)methyl]‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine (mesylate)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 31.889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐1‐methyl‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Climazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐1‐methyl‐4H‐imidazo[1, 5‐a][1, 4]benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cloxazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS 370 MT 14‐411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐chloro‐11b‐(o‐chlorophenyl)‐2, 3, 7, 11b‐tetrahydro‐oxazolo[3, 2‐d][1, 4]benzodiazepin‐6 (5H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estazolam noralprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 40 TA Lu 7426 Abbott 47631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4] benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flutazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MS 4101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐chloro‐11b‐(2‐flurophenyl)‐2, 3, 7, 11b‐tetrahydro‐7‐(2‐hydroxyethyl‐oxazolo[ 3, 2‐d] [1, 4] benzodiazepin‐6(5H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gp 55.129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 40125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine‐1‐methanol</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloxazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS 430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐bromo‐11b‐(o‐fluorophenyl)‐2, 3, 7, 11b‐tetrahydrooxazolo[3, 2‐d][1, 4]benzodiazepin‐6(5H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 28.774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>11‐chloro‐8, 12b‐dihydro‐2, 8‐dimethyl‐12b‐phenyl‐4H‐[1, 3]oxazino[3, 2‐d][1, 4]benzodiazepine‐4, 7(6H)‐ dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU 31.158 HR 158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(Z)‐6‐(o‐chlorophenyl)‐2, 4‐dihydro‐2‐[(4‐methylpiperazin‐1‐yl)methylene]‐8‐nitro‐1H‐ imidazo[1, 2‐a][1,~ 4]benzodiazepin‐1‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS 386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐chloro‐11b‐(o‐chlorophenyl)‐2, 3, 7, 11b‐tetrahydro‐3‐methyl‐oxazolo[3, 2‐d][1, 4]benzodiazepin‐6(5)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 21‐3981 (maleate) Ro 21‐3981/003 (HCl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐fluorophenyl)‐1‐methyl‐4H‐imidazo [1, 5‐a][1, 4]benzodiazepine maleate (1: 1)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Noradinazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 42.352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐1‐(methylamino)methyl]‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐chloro‐2, 3, 7, 11b‐tetrahydro‐2‐methyl‐11b‐phenyloxazolo[3, 2‐d][1, 4]benzodiazepin‐ 6(5H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ru 31.124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐2‐(4‐ethylpiperazin‐1‐yl)methyl]‐2, 4‐dihydro‐1H‐imidazo[1, 2‐a][1, 4]benzodiazepin‐1‐one (methyl bridge or methylene group uncertain)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 33.030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐1‐methyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine</i> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines with atypical mode of action</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arfendazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl 7‐chloro‐2, 3, 4, 5‐tetrahydro‐4‐oxo‐5‐phenyl‐1H‐1, 5‐benzodiazepine‐1‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Devazepide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L 364.718 (former designation) MK 329 (Merck and Co., USA) L 365.031(Merck)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(S)‐N‐(2, 3‐dihydro‐1‐methyl‐2‐oxo‐5‐phenyl‐1H‐1, 4‐ benzodiazepin‐3‐yl)‐indole‐2‐carboxamideL 365031 N‐(2, 3‐ dihydro‐1‐methyl‐2‐oxo‐5‐phenyl‐1H‐1, 4‐benzodiazepin‐3‐yl)‐1H‐p‐bromobenzamide</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gyki 52.322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EGIS 6775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1‐(4‐aminophenyl)‐4‐methyl‐7, 8‐dimethoxy‐5H‐2, 3‐benzodiazepine 2, 3‐</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L 365260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(R)‐N‐(2, 3‐dihydro‐1‐methyl‐2‐oxo‐5‐phenyl‐1H‐1, 4‐benzodiazepin‐3‐yl)‐N’‐(3‐methylphenyl)‐urea</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 15‐4513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl 8‐azido‐5, 6‐dihydro‐6‐oxo‐4H‐imidazo[1, 5‐a][1, 4]benzodiazepine‐3‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐4864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(p‐chlorophenyl)‐1, 3‐dihydro‐1‐methyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tifluadom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KC 5103 (+)‐tifluadom KC 6128 (Sandoz/Kali‐ Chemie, BRD) (‐)‐tifluadom KC5911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(+/‐)‐N‐[[5‐(o‐fluorophenyl)‐2, 3‐dihydro‐1‐methyl‐1H‐1, 4‐benzodiazepin‐2‐yl]methyl]‐3‐thiophenecarboxamide</i> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Fused benzodiazepines</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brotizolam Ladormin (provisional name)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We 941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐bromo‐4‐(o‐chlorophenyl)‐9‐methyl‐6H‐thieno [3, 2‐f]‐s‐triazolo[4, 3‐a][1, 4]diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclotizolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We 973‐BS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐bromo‐4‐(o‐chlorophenyl)‐9‐cyclohexyl‐6H‐thieno[3, 2‐f]‐s‐triazolo[4, 3‐a][1, 4]diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotiazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y 6047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐(o‐chlorophenyl)‐7‐ethyl‐1, 3‐dihydro‐1‐methyl‐2H‐thieno[2, 3‐e][1, 4]diazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Etizolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AHR 3219 Y 7131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>4‐(o‐chlorophenyl)‐2‐ethyl‐9‐methyl‐6H‐thieno [3, 2‐f]‐s‐triazolo[4, 3‐a][1, 4]diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lopirazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 12524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1, 2‐dihydro‐3‐hydroxy‐3H‐pyrido[3, 2‐ e][1, 4]diazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDL 181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>3, 7‐dihydro‐6, 7‐dimethyl‐5‐phenylpyrrolo[3, 4‐e][1, 4]diazepin‐2(1H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Razobazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hoe 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>4, 8‐dihydro‐3, 8‐dimethyl‐4‐phenylpyrazolo[3, 4‐b][1, 4]diazepine‐5, 7(1H, 6H)‐dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ripazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CI 683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1‐ethyl‐4, 6‐dihydro‐3‐methyl‐8‐phenylpyrazolo[4, 3‐e][1, 4]diazepin‐5(1H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 11‐7800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>9‐aminomethyl‐2‐chloro‐4‐(o‐chlorophenyl)‐6H‐thieno[3, 2‐f]‐s‐triazolo[4, 3‐a][1, 4] diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiadipone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CI 718 bentazepam QM 6008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1, 3, 6, 7, 8, 9‐hexahydro‐5‐phenyl‐2H‐[1]benzothieno[2, 3‐e][1, 4]diazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zapizolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐4H‐pyrido[2, 3‐f]‐s‐triazolo[4, 3‐a][1, 4]diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zomebazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>4, 8‐dihydro‐1, 3, 8‐trimethyl‐4‐phenylpyrazolo [3, 4‐b][1, 4]diazepine‐5, 7(1H, 6H)‐dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zometapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CI 781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7, 8‐dihydro‐1, 3‐dimethyl‐4‐phenyl‐6H‐pyrazolo[3, 4‐e][1, 4] diazepine</i> </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003079-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Half lives of some benzodiazepines</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzodiazepine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Half‐life</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>1. Long</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlordiazepoxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐30 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16‐60 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clorazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐2 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20‐40 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flurazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐2 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>~30 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metaclazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7‐23 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>~30 hours</p> </td> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>2. Medium/short</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐15 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐20 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brotizolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐7 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotiazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐15 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐8 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐24 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lormetazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐14 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐30 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐15 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐14 hours</p> </td> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>3. Extremely short</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐7 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5‐5 hours</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003079-sec-0012"> <h3 class="title" id="CD003079-sec-0012">How the intervention might work</h3> <p>Among other actions, benzodiazepines enhance the effect of the inhibitory neurotransmitter gamma‐aminobutyric acid (GABA), which results in sleep inducing, sedative, antianxiety, muscle relaxant and amnesic effects. First discovered in 1955, through long experience, it is clear that these drugs are effective for managing aggression, but it is unclear just how effective and, if they are better or worse than other compounds or combinations of compounds. </p> </section> <section id="CD003079-sec-0013"> <h3 class="title" id="CD003079-sec-0013">Why it is important to do this review</h3> <p>Guidance suggests benzodiazepines are at least as effective as antipsychotics in controlling severely agitated behaviour (<a href="./references#CD003079-bbs2-0071" title="AllenMH . Managing the agitated psychotic patient: a reappraisal of the evidence. Journal of Clinical Psychiatry2000;61(Suppl 14):11-20.">Allen 2000</a>; <a href="./references#CD003079-bbs2-0109" title="National Institute for Health and Care Excellence. Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments, NG10. www.nice.org.uk/guidance/ng10 (accessed prior to 17 October 2017).">NICE 2015</a>; <a href="./references#CD003079-bbs2-0114" title="RoccaP , VillariV , BogettoF . Managing the aggressive and violent patient in the psychiatric emergency. Progress in Neuro-Psychopharmacology and Biological Psychiatry2006;30(4):586-98.">Rocca 2006</a>), and indeed this was the finding of the original Cochrane review (<a href="./references#CD003079-bbs2-0127" title="GilliesD , BeckA , McCloudA , RathboneJ . Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003079. [DOI: 10.1002/14651858.CD003079.pub2]">Gillies 2005</a>). Some authors suggest that the combination of antipsychotics with benzodiazepines may be more advantageous than either drug alone (<a href="./references#CD003079-bbs2-0114" title="RoccaP , VillariV , BogettoF . Managing the aggressive and violent patient in the psychiatric emergency. Progress in Neuro-Psychopharmacology and Biological Psychiatry2006;30(4):586-98.">Rocca 2006</a>), but there was inadequate evidence of this in the original Cochrane review (<a href="./references#CD003079-bbs2-0127" title="GilliesD , BeckA , McCloudA , RathboneJ . Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003079. [DOI: 10.1002/14651858.CD003079.pub2]">Gillies 2005</a>). This update includes all new trials comparing benzodiazepines (alone or combined with antipsychotics) with antipsychotics (alone or in combination with benzodiazepines). In addition, in this update, we included trials that compared benzodiazepines alone or in combination with antipsychotics, compared to other antipsychotics, benzodiazepines or antihistamines. </p> <p>While there is evidence that both benzodiazepines and antipsychotics are effective in decreasing agitation, both can cause undesirable adverse effects. Acute phase treatment with typical antipsychotic drugs may result in debilitating extrapyramidal symptoms (EPS) including Parkinson's‐like symptoms, hypotension, lowering of the seizure threshold, cardiac arrhythmia and neuroleptic malignant syndrome (<a href="./references#CD003079-bbs2-0073" title="BattagliaJ . Pharmacological management of acute agitation. Drugs2005;65(9):1207-22.">Battaglia 2005</a>; <a href="./references#CD003079-bbs2-0109" title="National Institute for Health and Care Excellence. Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments, NG10. www.nice.org.uk/guidance/ng10 (accessed prior to 17 October 2017).">NICE 2015</a>; <a href="./references#CD003079-bbs2-0114" title="RoccaP , VillariV , BogettoF . Managing the aggressive and violent patient in the psychiatric emergency. Progress in Neuro-Psychopharmacology and Biological Psychiatry2006;30(4):586-98.">Rocca 2006</a>). Benzodiazepines produce EPS less frequently, but can cause respiratory depression, ataxia, excessive sedation, memory impairment and paradoxical disinhibition (<a href="./references#CD003079-bbs2-0073" title="BattagliaJ . Pharmacological management of acute agitation. Drugs2005;65(9):1207-22.">Battaglia 2005</a>; <a href="./references#CD003079-bbs2-0104" title="MarderSR . A review of agitation in mental illness: treatment guidelines and current therapies. Journal of Clinical Psychiatry2006;67(Suppl 10):13-21.">Marder 2006</a>; <a href="./references#CD003079-bbs2-0114" title="RoccaP , VillariV , BogettoF . Managing the aggressive and violent patient in the psychiatric emergency. Progress in Neuro-Psychopharmacology and Biological Psychiatry2006;30(4):586-98.">Rocca 2006</a>). The adverse effect profile of combined therapy with benzodiazepines and antipsychotics is as yet unclear (<a href="./references#CD003079-bbs2-0127" title="GilliesD , BeckA , McCloudA , RathboneJ . Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003079. [DOI: 10.1002/14651858.CD003079.pub2]">Gillies 2005</a>), although it has been suggested that combination therapy may decrease the incidence of adverse effects (<a href="./references#CD003079-bbs2-0073" title="BattagliaJ . Pharmacological management of acute agitation. Drugs2005;65(9):1207-22.">Battaglia 2005</a>). It is also thought that the broader activity profile of atypical antipsychotics may mean they are less likely to produce the EPS adverse effects of the typical antipsychotics (<a href="./references#CD003079-bbs2-0084" title="DugganL , FentonM , RathboneJ , DardennesR , El-DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001359. [DOI: 10.1002/14651858.CD001359]">Duggan 2005</a>; <a href="./references#CD003079-bbs2-0087" title="EssaliA , Al-Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD000059. [DOI: 10.1002/14651858.CD000059]">Essali 2009</a>; <a href="./references#CD003079-bbs2-0118" title="Silveira da Mota NetoJI , SoaresB , Silva de LimaM . Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD001357. [DOI: 10.1002/14651858.CD001357]">Silveira da Mota Neto 2002</a>), but there have been reports of severe adverse events associated with the IM administration of these drugs (<a href="./references#CD003079-bbs2-0073" title="BattagliaJ . Pharmacological management of acute agitation. Drugs2005;65(9):1207-22.">Battaglia 2005</a>). </p> <p>This is one of a series of similar reviews (<a href="#CD003079-tbl-0010">Table 3</a>). </p> <div class="table" id="CD003079-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reviews focusing on similar participant groups</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Focus of review</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Reference</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0111" title="PagadalaB , JayaramMB , MitraL . Aripiprazole for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD008074. [DOI: 10.1002/14651858.CD008074]">Pagadala 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepines for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0122" title="VolzA , KhorsandV , GilliesD , LeuchtS . Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD006391. [DOI: 10.1002/14651858.CD006391]">Volz 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Containment strategies for people with serious mental illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0108" title="MuralidharanS , FentonM . Containment strategies for people with serious mental illness. Cochrane Database of Systematic Reviews2006, Issue 3. Art. No: CD002084. [DOI: 10.1002/14651858.CD002084.pub2]">Muralidharan 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0069" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD007445. [DOI: 10.1002/14651858.CD007445.pub2]">Ahmed 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol (rapid tranquillisation) for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0112" title="PowneyMJ , AdamsCE , JonesH . Haloperidol (rapid tranquilisation) for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD009377. [DOI: 10.1002/14651858.CD009377]">Powney 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol for long‐term aggression in psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0100" title="KhushuA , PowneyMJ , AdamsCE . Haloperidol for long-term aggression in psychosis. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD009830. [DOI: 10.1002/14651858.CD009830]">Khushu 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol plus promethazine for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0097" title="HufG , AlexanderJ , AllenMH , RaveedranNS . Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD005146. [DOI: 10.1002/14651858.CD005146.pub2]">Huf 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loxapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0080" title="ChakrabartiA , BagnallAM , ChueP , FentonM , PalaniswamyV , WongW , et al. Loxapine for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD001943. [DOI: 10.1002/14651858.CD001943.pub2]">Chakrabarti 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loxapine inhaler for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0121" title="VangalaR , AhmedU , AhmedR . Loxapine inhaler for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD010190. [DOI: 10.1002/14651858.CD010190]">Vangala 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0074" title="BelgamwarRB , FentonM . Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD003729. [DOI: 10.1002/14651858.CD003729.pub2]">Belgamwar 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0123" title="WilkieF , FentonM . Quetiapine for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD009801. [DOI: 10.1002/14651858.CD009801]">Wilkie 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0070" title="AhmedU , RehmanF , JonesH , AdamsCE . Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 11. Art. No: CD009412. [DOI: 10.1002/14651858.CD009412]">Ahmed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seclusion and restraint for people with serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0115" title="SailasEES , FentonM . Seclusion and restraint for people with serious mental illnesses. Cochrane Database of Systematic Reviews2000, Issue 1. Art. No: CD001163. [DOI: 10.1002/14651858.CD001163]">Sailas 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0090" title="JayakodyK , GibsonRC , KumarA , GunadasaS . Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD000525. [DOI: 10.1002/14651858.CD000525.pub3]">Gibson 2012</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003079-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003079-sec-0014"></div> <p>To examine whether benzodiazepines, alone or in combination with other pharmacological agents, is an effective treatment for psychosis‐induced aggression or agitation when compared with placebo, other pharmacological agents (alone or in combination) or non‐pharmacological approaches. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003079-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003079-sec-0015"></div> <section id="CD003079-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003079-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials (RCTs). We excluded quasi‐randomised trials, such as those allocating by days of the week. If a trial was described as 'double blind' but implied randomisation, we included such trials in a sensitivity analysis (see <a href="#CD003079-sec-0071">Sensitivity analysis</a>). If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion resulted in a clear effect, we did not add the data from these lower‐quality studies to the results of the better‐designed trials, but presented such data within a subcategory. </p> </section> <section id="CD003079-sec-0018"> <h4 class="title">Types of participants</h4> <p>Any people presenting to the adult services with acutely disturbed/aggressive/agitated behaviour thought to be secondary to psychotic illnesses such as schizophrenia, schizoaffective disorder, mixed affective disorders, manic phase of bipolar disorder or brief psychotic episode. For the purposes of this review, we defined 'acute' as where authors of trials stated or implied that the behavioural disturbance was of sudden onset or extreme in nature, or both. Where trials included people with organic illnesses or people abusing substances, we only included these trials if over 60% of participants were exhibiting disturbed behaviour resulting from a psychotic episode. </p> </section> <section id="CD003079-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD003079-sec-0020"> <h5 class="title">Benzodiazepines ‐ given alone</h5> <p>Benzodiazepines included: alprazolam, bretazenil, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clotiazepam, cloxazolam, delorazepam, diazepam, estazolam, flunitrazepam, halazepam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam, triazolam (<a href="#CD003079-tbl-0008">Table 1</a>). </p> <p>Any dose, any means of administration.</p> <p>Compared with the following:</p> <p><b>1. Placebo</b> </p> <p><b>2. Other benzodiazepine ‐ given alone</b> </p> <p>Any dose, any means of administration.</p> <p><b>3. Antipsychotics</b> </p> <p><i>First generation/typical</i>, including: chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, droperidol, flupentixol/flupenthixol, fluphenazine, haloperidol, levomepromazine, loxapine, mesoridazine, molindone, periciazine, perphenazine, pimozide, prochlorperazine, promazine, promethazine, thioridazine, thiothixene, trifluoperazine, triflupromazine, zuclopenthixol. </p> <p><i>Second generation/atypical,</i> including: amisulpride, aripiprazole, asenapine, clozapine, clothiapine, clotiapine, iloperidone, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, risperidone, sertindole, sulpiride, ziprasidone, zotepine. </p> <p>Any dose, any means of administration.</p> <p><b>4. Other combinations of drugs</b> </p> <p>4.1. Benzodiazepines plus antipsychotics (where the benzodiazepine is the same in both groups). </p> <p>4.2. Antipsychotics plus antihistamine/anticholinergic drugs.</p> <p>Antihistamines including: azelastine<i>,</i> brompheniramine<i>,</i> buclizine<i>,</i> bromodiphenhydramine<i>,</i> carbinoxamine<i>,</i> cetirizine<i>,</i> cyclizine<i>,</i> chlorpheniramine<i>,</i> chlorodiphenhydramine<i>,</i> clemastine<i>,</i> cyproheptadine<i>,</i> desloratadine<i>,</i> dexbrompheniramine<i>,</i> deschlorpheniramine<i>,</i> dexchlorpheniramine<i>,</i> dimenhydrinate<i>,</i> dimethindene<i>,</i> diphenhydramine<i>,</i> doxylamine<i>,</i> ebastine<i>,</i> embramine<i>,</i> fexofenadine<i>,</i> levocetirizine<i>,</i> loratadine<i>,</i> meclozine<i>,</i> olopatadine<i>,</i> orphenadrine<i>,</i> phenindamine<i>,</i> pheniramine<i>,</i> phenyltoloxamine<i>,</i> promethazine<i>,</i> pyrilamine<i>,</i> rupatadine<i>,</i> tripelennamine<i>,</i> triprolidine. </p> <p>Any dose, any means of administration.</p> <p><b>5. Non‐pharmacological approaches</b> </p> </section> <section id="CD003079-sec-0021"> <h5 class="title">Benzodiazepines plus antipsychotics</h5> <p>Compared with the following.</p> <p><b>1. Placebo</b> </p> <p><b>2. Any antipsychotics (where the antipsychotic was the same in both groups)</b> </p> <p>Any dose, any means of administration.</p> <p><b>3. Other combinations of drugs</b> </p> <p>3.1. Benzodiazepines plus antipsychotics (where the antipsychotic was the same in both groups). </p> <p>3.2. Antipsychotics plus antihistamines (where the antipsychotic was the same in both groups). </p> <p><b>4. Non‐pharmacological approaches</b> </p> </section> </section> <section id="CD003079-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>We divided into immediate term (zero to 15 minutes), short term (15 minutes to one hour) and medium term (one to 48 hours). We chose 48 hours as a maximum follow‐up as most benzodiazepines act rapidly (see <a href="#CD003079-tbl-0009">Table 2</a>), and for this review our primary outcome was tranquillisation or asleep, which we considered not to be a long‐term outcome. We recognise some outcomes such as mental state and adverse effects need longer‐term follow‐up and will include long‐term data in future updates of this review. </p> <section id="CD003079-sec-0023"> <h5 class="title">Primary outcomes</h5> <p><b>1. Tranquillisation or asleep</b> </p> <p>1.1. Tranquil or asleep ‐ by up to 30 minutes.<br/>1.2. Repeated need for rapid tranquillisation. </p> </section> <section id="CD003079-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p><b>1. Tranquillisation or asleep</b> </p> <p>1.1. Not tranquil ‐ over 30 minutes.</p> <p>1.2. Not asleep ‐ over 30 minutes.</p> <p>1.3. Time to tranquillisation/sleep.</p> <p>1.4. Time to tranquillisation.</p> <p>1.5. Time to sleep.</p> <p><b>2. Behaviours</b> </p> <p><i>2.1. Specific behaviours</i> </p> <p>2.1.1. Self‐harm, including suicide.</p> <p>2.1.2. Injury to others.</p> <p><i>2.2. Agitation.</i> </p> <p>2.2.1. Another episode of agitation by 24 hours.</p> <p>2.2.2. Clinically important change in agitation.</p> <p>2.2.3. Change in agitation.</p> <p>2.2.4. Mean endpoint in agitation score.</p> <p>2.2.5. Mean change in agitation scores.</p> <p><i>2.3. Aggression.</i> </p> <p>2.3.1. Another episode of aggression by 24 hours.</p> <p>2.3.2. Clinically important change in aggression.</p> <p>2.3.3. Change in aggression.</p> <p>2.3.4. Mean endpoint in aggression score.</p> <p>2.3.5. Mean change in aggression scores.</p> <p><i>2.4. General.</i> </p> <p>2.4.1. Clinically important change in behaviour.</p> <p>2.4.2. Mean endpoint/change score behaviour scale.</p> <p><b>3. Global state</b> </p> <p><i>3.1. General.</i> </p> <p>3.1.1. Clinically important change in global state ‐ as defined by individual studies.</p> <p>3.1.2. Any change in global state ‐ as defined by individual studies.</p> <p>3.1.3. Mean endpoint/change score global state scale.</p> <p>3.1.4. Need for additional medication.</p> <p>3.1.5. Change in medication dosage.</p> <p><b>4. Mental state</b> </p> <p><i>4.1. General.</i> </p> <p>4.1.1. Clinically important change in general mental state scores.</p> <p>4.1.2. Mean endpoint general mental state score.</p> <p><b>5. Adverse effects/events</b> </p> <p><i>5.1. General.</i> </p> <p>5.1.1. Incidence of adverse effects, general or specific.</p> <p>5.1.2. Severity of symptoms.</p> <p>5.1.3. Measured acceptance of treatment.</p> <p>5.1.4. Sudden or unexpected death.</p> <p><i>5.2. Specific.</i> </p> <p>5.2.1. Extrapyramidal symptoms (EPS).</p> <p>5.2.2. Use of medication for EPS.</p> <p><b>6. Hospital and service outcomes</b> </p> <p><i>6.1. Hospitalisation.</i> </p> <p>6.1.1. Time to hospitalisation.</p> <p>6.1.2. Hospitalisation of people in the community.</p> <p>6.1.3. Duration of hospital stay.</p> <p>6.1.4. Changes in services provided by community teams.</p> <p><i>6.2. Seclusion.</i> </p> <p>6.2.1. Time in seclusion.</p> <p>6.2.2. Changes in hospital status (e.g. changes from voluntary to involuntary care, changes in level of observation, use of seclusion). </p> <p><b>7. Satisfaction with treatment</b> </p> <p><i>7.1. Specific.</i> </p> <p>7.1.1. Consumers.</p> <p>7.1.2. Family and informal carers.</p> <p>7.1.3. Professionals/carers.</p> <p><b>8. Economic outcomes</b> </p> <p><i>8.1. Specific.</i> </p> <p>8.1.1. Direct costs ‐ as defined by trial authors.</p> <p>8.1.2. Indirect costs ‐ as defined by trial authors.</p> <p>8.1.3. Cost‐effectiveness ‐ as defined by trial authors.</p> <p><b>9. Leaving the study early</b> </p> <p><b>10. 'Summary of findings' tables</b> </p> <p>We used the GRADE approach to interpret findings (<a href="./references#CD003079-bbs2-0116" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley &amp; Sons, 2008:359-83.">Schünemann 2008</a>) and used GRADE profiler (<a href="http://www.ims.cochrane.org/revman" target="_blank">GRADEpro</a>) to import data from Review Manager 5 (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on all outcomes we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p> <ol id="CD003079-list-0001"> <li> <p>Tranquillisation or asleep: sedation ‐ medium term.</p> </li> <li> <p>Global state: no improvement ‐ medium term.</p> </li> <li> <p>Global state: need for additional medication ‐ medium term.</p> </li> <li> <p>Adverse effects/events: clinically important ‐ EPS ‐ medium term.</p> </li> <li> <p>Satisfaction with treatment: from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage. </p> </li> <li> <p>Economic outcomes: cost‐effectiveness.</p> </li> </ol> </p> </section> </section> </section> <section id="CD003079-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003079-sec-0026"> <h4 class="title">Electronic searches</h4> <section id="CD003079-sec-0027"> <h5 class="title">Cochrane Schizophrenia Group's Trials Register</h5> <p>On 3 August 2016, the information specialist searched the register using the following search strategy: </p> <p>(*All_Aggression* AND *ALL_Benzodizepines*) in Keyword Field of REFERENCE</p> <p>In such a study‐based register, searching the major concept retrieves all the relevant keywords and studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>The Cochrane Schizophrenia Group's Register of Trials is compiled by systematic searches of major resources (including MEDLINE, Embase, AMED, BIOSIS, CINAHL, PsycINFO, PubMed and registries of clinical trials) and their monthly updates, handsearches, grey literature and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). There is no language, date, document type or publication status limitations for inclusion of records into the register. </p> <p>For previous searches, see <a href="./appendices#CD003079-sec-0201">Appendix 1</a>. </p> </section> </section> <section id="CD003079-sec-0028"> <h4 class="title">Searching other resources</h4> <section id="CD003079-sec-0029"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD003079-sec-0030"> <h5 class="title">2. Handsearching</h5> <p>We sought additional relevant trials by handsearching reference lists of included and excluded trials. </p> </section> <section id="CD003079-sec-0031"> <h5 class="title">3. Requests for additional data</h5> <p>We attempted to contact authors of relevant trials to inquire about other sources of relevant information. </p> </section> </section> </section> <section id="CD003079-sec-0032"> <h3 class="title" id="CD003079-sec-0032">Data collection and analysis</h3> <section id="CD003079-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Material downloaded from electronic sources included details of author, institution or journal of publication. One review author (HZ) inspected all reports, which were then inspected the other review authors (DG, TS, SJS, FC, JX or SZ) to ensure reliable selection. We resolved any disagreements by discussion, and where there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought further information and added these trials to the list of those awaiting assessment. </p> </section> <section id="CD003079-sec-0034"> <h4 class="title">Data extraction and management</h4> <section id="CD003079-sec-0035"> <h5 class="title">1. Extraction</h5> <p>The review authors (DG, TS, SJS, FC or SZ) independently extracted data from all included studies. In addition, to ensure reliability, one review author (JX) independently extracted data from a random sample of these studies, comprising 10% of the total. Any disagreements were discussed, decisions documented and, if necessary, we contacted authors of studies for clarification. With remaining problems, one review author (CA) helped clarify issues and these final decisions were documented. Data presented only in graphs and figures were extracted whenever possible, but included only if two review authors independently had the same result. We attempted to contact authors through an open‐ended request to obtain missing information or for clarification whenever necessary. If studies were multi‐centre, where possible, we extracted data relevant to each component centre separately. </p> </section> <section id="CD003079-sec-0036"> <h5 class="title">2. Management</h5> <section id="CD003079-sec-0037"> <h6 class="title">2.1. Forms</h6> <p>We extracted binary, continuous and other data onto standard, simple forms.</p> </section> <section id="CD003079-sec-0038"> <h6 class="title">2.2. Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p> <ul id="CD003079-list-0002"> <li> <p>the psychometric properties of the measuring instrument were described in a peer‐reviewed journal (<a href="./references#CD003079-bbs2-0105" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249-52.">Marshall 2000</a>); and </p> </li> <li> <p>the measuring instrument had not been written or modified by one of the trialists for that particular trial. </p> </li> </ul> </p> <p>Ideally, the measuring instrument was a self‐report or was completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in <a href="#CD003079-sec-0078">Description of studies</a>, we noted if this was the case or not. </p> </section> <section id="CD003079-sec-0039"> <h6 class="title">2.3. Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. However, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if endpoint data were not available. Because endpoint and change data are combined in the analysis, we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD003079-sec-0040"> <h6 class="title">2.4. Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the problem of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: </p> <p> <ul id="CD003079-list-0003"> <li> <p>standard deviations (SDs) and means were reported in the paper or obtainable from the authors; </p> </li> <li> <p>when a scale starts from the finite number zero, the SD is more than the mean, this is considered strong evidence of skew (<a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>); </p> </li> <li> <p>if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases, skew is present if SD &gt; (S ‐ S<sub>min</sub>), where S is the mean score and S<sub>min</sub> is the minimum score. Where skewed data were present, we presented results in a separate table. </p> </li> </ul> </p> <p>Skewed endpoint data from trials of fewer than 200 participants were entered in additional tables rather than into an analysis. Skewed endpoint data pose less of a problem when looking at means if the sample size is large (over 200 participants) and these were entered into syntheses. </p> <p>When continuous data are presented on a scale that includes the possibility of negative values (such as change data), it is difficult to determine whether data are skewed or not; we entered change data from both large and small trials. </p> </section> <section id="CD003079-sec-0041"> <h6 class="title">2.5. Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that could be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month) if necessary. </p> </section> <section id="CD003079-sec-0042"> <h6 class="title">2.6. Direction of graphs</h6> <p>We entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for benzodiazepines alone, or (in the absence of a benzodiazepine alone) benzodiazepines in combination with antipsychotics. </p> </section> </section> </section> <section id="CD003079-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HZ and JX) independently assessed risk of bias using criteria described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> to assess trial quality (<a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where the raters disagreed, the final rating was made by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the trials to obtain further information. Non‐concurrence in quality assessment was reported, but where disputes arose as to which category a trial was to be allocated, we resolved issues by discussion. </p> <p>The level of risk of bias was noted in both the text of the review and in the 'Summary of findings' tables. </p> </section> <section id="CD003079-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <section id="CD003079-sec-0045"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD003079-bbs2-0076" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405-11.">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD003079-bbs2-0082" title="DeeksJ . Issues in the selection for meta-analyses of binary data. In: 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa. 2000.">Deeks 2000</a>). If heterogeneity was identified (<a href="#CD003079-sec-0058">Assessment of heterogeneity</a>), we used a random‐effects model to explore whether this had an effect on findings. For statistically significant results, we used 'Summary of findings' tables to calculate the number needed to treat for an additional beneficial or harmful outcome and its 95% CI. </p> </section> <section id="CD003079-sec-0046"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we calculated estimated MD between groups as change and endpoint data were combined. If scales of considerable similarity had been used, we would have presumed there was a small difference in measurement, calculated the effect size and transformed the effect back to the units of one or more of the specific instruments. However, data of this type were not identified. </p> </section> </section> <section id="CD003079-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <section id="CD003079-sec-0048"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ cluster randomisation (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. First, authors often fail to account for intraclass correlation in clustered trials, leading to a 'unit of analysis' error (<a href="./references#CD003079-bbs2-0083" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623-9.">Divine 1992</a>) whereby P values are spuriously low, CIs unduly narrow and statistically significant difference overestimated. This causes type I errors (<a href="./references#CD003079-bbs2-0075" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600.">Bland 1997</a>; <a href="./references#CD003079-bbs2-0092" title="GullifordMC . Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876-83.">Gulliford 1999</a>). </p> <p>None of the present included trials used cluster randomisation. For the purposes of future updates of this review, where clustering is not accounted for in primary studies, we will present data in a table, with an * symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of trials to obtain intraclass correlation coefficients for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD003079-bbs2-0092" title="GullifordMC . Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876-83.">Gulliford 1999</a>). Where clustering may be incorporated into the analysis of primary studies, we will present these data as if from a non‐cluster randomised study, but adjust for the clustering effect. </p> </section> <section id="CD003079-sec-0049"> <h5 class="title">2. Cross‐over trials</h5> <p>None of the present included trials employed a cross‐over trial design; for the purposes of future updates of this review, a major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a washout phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD003079-bbs2-0086" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we will only use data of the first phase of cross‐over trials. </p> </section> <section id="CD003079-sec-0050"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if two or more of the interventions were similar, we pooled data. If data were binary, these were simply added. If data were continuous, we combined data following the formula in Section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Where the additional treatment arms were not relevant, we did not use these data. </p> </section> </section> <section id="CD003079-sec-0051"> <h4 class="title">Dealing with missing data</h4> <section id="CD003079-sec-0052"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD003079-bbs2-0124" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El-SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254-7.">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for in either group, we would not present these data or use them within analyses (except for the outcome 'leaving the study early'). </p> </section> <section id="CD003079-sec-0053"> <h5 class="title">2. Binary</h5> <p>Where attrition for a binary outcome was between 0% and 50%, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis) by including those leaving the study early in the denominator. </p> </section> <section id="CD003079-sec-0054"> <h5 class="title">3. Continuous</h5> <section id="CD003079-sec-0055"> <h6 class="title">3.1. Attrition</h6> <p>Where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we presented and used these data. </p> </section> <section id="CD003079-sec-0056"> <h6 class="title">3.2. Standard deviations</h6> <p>If SDs were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and CIs available for group means, and either P value or t value available for differences in mean, we could calculate them according to the rules described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). When only the SE was reported, SDs were calculated by the formula SD = SE × square root (n). Sections 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> present detailed formulae for estimating SDs from P values, t or F values; CIs; ranges or other statistics (<a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). If these formulae did not apply, we calculated the SDs according to a validated imputation method, which is based on the SDs of the other included trials (<a href="./references#CD003079-bbs2-0089" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7-10.">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. Where the only variance given was range (<a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>), SDs were also estimated from the difference between the upper and lower value divided by four. </p> </section> <section id="CD003079-sec-0057"> <h6 class="title">3.3. Last observation carried forward</h6> <p>We anticipated that some trials would employ the method of last observation carried forward (LOCF) within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD003079-bbs2-0102" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?Schizophrenia Bulletin2007;33(1):183-91. [PMID: 16905632]">Leucht 2007</a>). Therefore, where LOCF data were used in the trial, if less than 50% of the data had been assumed, we would have presented and used these data and indicated that they were the product of LOCF assumptions. Where LOCF were not used, data were analysed as they were presented in the original publications. </p> </section> </section> </section> <section id="CD003079-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD003079-sec-0059"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included trials initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all trials for clearly outlying people or situations that we had not predicted would arise. When such situations or participant groups arose, these implications were covered in the <a href="#CD003079-sec-0162">Discussion</a>. </p> </section> <section id="CD003079-sec-0060"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included trials initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all trials for clearly outlying methods that we had not predicted would arise. When such methodological differences arose, these were considered in the <a href="#CD003079-sec-0162">Discussion</a>. </p> </section> <section id="CD003079-sec-0061"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD003079-sec-0062"> <h6 class="title">3.1. Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD003079-sec-0063"> <h6 class="title">3.2. Employing the I<sup>2</sup> statistic </h6> <p>Heterogeneity between trials was investigated by considering the I<sup>2</sup> statistic alongside the Chi<sup>2</sup> statistic (P &gt; 0.10). The I<sup>2</sup> statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD003079-bbs2-0094" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Chichester (UK): John Wiley &amp; Sons, 2008.">Higgins 2008</a>). The importance of the observed value of I<sup>2</sup> statistic depends on the magnitude and direction of effects and the strength of evidence for heterogeneity (e.g. P value from the Chi<sup>2</sup> test, or a CI for the I<sup>2</sup> statistic). An I<sup>2</sup> statistic estimate of 50% or greater accompanied by a statistically significant Chi<sup>2</sup> statistic is interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2; <a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). When there were substantial levels of heterogeneity in the primary outcome, we explored reasons for heterogeneity (<a href="#CD003079-sec-0068">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD003079-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD003079-sec-0065"> <h5 class="title">1. Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). We attempted to locate protocols of included randomised trials. If the protocol was available, outcomes in the protocol and in the published report were compared. If the protocol was not available, outcomes listed in the methods section of the trial report were compared with actually reported results. </p> </section> <section id="CD003079-sec-0066"> <h5 class="title">2. Funnel plot</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD003079-bbs2-0085" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). These are described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003079-bbs2-0095" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer trials, or where all trials were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. Because there were more data available for the secondary outcome of sedation, we completed a funnel plot analysis for this outcome (<a href="#CD003079-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003079-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 benzodiazepines versus antipsychotics, outcome: 2.1 Tranquillisation or asleep: 1. sedation." data-id="CD003079-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 benzodiazepines versus antipsychotics, outcome: 2.1 Tranquillisation or asleep: 1. sedation. </p> </div> </div> </div> </section> </section> <section id="CD003079-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different trials are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between trials even if there is no statistically significant heterogeneity. However, there is a disadvantage to the random‐effects model as it puts added weight onto small trials, which often are the most biased ones. Depending on the direction of effect, these trials can either inflate or deflate the effect size. We chose a fixed‐effect model for all analyses, and if heterogeneity was identified, we used a random‐effects model. </p> <p>As this is a review of the effects on acute psychosis, we included only those outcomes up to and including 48 hours after the initial dose of medication. Where data were for more than one time interval within the immediate (zero to 15 minutes), short term (15 minutes to one hour) and medium term (one to 48 hours) categories, we used the earlier data. The only exception to this were the data from <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; this trial reported Clinical Global Impression (CGI) data at four and 24 hours (medium term) but because the loss to follow‐up was more than 50% for one group at four hours and complete at 24 hours, we used the latter data. </p> </section> <section id="CD003079-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD003079-sec-0069"> <h5 class="title">1. Subgroup analyses</h5> <p>Subgroup analyses were carried out for different antipsychotics.</p> </section> <section id="CD003079-sec-0070"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, this was reported. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and if the results of trials were clearly different, these data were not pooled. Where there was evidence of substantial statistical heterogeneity data (<a href="./references#CD003079-fig-0057" title="">Analysis 5.1</a>; <a href="./references#CD003079-fig-0061" title="">Analysis 5.5</a>; <a href="./references#CD003079-fig-0024" title="">Analysis 2.9</a>), these were also analysed using a random‐effects model and any differences in the results of fixed‐effect and random‐effects models covered in the <a href="#CD003079-sec-0162">Discussion</a>. Possible reasons for identified heterogeneity are also considered in the <a href="#CD003079-sec-0162">Discussion</a>. </p> </section> </section> <section id="CD003079-sec-0071"> <h4 class="title">Sensitivity analysis</h4> <section id="CD003079-sec-0072"> <h5 class="title">1. Implication of randomisation</h5> <p>If trials were described in some way as to imply randomisation, we undertook a sensitivity analyses for the primary outcome. We included these studies in the analyses and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we used relevant data from these studies. </p> </section> <section id="CD003079-sec-0073"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD003079-sec-0051">Dealing with missing data</a>), we compared the findings of the primary outcome when we used our assumption compared with completer data only. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption. </p> <p>Where assumptions had to be made regarding missing SDs data (see <a href="#CD003079-sec-0051">Dealing with missing data</a>), we compared the findings of the primary outcome when we used our assumption compared with completer data only. We undertook a sensitivity analysis testing how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption. </p> </section> <section id="CD003079-sec-0074"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation for the meta‐analysis of the primary outcome (see <a href="#CD003079-sec-0043">Assessment of risk of bias in included studies</a>). If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we included data from these trials in the analysis </p> </section> <section id="CD003079-sec-0075"> <h5 class="title">4. Imputed values</h5> <p>We undertook a sensitivity analysis to assess the effects of including data from trials where we used imputed values for intraclass correlation coefficients in calculating the design effect in cluster randomised trials. If we found substantial differences in the direction or precision of effect estimates, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately. </p> </section> <section id="CD003079-sec-0076"> <h5 class="title">5. Fixed and random effects</h5> <p>We synthesised data using a fixed‐effect model, however, we also synthesised data for the primary outcome using a random‐effects model to evaluate whether this altered the significance of the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003079-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003079-sec-0077"></div> <section id="CD003079-sec-0078"> <h3 class="title">Description of studies</h3> <section id="CD003079-sec-0079"> <h4 class="title">Results of the search</h4> <p>The update searches were undertaken on two occasions; August 2015 (75 references) and August 2016 (three references), totalling 78 new references. With the addition of the previous search results, we screened 2497 references. Of which, 2428 references were excluded after viewing the titles and abstracts and 84 full‐text reports were obtained for further screening. Forty‐eight studies (with 52 full‐text reports) were excluded due to ineligible study design, participants or comparisons. Finally, 20 studies (with 32 full‐text reports) were included in the review (see <a href="#CD003079-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD003079-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003079-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003079-sec-0080"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD003079-sec-0221" title="">Characteristics of included studies</a> table for descriptions of each study. This updated review adopted a different means of presenting included studies. We decided to present included studies in such a way as to describe the type of benzodiazepine employed in the study, as well as the year and country in which the study was undertaken. For example, in the study that was referenced in the previous review as 'Qu 1999', participants received either clonazepam 2 mg or haloperidol 10 mg and the study was undertaken in China in 1999; therefore, it is now presented as <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>. We felt that this method, although unconventional, would be most suitable way to present the findings in a logical and concise manner, as results are clustered in graphs for ease of understanding. </p> <p>The review included 20 trials. This is the total of the 17 trials from the previous review and three after the latest search (<a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a>; <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a>). In this 2016 update, we changed the inclusion criteria to include the comparison of antihistamines/anticholinergics in combination with antipsychotics, as we considered that a review of the effect of benzodiazepines for psychosis‐induced aggression should take into account the potential use of antihistamines for the treatment of psychosis‐induced aggression due to its potential sedative and anticholinergic properties and the widespread use of this combination. The inclusion criteria were clarified to specify the inclusion of benzodiazepines either alone or in combination with any other antipsychotic drug, versus placebo, non‐pharmacological approaches, other benzodiazepines or antipsychotics alone, or combined with any other antipsychotic, antihistaminic/anticholinergic drugs or other benzodiazepine<i>.</i> The inclusion criteria were further refined to ensure that the benzodiazepine was the same in the intervention and comparator arm of the trials where benzodiazepine alone was compared to benzodiazepine combined with antipsychotic. This enabled us to detect whether the apparent effect was due to combination with an antipsychotic. Where a combination of benzodiazepine with an antipsychotic was compared to another benzodiazepine combined with an antipsychotic, it was ensured that the antipsychotic was the same in both the intervention and the comparator arm. This allowed us to detect whether the apparent effect was due to the superiority of one benzodiazepine over another. Moreover, this had the result of permitting the exclusion of previously included studies, which were excluded due to comparing benzodiazepines plus antipsychotics versus different antipsychotics (<a href="./references#CD003079-bbs2-0031" title="HanZ , WangL , WangJ . Efficacy of risperidone, clonazepam in the treatment of excitement state of schizophrenia. Ningxia Medical Journal2005;27(9):631-2. ">Han 2005</a>; <a href="./references#CD003079-bbs2-0056" title="WangG , CaiZJ , WangLF . A multicenter study of risperidone treatment for acute agitation in patients with schizophrenia. Chinese Journal of Psychiatry2004;37(2):88-91. ">Wang 2004</a>; <a href="./references#CD003079-bbs2-0060" title="YangX , WangZ , LingZ . A randomly controlled comparison of risperidone added with intramuscular clonazepam in the treatment of excitement of schizophrenia. Shanghai Archives of Psychiatry2003;15(2):98-9. ">Yang 2003</a>; <a href="./references#CD003079-bbs2-0063" title="ZhangHS . Study of olanzapine combined with clonazepam in treatment of schizophrenia with acute psychomotor excitation. Linchuang Jingshen Yixue Zazhi2007;17(4):239-40. ">Zhang 2007</a>). </p> <p>One trial compared benzodiazepines with placebo (<a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>); 11 trials compared benzodiazepines with antipsychotics (<a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>; <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>; <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>); five trials compared benzodiazepines combined with antipsychotics with the same benzodiazepines alone (<a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>); six trials compared benzodiazepines combined with antipsychotics with the same antipsychotics alone (<a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>); four trials compared benzodiazepines with antihistamines combined with antipsychotics (<a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>); one trial compared benzodiazepines combined with antipsychotics versus two different antipsychotics (<a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>); and one trial compared benzodiazepines combined with antipsychotics versus antipsychotics and antihistamines (<a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>). Seven trials had with multiple treatment arms (<a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>; <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>; <a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>). </p> <section id="CD003079-sec-0081"> <h5 class="title">1. Setting</h5> <p>Three trials were set in general emergency departments (<a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>; <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>); five trials were set in psychiatric hospitals (<a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>; <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>); one was implied as having taken place in a psychiatric hospital (<a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>); and one within a general hospital (<a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>). Five trials were conducted in psychiatric emergency departments (<a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>; <a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>); one trial took place in a locked intensive care unit (<a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>); two trials were implied as having taken place in a Chinese hospital (<a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>); one trial was conducted in a institute of mental health in India (<a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a>), one trial did not state the settings of enrolling participants (<a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a>). The majority of these trials took place in the Americas, followed by China, India, Israel, Canada, Australia, Romania, South Africa and South Korea. </p> </section> <section id="CD003079-sec-0082"> <h5 class="title">2. Length of trials</h5> <p>The duration of included trials varied from one hour (<a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>) to seven days (<a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>), and two weeks (<a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>), although only data up to 48 hours were included for this review. </p> </section> <section id="CD003079-sec-0083"> <h5 class="title">3. Participants</h5> <p>Participants in seven of the included trials appeared to have been inpatients (<a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>; <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>; <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>), while in 12 trials, participants appeared to have been newly admitted (<a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>; <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; <a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>; <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>; <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>; <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>), and in one trial, participants were a mixture of inpatients and new admissions (<a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>). </p> <p>In most trials, participants were of mixed diagnoses (<a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>; <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; <a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>; <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>; <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>; <a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>). Participants in <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> were diagnosed as having schizophrenia and in <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>, participants had schizophrenia with agitation/aggression. In <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a> and <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a>, the diagnosis was not explicit but was described as a 'mental illness/psychotic diagnosis.' </p> </section> <section id="CD003079-sec-0084"> <h5 class="title">4. Trial size</h5> <p>The overall sample size in all the included trials was generally small. The total number of participants in each trial ranged from 16 (<a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>) to 301 (<a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>). </p> </section> <section id="CD003079-sec-0085"> <h5 class="title">5. Interventions</h5> <section id="CD003079-sec-0086"> <h6 class="title">5.1. Benzodiazepines versus placebo</h6> <p>We were able to include one trial comparing benzodiazepines with placebo (<a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>). This trial compared one to three IM injections of lorazepam (2 mg to 5 mg) with IM placebo. </p> </section> <section id="CD003079-sec-0087"> <h6 class="title">5.2. Benzodiazepines versus antipsychotics</h6> <p>Eleven trials compared benzodiazepines with antipsychotics. Four trials compared lorazepam with haloperidol (<a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>); three trials compared lorazepam 2 mg versus haloperidol 5 mg (<a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>); and one trial compared lorazepam 4 mg to haloperidol 5 mg (<a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>). In all these trials, both interventions were given as an IM injection, although in the trial by <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>, participants were able to receive the administered dose as an oral concentrate. Medications were given as a single injection in the trials by <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a> and <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>. In the trial by <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>, doses were administered every 30 minutes for four hours or until the participant was sedated. Additional doses could be given in the trial by <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>, where the mean number of doses of lorazepam was 1.13 and haloperidol was 1.10. Participants in <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> could have been given up to six doses over eight hours although the majority (71% of participants receiving haloperidol and 74% receiving lorazepam) received fewer than three doses. <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a> compared lorazepam 2 mg to 5 mg IM with olanzapine 10 mg to 25 mg IM. In this trial, participants received one to three doses based on the clinical judgement of 'the investigator.' </p> <p>In the remaining trials that compared benzodiazepines with antipsychotics, three compared IM clonazepam with IM haloperidol (<a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>; <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>). <a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a> compared clonazepam 1 mg to 2 mg with haloperidol 5 mg to 10 mg at 0 minutes, 30 minutes and one hour. <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a> compared clonazepam 2 mg with haloperidol 10 mg. <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a> compared clonazepam 2 mg to 6 mg with haloperidol 5 mg to 15 mg. <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a> compared single doses of flunitrazepam 1 mg with haloperidol 5 mg. The trial by <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a> compared diazepam (mean dose 35 mg over three hours) with high‐dose haloperidol (35 mg over three hours) and low‐dose haloperidol (20 mg over three hours) and <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a> compared clonazepam 2 mg IM with haloperidol 10 mg IM. <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a> compared midazolam 5 mg with droperidol 10 mg, both of which were given intravenously, with repeat doses given until sedation was achieved. </p> </section> <section id="CD003079-sec-0088"> <h6 class="title">5.3. Benzodiazepines plus antipsychotics versus same benzodiazepines</h6> <p>Five trials compared a combination of lorazepam with haloperidol versus lorazepam alone. <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> and <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a> compared lorazepam 2 mg plus haloperidol 5 mg with lorazepam 2 mg alone while <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a> compared lorazepam 4 mg plus haloperidol 5 mg with lorazepam 4 mg. All were given by IM injection. <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a> compared lorazepam 2 mg IM plus risperidone 2 mg oral, or lorazepam 2 mg IM plus haloperidol 5 mg oral with lorazepam 2 mg IM (plus oral placebo). <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a> compared clonazepam 2 mg to 6 mg IM plus haloperidol 5 mg to 15 mg IM with clonazepam 2 mg to 6 mg IM (plus placebo). <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a> and <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a> gave single doses. Participants in <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a> could receive a second dose within the first hour, and in <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> participants could be given up to six doses over eight hours. In <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>, the participant received at least one dose but no more than three doses. However, majority of participants received fewer than three doses. </p> </section> <section id="CD003079-sec-0089"> <h6 class="title">5.4. Benzodiazepines plus antipsychotics versus same antipsychotics</h6> <p>We found six trials comparing combined benzodiazepines/antipsychotics with the same antipsychotics alone. In each study, benzodiazepines were combined with and compared with haloperidol; <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> compared alprazolam 1 mg plus haloperidol 5 mg with haloperidol 5 mg plus placebo; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> compared lorazepam 2 mg plus haloperidol 5 mg with haloperidol 5 mg alone; and <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a> compared lorazepam 4 mg plus haloperidol 5 mg with haloperidol 5 mg. <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a> compared clonazepam 2 mg to 6 mg IM plus haloperidol 5 mg to 15 mg IM with haloperidol 5 mg to 15 mg IM (plus placebo). All drugs were administered as an IM injection. In the trials by <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a> single doses were given; in <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> medications were administered as a daily oral dose although additional doses could be given if the psychosis scores were high; and in <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>, 9% of the participants receiving both drugs and 29% of the participants receiving haloperidol were given three or more doses. <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a> compared midazolam 15 mg combined with haloperidol 5 mg IM versus haloperidol 5 mg IM. </p> </section> <section id="CD003079-sec-0090"> <h6 class="title">5.5. Benzodiazepines versus antipsychotics plus antihistamines</h6> <p>We found three trials comparing benzodiazepines versus antipsychotics plus antihistamines (<a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>). Two were large, higher‐quality trials that compared the effects of benzodiazepines versus combined haloperidol/promethazine. In <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>, midazolam 15 mg IM (with flumazenil made available for use in the event of midazolam toxicity) was compared with haloperidol 5 mg to 10 mg IM (77 participants received 5 mg, 71 participants received 10 mg) combined with promethazine 25 mg to 50 mg IM (147 participants received 50 mg, one participant received 25 mg). Similarly, <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a> compared lorazepam 4 mg IM with haloperidol 10 mg IM combined with promethazine 25 mg to 50 mg IM (96 participants received 50 mg, four participants received 25 mg); all doses were given at the discretion of the treating physician. <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a> compared lorazepam 4 mg IM with haloperidol 10 mg IM. </p> </section> <section id="CD003079-sec-0091"> <h6 class="title">5.6. Benzodiazepines plus antipsychotics versus antipsychotics plus antipsychotics</h6> <p>One trial compared benzodiazepines plus antipsychotics versus antipsychotics plus antipsychotics (<a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>). The trial compared lorazepam 4 mg IM with clotiapine 40 mg IM given at six hourly intervals 'if warranted.' Both groups also received haloperidol 10 mg IM at the same time. </p> </section> <section id="CD003079-sec-0092"> <h6 class="title">5.7. Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines</h6> <p>One trial compared benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines (<a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>). The trial compared midazolam 15 mg plus haloperidol 5 mg (each administered IM) with promethazine 50 mg plus haloperidol 5 mg (each administered IM). After the initial dose, only additional doses of combined haloperidol/promethazine could be used, according to clinical judgement. If a participant needed another intervention, he or she were immediately removed from the study. </p> </section> </section> <section id="CD003079-sec-0093"> <h5 class="title">6. Outcomes scales</h5> <p>The trials used the following outcome scales.</p> <section id="CD003079-sec-0094"> <h6 class="title">6.1. Global state</h6> <p>1.1. Clinical Global Impression (CGI, <a href="./references#CD003079-bbs2-0077" title="BusnerJJ , TargumSD . The Clinical Global Impressions scale: applying a research tool in clinical practice. Psychiatry2007;4(7):28-37.">Busner 2007</a>; <a href="./references#CD003079-bbs2-0093" title="GuyW , BonatoRR . Clinical global impressions. In: GuyW , BonatoRR , editors(s). Manual for the ECDEU Assessment Battery. 2 edition. Bethesda (MD),: National Institute of Mental Health, 1970:12-1-12-6.">Guy 1970</a>) (high = worse). </p> <p>The CGI scale was designed to quantify severity of illness and overall clinical improvement in people with a psychiatric disorder. A 7‐point scoring system is usually used for severity and improvement with lower scores indicating decreased severity or greater recovery, or both. <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>; <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; and <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a> used this scale. <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a> dichotomised scores by defining a reduction of at least 3 points on the CGI as improvement. <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a> dichotomised the outcomes of this scale to present outcomes of those clinically improved. </p> <p>6.1.2. Ramsay Sedation Scale (RSS, <a href="./references#CD003079-bbs2-0113" title="RamsayMA , SavegeTM , SimpsonBR , GoodwinR . Controlled sedation with alphaxalone-alphadolone. British Medical Journal1974;2:656-9.">Ramsay 1974</a>) </p> <p>The RSS is a six‐item rating scale used to assess levels of sedation by selecting the most appropriate level of response. A rating of one indicates an agitated, anxious state, and a rating of six indicates an unresponsive state. <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a> reported data using this scale. </p> </section> <section id="CD003079-sec-0095"> <h6 class="title">6.2. Behaviour</h6> <p>6.2.1. Agitated Behaviour Scale (ABS, <a href="./references#CD003079-bbs2-0081" title="CorriganJD , MysiwWJ . Agitation following traumatic head injury. Archives of Physical Medicine and Rehabilitation1988;69:487-92.">Corrigan 1988</a>) (high = worse) </p> <p>The ABS was originally developed in response to the need to make serial assessments of agitation during the acute period following traumatic brain injury (<a href="./references#CD003079-bbs2-0079" title="CaplanB . Reliability of the Agitated Behaviour Scale. Journal of Head Trauma Rehabilitation1999;14(1):91-6.">Caplan 1999</a>). It originally consisted of 39 items, but was subsequently reduced to 14 items following validation and includes a range of agitated behaviour, such as short attention span, impulsiveness, violence/threatening violence, unco‐operativeness, restlessness and repetitive behaviour. The 14‐item ratings range on a scale of one to four, with one indicating the absence of agitated behaviour, and four indicating the extreme presence of agitated behaviour. <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a> used this scale. <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> also used this scale, but presented skewed data (see <a href="./references#CD003079-sec-0199" title="">Data and analyses</a>). </p> <p>6.2.2. Overt Aggression Scale (OAS, <a href="./references#CD003079-bbs2-0125" title="YudofskySC , SilverJM , JacksonW , EndicottJ , WilliamsD . The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry1986;143(1):35-9.">Yudofsky 1986</a>) (high = worse) </p> <p>The OAS is designed to assess observable aggressive or violent behaviour and consists of four categories: verbal aggression, physical aggression against objects, physical aggression against self and physical aggression against other people. Within each category, there are four types of aggressive behaviour listed. <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>; and <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a> used this scale. <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a> defined improvement as a reduction of at least 4 points on the OAS and <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a> defined improvement as a decrease of 50% or more. <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a> also used this scale, defining improvement as a 'greater than mean decrease' in scores at two hours. </p> <p>6.2.3. Overt Agitation Severity Scale (OASS, <a href="./references#CD003079-bbs2-0126" title="YudofskySC , KopeckyHJ , KunikM , SilverJM , EndicottJ . The Overt Agitation Severity Scale for the objective rating of agitation. Journal of Neuropsychiatry1997;9(4):541-8.">Yudofsky 1997</a>) (high = worse) </p> <p>The OASS is designed to define and objectively rate the severity of agitated behaviour and confines its rating exclusively to observable behavioural manifestations of agitation. This comprises three categories: vocalisations and oral/facial movements, upper torso and upper extremity movements, and lower extremity movements, each with four types of agitated behaviour listed. These types of behaviour are rated on a 0‐ to 4‐point scale, with 0 = not present and 4 = always present. <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a> reported data using this scale. </p> <p>6.2.4. Positive and Negative Symptom Scale (PANSS, <a href="./references#CD003079-bbs2-0099" title="KaySR , FiszbeinA , OplerLA . The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261-76.">Kay 1987</a>) (high = worse) </p> <p>PANSS was developed from the Brief Psychiatric Rating Scale (BPRS) and the Psychopathology Rating Scale. It is used to evaluate positive, negative and other symptom dimensions in schizophrenia. The scale has 30 items, each measured on a 7‐point scoring system varying from one (absent) to seven (extreme). <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>; however, data were skewed for <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>. <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a> each reported data from the PANSS‐Excited Component subscale (PANSS‐EC); <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a> defined a reduction of 40% or more on the PANSS‐EC as a measure of improvement. </p> </section> <section id="CD003079-sec-0096"> <h6 class="title">6.3. Mental state</h6> <p>6.3.1. Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD003079-bbs2-0110" title="OverallJE , HollisterLE , PichotP . Major psychiatric disorders: a four dimensional model. Archives of General Psychiatry1967;16(2):146-51.">Overall 1967</a>; <a href="./references#CD003079-bbs2-0117" title="ShaferA . Meta-analysis of the Brief Psychiatric Rating Scale factor structure. Psychological Assessment2005;17(3):324-35.">Shafer 2005</a>) (high = worse) </p> <p>The BPRS lists a range of psychiatric symptoms generally associated with the domains of anxiety and depression, hostility and suspiciousness, thought disturbance and withdrawal/motor retardation. The original scale has 16 items, but a revised 18‐item scale is commonly used. Each item is rated on a 7‐point scale varying from 'not present' to 'extremely severe.' <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>, <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; and <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a> reported data from this scale. <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> and <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> also reported data using the 11 psychosis‐anxiety items from the BPRS, classified as the BPRS‐psychosis subscale (<a href="./references#CD003079-bbs2-0088" title="FaustmanWO , MosesJA , CsernanskyJG , WhitePA . Correlations between the MMPI and the Brief Psychiatric Rating Scale in schizophrenic and schizoaffective patients. Psychiatry Research1989;28:135-43.">Faustman 1989</a>). <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a> reported skew data from this scale. </p> <p>6.3.2. Inpatient Multidimensional Psychiatric Scale (IMPS, <a href="./references#CD003079-bbs2-0078" title="CairnsV , vonZerssenD , StutteKH , MombourW . The stability of the symptom groupings in the Inpatient Multidimensional Psychiatric Scale (IMPS). Journal of Psychiatric Research1983;17(1):19-28.">Cairns 1983</a>; <a href="./references#CD003079-bbs2-0103" title="LorrM , KlettCJ , McNairDM , LaskyJJ . Inpatient Multidimensional Psychiatric Scale. Palo Alto (CA): Consulting Psychologists Press, 1963.">Lorr 1963</a>) </p> <p>The IMPS measures psychotic symptom scales in psychiatric inpatients. It originally consisted of 75 items and 10 domains. The addition of another 15 items resulted in 12 domains: excitement, hostile belligerence, grandiose expansiveness, paranoid projection, perceptual distortions, anxious depression, retardation and apathy, conceptual disorganisation, motor disturbances, disoriented behaviour, impaired functioning and obsessive‐phobic. The IMPS was used by <a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a> who reported a reduction of at least 50% as improvement. </p> </section> </section> </section> <section id="CD003079-sec-0097"> <h4 class="title">Excluded studies</h4> <p>We excluded 48 studies (with 52 full‐text reports). See <a href="./references#CD003079-sec-0222" title="">Characteristics of excluded studies</a> table. </p> <p> <ul id="CD003079-list-0004"> <li> <p>Four trials did not appear to be randomised (<a href="./references#CD003079-bbs2-0021" title="AranaGW , OrnsteenML , KanterF , FriedmanHL , GreenblattDJ , ShaderRI . The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacology Bulletin1986;22(1):77-87. ">Arana 1986</a>; <a href="./references#CD003079-bbs2-0043" title="梁芝国, 罗维肖. Clonazepam and haloperidol on patients with acute agitation control study [氯硝西泮和氟哌啶醇联用治疗急性激越的对照研究]. Medical Journal of Chinese Civil Administration2003;15(5):293-4. ">Liang 2003</a>; <a href="./references#CD003079-bbs2-0051" title="CurrierGW , SimpsonGM . Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Journal of Clinical Psychiatry2001;62(3):135-7. SimpsonGM , MoreinJD , Reyes-HardeM , GharabawiG . A pragmatic and convenient approach for the management or acute agitation: results from a series of clinical studies. In: 16th European College of Neuropsychopharmacology Congress; 2003 Sept 20-24; Prague, Czech Republic. ">Simpson 2003</a>; <a href="./references#CD003079-bbs2-0062" title="YuJ . Risperidone combined clonazepam controlled study of the treatment of acute schizophrenia [利培酮合并氯硝西泮治疗急性期精神分裂症的对照研究]. Nervous Diseases and Mental Hygiene2006;6(2):129-30. ">Yu 2006</a>). </p> </li> <li> <p>Participants in eight trials were agitated without psychosis, retarded catatonia or not acutely psychotic (<a href="./references#CD003079-bbs2-0029" title="GharabawiG , TurkozI , PandinaG . Emergency treatment of acute agitation in patients with schizophrenia and schizoaffective disorder: oral risperidone + lorazepam versus IM haloperidol + lorazepam. International Congress on Schizophrenia Research Biennial Meeting; 2003 Mar 29-Apr 2; Colorado Springs (CO). ">Gharabawi 2003</a>; <a href="./references#CD003079-bbs2-0042" title="LenoxRH , NewhousePA , CreelmanWL , WhitakerTM . Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. Journal of Clinical Psychiatry1992;53(2):47-52. ">Lenox 1992</a>; <a href="./references#CD003079-bbs2-0048" title="NestorosJN . Diazepam in high doses is effective in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry1982;6(4-6):513-6. ">Nestoros 1982</a>; <a href="./references#CD003079-bbs2-0049" title="NobayF , SimonBC , LevittMA , DresdenGM . A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Academic Emergency Medicine2004;11(7):744-9. ">Nobay 2004</a>; <a href="./references#CD003079-bbs2-0050" title="RichardsJR , DerletRW , DuncanDR . Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. Journal of Emergency Medicine1998;16(4):567-73. ">Richards 1998</a>; <a href="./references#CD003079-bbs2-0057" title="WetzelH , KlaweCJ , MullerMJ , WiesnerJ , BenkertO . Lorazepam for stupor and mutism: a double-blind placebo-controlled cross-over study. 10th European College of Neuropsychopharmacology Congress; 1997 Sept 13-17; Vienna, Austria. [MEDLINE: 1494594]">Wetzel 1997</a>). <a href="./references#CD003079-bbs2-0044" title="MartelM , SterzingerA , MinerJ , ClintonJ , BirosM . Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Academic Emergency Medicine2005;12(12):1167-72. ">Martel 2005</a> was excluded because agitation appeared to be due to alcohol intoxication in 93% of participants. <a href="./references#CD003079-bbs2-0038" title="IsbisterGK , CalverLA , PageCB , StokesB , BryantJL , DownesMA . Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Annals of Emergency Medicine2010;56(4):392-401. ">Isbister 2010</a> was excluded because it enrolled participants with acutely disturbed/aggressive/agitated behaviour believed to be secondary to psychotic illnesses. </p> </li> <li> <p>19 trials had ineligible comparisons (<a href="./references#CD003079-bbs2-0023" title="CurrierGW , SimpsonGA . Risperidone oral solution versus intramuscular haloperidol for control of psychotic agitation. European Neuropsychopharmacology2000;10(Suppl 3):S296. ">Currier 2000</a>; <a href="./references#CD003079-bbs2-0024" title="CurrierGW , ChouJC , FeifelD , BossieCA , TurkozI , MahmoudR , et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Journal of Clinical Psychiatry2004;65(3):386-94. [MEDLINE: 15096079]">Currier 2004</a>; <a href="./references#CD003079-bbs2-0031" title="HanZ , WangL , WangJ . Efficacy of risperidone, clonazepam in the treatment of excitement state of schizophrenia. Ningxia Medical Journal2005;27(9):631-2. ">Han 2005</a>; <a href="./references#CD003079-bbs2-0035" title="侯春兰, 侯凌峰, 张东升, 董继雪. Risperidone oral solution with lorazepam treatment of schizophrenia excited state [利培酮口服液合并劳拉西泮治疗精神分裂症兴奋状态]. China Journal of Health Psychology [中国健康心理学杂志]2011;19(7):787-9. [MEDLINE: Biosis:prev201100319442]">Hou 2011</a>; <a href="./references#CD003079-bbs2-0036" title="HufG , CoutinhoESF , AdamsCE . Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ2007;335(7625):869-72. [MEDLINE: 17954515]">Huf 2007</a>; <a href="./references#CD003079-bbs2-0037" title="HwangTJ , ChenYH , HuangLC , HuangGH , HwuHG . Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam in the treatment of acute agitation in schizophrenia. European Neuropsychopharmacology2012;22(Suppl 2):S333-S4. ">Hwang 2012</a>; <a href="./references#CD003079-bbs2-0040" title="KinonB , RotelliMD , GilmoreJA . Efficacy of olanzapine and adjunctive lorazepam to control agitation in schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S128. ">Kinon 2002</a>; <a href="./references#CD003079-bbs2-0041" title="KinonBJ , AhlJ , RotelliMD , McMullenE . Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. American Journal of Emergency Medicine2004;22(3):181-6. [MEDLINE: 15138953]">Kinon 2004</a>; <a href="./references#CD003079-bbs2-0046" title="NCT00797277. IM olanzapine versus IM haloperidol plus lorazepam for acute agitation in schizophrenia. clinicaltrials.gov/ct2/show/study/NCT00797277 (accessed prior to 17 October 2008). ">NCT00797277</a>; <a href="./references#CD003079-bbs2-0047" title="NCT00859872. Efficacy and safety of risperidone oral solution combination clonazepam versus haloperidol intramuscular (IM) injection for treatment of acute psychotic agitation in schizophrenia. clinicaltrials.gov/ct2/show/NCT00859872 (accessed prior to 17 October 2017). ">NCT00859872</a>; <a href="./references#CD003079-bbs2-0054" title="VeraksaA , EgorovA . Pharmacotherapy of acute psychotic states: the reason for benzodiazepines and valproic acid augmentation. European Psychiatry2016;33:S612. ">Veraksa 2016</a>; <a href="./references#CD003079-bbs2-0056" title="WangG , CaiZJ , WangLF . A multicenter study of risperidone treatment for acute agitation in patients with schizophrenia. Chinese Journal of Psychiatry2004;37(2):88-91. ">Wang 2004</a>; <a href="./references#CD003079-bbs2-0058" title="WuZ . Risperidone combined clonazepam treatment of acute schizophrenia psychomotor excitement [利培酮合并氯硝西泮治疗精神分裂症急性精神运动性兴奋的研究]. Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao][齊齊哈爾醫學院學報]2006;27(5):536-7. WuZ . The combination of risperidone clonazepam in the treatment of acute schizophrenia research psychomotor excitement [利培酮合用氯硝西泮治疗精神分裂症急性精神运动性兴奋的研究]. Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao][齊齊哈爾醫學院學報]2006;27(8):913-4. ">Wu 2006</a>; <a href="./references#CD003079-bbs2-0060" title="YangX , WangZ , LingZ . A randomly controlled comparison of risperidone added with intramuscular clonazepam in the treatment of excitement of schizophrenia. Shanghai Archives of Psychiatry2003;15(2):98-9. ">Yang 2003</a>; <a href="./references#CD003079-bbs2-0061" title="YangS . Quetiapine combination clonazepam diazepam treatment of acute schizophrenia clinical studies of excitement [奎硫平合用氯硝西泮治疗精神分裂症急性期兴奋的临床研究]. Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao][齊齊哈爾醫學院學報]2006;27(9):1034-5. ">Yang 2006</a>; <a href="./references#CD003079-bbs2-0063" title="ZhangHS . Study of olanzapine combined with clonazepam in treatment of schizophrenia with acute psychomotor excitation. Linchuang Jingshen Yixue Zazhi2007;17(4):239-40. ">Zhang 2007</a>; <a href="./references#CD003079-bbs2-0065" title="ZhongY . Risperidone combining clonazepam and haloperidol in the treatment of first episode of acute schizophrenia clinical control study [利培酮合并氯硝西泮与氟哌啶醇治疗首发精神分裂症急性期的临床对照研究]. 中国医药导报2006;3(32):69-70. ">Zhong 2006</a>; <a href="./references#CD003079-bbs2-0067" title="周升宝, 孙晓丹, 庞琦, 李志梅, 赵继舒, 张峰. 齐拉西酮联合氯硝西泮治疗精神分裂症急性期兴奋激越症状对照研究. 长治医学院学报2014;20(2):17-20. ">Zhou 2014</a>; <a href="./references#CD003079-bbs2-0068" title="ZhuC , FuR , YangY . Sodium valproate and clonazepam for the treatment of agitated symptoms of patients with schizophrenia: a controlled trial. Medical Journal of the Chinese People's Armed Police Forces2005;16(12):934-5. [MEDLINE: 18433659]">Zhu 2005</a>). </p> </li> <li> <p>None of the outcomes of interest were reported in 17 trials within the 48‐hour time period (<a href="./references#CD003079-bbs2-0022" title="陈琦, 薄奇静, 迟勇, 赵幸福, 李晓驷, 谭云龙, et al. 齐拉西酮合并氯硝西泮治疗急性期伴激越精神分裂症患者的对照研究. 临床精神医学杂志2012;4:217-9. ">Chen 2012</a>; <a href="./references#CD003079-bbs2-0025" title="DavisJM , WangB , HeY , JinH , HuQ , ZhangM . The emergency treatment of acutely agitated psychotic schizophrenia patients. International Journal of Neuropsychopharmacology2008;11(Suppl 1):163. ">Davis 2008</a>; <a href="./references#CD003079-bbs2-0026" title="邓云峰, 刘重阳, 刘峥嵘, 张威. The combination of risperidone clonazepam therapy of acute schizophrenia excited state efficacy [利培酮合用氯硝西泮治疗精神分裂症急性期兴奋状态疗效观察]. Chinese Journal of Practical Internal Medicine2004;24(8):496-7. ">Deng 2004</a>; <a href="./references#CD003079-bbs2-0028" title="GeQ , LiangX , WangX . A comparative study of risperidone combining clonazepam and haloperidol in the treatment of patients with schizophrenia. Shandong Archives of Psychiatry [山东精神医学]2004;17(3):134-6. ">Ge 2004</a>; <a href="./references#CD003079-bbs2-0030" title="GuzI , MoraesR , SartorettoJN . The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: a double blind study. Therapeutic Research Press1972;14(12):767-74. GuzI . Lorazepam and haloperidol in the treatment of schizophrenic patients [Lorazepam e haloperidol em esquizofrenia]. Jornal Brasileira de Psiquiatria1988;37(4):205-7. ">Guz 1972</a>; <a href="./references#CD003079-bbs2-0032" title="HankoffLD , RudorferL , PaleyHM . A reference study of ataraxics: a two-week double blind outpatient evaluation. Journal of New Drugs1962;2:173-8. ">Hankoff 1962</a>; <a href="./references#CD003079-bbs2-0033" title="HanlonTE , OtaKY , KurlandAA . Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine. Diseases of the Nervous System1970;31(3):171-7. ">Hanlon 1970</a>; <a href="./references#CD003079-bbs2-0034" title="何震, 吴延海, 翟长平. The clonazepam intramuscular combination of aripiprazole treatment of men with acute schizophrenia excited control study [氯硝西泮肌注合用阿立哌唑治疗男性精神分裂症急性兴奋的对照研究]. Medical Journal of Chinese Civil Administration [中国民康医学]2011;23(13):1588-9. [MEDLINE: Biosis:prev201100319442]">He 2011</a>; <a href="./references#CD003079-bbs2-0039" title="KangMX . Clinical study on efficacy of quetiapine combined with clonazepam treated with acute agitation in schizophrenia patients. Linchuang Jingshen Yixue Zazhi2006;16(4):221-2. ">Kang 2006</a>; <a href="./references#CD003079-bbs2-0045" title="MeiY , PanJPM . Clinical observation on acute excitation of schizophrenia treated with QIWEI combined with clonazepam. Chinese Nursing Research2006;20(5):1176-7. WangDB , XuSQ , TangQP , YingYF , MeiYT , HeFX . Treatment of 80 cases of schizophrenia manifesting acute erethitic symptoms with quetiapine combined with clonazepam. Herald of Medicine2005;24(8):687-8. ">Mei 2006</a>; <a href="./references#CD003079-bbs2-0052" title="StevensA , StevensI , MahalA , GaertnerHJ . Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Pharmacopsychiatry1992;25(6):273-7. [MEDLINE: 1494594]">Stevens 1992</a>; <a href="./references#CD003079-bbs2-0053" title="TangQ , YangL , LaiG , ZhandJ . A clinical study of risperidone oral solution combined with clonazepam injection in the treatment of acute excitement phase schizophrenia patient. Shanghai Archives of Psychiatry2007;19(3):153-5. ">Tang 2007</a>; <a href="./references#CD003079-bbs2-0055" title="WanZ , ZhongZ . Curative effect of risperidone with BDZs in the treatment of excitement and agitation with schizophrenia in acute phase. Chinese Journal of Health Psychology2005;13(1):23-4. ">Wan 2005</a>; <a href="./references#CD003079-bbs2-0059" title="WyantM , DiamondBI , O'NealE , SloanA , BorisonRL . The use of midazolam in acutely agitated psychiatric patients. Psychopharmacology Bulletin1990;26(1):126-9. ">Wyant 1990</a>; <a href="./references#CD003079-bbs2-0064" title="ZhangY . Efficacy of quetiapine combined clonazepam treatment of acute schizophrenia excited [喹硫平联合氯硝西泮治疗精神分裂症急性兴奋疗效观察]. Shandong Archives of Psychiatry [山东精神医学]2008;21(1):59-60. ">Zhang 2008</a>; <a href="./references#CD003079-bbs2-0066" title="周德祥, 蒋幸衍, 徐清, 方馨怡, 夏鸣华, 陆雅娜. 利培酮口服液合并氯硝西泮治疗精神分裂症兴奋激越症状的随机对照研究. 中国健康心理学杂志2012;8:1123-4. ">Zhou 2012</a>). </p> </li> </ul> </p> </section> </section> <section id="CD003079-sec-0098"> <h3 class="title">Risk of bias in included studies</h3> <p>For a summary of the overall risk of bias in included trials, see <a href="#CD003079-fig-0003">Figure 3</a> and <a href="#CD003079-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD003079-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003079-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003079-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003079-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD003079-sec-0099"> <h4 class="title">Allocation</h4> <p>All 20 included trials were described as randomised but overall the description of allocation and concealment was poor. Only <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>, <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>, and <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a> adequately described the process used for randomisation and the concealment of allocation. Four trials stated that a table of random numbers was used to allocate participants (<a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>). <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a> was described as a randomised trial but also referred to alternate allocation. There was no description of the method of allocation and concealment in the remaining trials. </p> </section> <section id="CD003079-sec-0100"> <h4 class="title">Blinding</h4> <section id="CD003079-sec-0101"> <h5 class="title">1. Blinding of participants</h5> <p>Twelve of the included trials were described as double blinded; however, the method of blinding was unclear (<a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>; <a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; <a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>; <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>; <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>; <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>), with only three trials explaining blinding methods (<a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>). </p> <p>Four trials were single/observer blinded (<a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>; <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>). <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a> and <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a> were blind up until point of treatment assignment. <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a> and <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a> were not blinded. <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a> and <a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a> did not state whether blinding was used. </p> </section> </section> <section id="CD003079-sec-0102"> <h4 class="title">Incomplete outcome data</h4> <p>High loss to follow‐up was where the number of participants lost to follow‐up was more than 5% in the first two hours or between 25% and 50% overall. In six of the trials, there was a high loss to follow‐up rate observed (<a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>; <a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>; <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>; <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>; <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>), and 12 trials had a low loss to follow‐up (<a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; <a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>; <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>; <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>). Two trials had unclear rate of loss to follow‐up, as only abstracts of these two trials are available (<a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a>; <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a>; see <a href="#CD003079-tbl-0011">Table 4</a>). </p> <div class="table" id="CD003079-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">High and low attrition studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% loss</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33% participants lost to follow‐up for EPS outcome and 12% loss for 'sedation'</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only abstract available.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only abstract available.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Trials were considered to have a high attrition rates if it was more than 5% within the first two hours or 25% to 50% overall. </p> <p>EPS: extrapyramidal symptoms.</p> </div> </div> </section> <section id="CD003079-sec-0103"> <h4 class="title">Selective reporting</h4> <p>Most of the studies were rated as low risk of bias in this domain as all measured outcomes of each study were reported. In <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>, there was a higher risk of bias noted, as the trial authors changed the criteria for 'improvement' (using a visual analogue scale (VAS) post‐study, after analysis had taken place. We considered there were potential risks of selective reporting in four trials: <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> did not report the data measured by Simpson‐Angus Side Effects Profile. <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a> did not report the SD of BPRS and CGI. <a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a> and <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a> were reported as abstracts, so it is unclear whether there was selective reporting. </p> </section> <section id="CD003079-sec-0104"> <h4 class="title">Other potential sources of bias</h4> <section id="CD003079-sec-0105"> <h5 class="title">Funding sources</h5> <p>Six trials were funded by pharmaceutical companies:</p> <p><a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> was supported in part by a grant from The Upjohn Company (now Pfizer); <a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a> was partially funded by Hoffmann La Roche Ltd; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a> was supported in part by Wyeth Laboratories; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> was supported in part by a grant from Wyeth‐Ayerst Research (now also part of Pfizer); and <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a> was funded by a grant from Janssen Pharmaceutica. However, as the study did not reveal more information, we are unsure whether the pharmaceutical companies were involved in the study design and reporting process. <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a> was funded by Lilly Research Laboratories, Indiana, and developed a rating scale for use in the study (which was excluded from analysis); 90% of the trial authors of this study were also employed by the same pharmaceutical company. Therefore, the company was probably involved in the study design and reporting process, and we suspect there is conflict of interests. </p> <p>Other sources of funding include support from the National Alliance for Research on Schizophrenia and Depression (<a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>); a postgraduate scholarship from the National Health and Medicine Research Council and a research grant from the Australasian College for Emergency Medicine (Morson Taylor Award, <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>); a grant from the Gralnick Foundation, High Point Hospital, Port Chester, New York (<a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>); funding from Fundação Oswaldo Cruz, the British Council, CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and FAPERJ (Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>); funding by intramural research grants from Fluid Research Fund (Christian Medical College, Vellore), and the Cochrane Schizophrenia Group general fund (<a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>). American John M Davis Funding supported the <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a> study. </p> <p>Eight trials did not reveal information about funding source: <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>; <a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a>; <a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>. </p> </section> </section> </section> <section id="CD003079-sec-0106"> <h3 class="title" id="CD003079-sec-0106">Effects of interventions</h3> <p>See: <a href="./full#CD003079-tbl-0001"><b>Summary of findings 1</b> Benzodiazepines compared to placebo for psychosis‐induced aggression or agitation</a>; <a href="./full#CD003079-tbl-0002"><b>Summary of findings 2</b> Benzodiazepines compared to antipsychotics for psychosis‐induced aggression or agitation</a>; <a href="./full#CD003079-tbl-0003"><b>Summary of findings 3</b> Benzodiazepines compared to antihistamines plus antipsychotics for psychosis‐induced aggression or agitation</a>; <a href="./full#CD003079-tbl-0004"><b>Summary of findings 4</b> Benzodiazepines + antipsychotics compared to same enzodiazepines for psychosis‐induced aggression or agitation</a>; <a href="./full#CD003079-tbl-0005"><b>Summary of findings 5</b> Benzodiazepines + antipsychotics compared to same antipsychotics for psychosis‐induced aggression or agitation</a>; <a href="./full#CD003079-tbl-0006"><b>Summary of findings 6</b> Benzodiazepines plus antipsychotics compared to antipsychotics plus antipsychotics for psychosis‐induced aggression or agitation</a>; <a href="./full#CD003079-tbl-0007"><b>Summary of findings 7</b> Benzodiazepines plus antipsychotics compared to antihistamines plus antipsychotics for psychosis‐induced aggression or agitation</a> </p> <section id="CD003079-sec-0107"> <h4 class="title">Comparison 1: Benzodiazepines versus placebo</h4> <p>All data for this comparison came from <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>) (n = 102). This comparison has 11 outcomes. </p> <section id="CD003079-sec-0108"> <h5 class="title">1.1 Tranquillisation or asleep</h5> <p>There was no clear difference between the benzodiazepine and placebo groups in the number of people who were sedated (n = 102, RR 1.67, 95% CI 0.42 to 6.61, <a href="./references#CD003079-fig-0005" title="">Analysis 1.1</a>, <i>very low quality evidence</i>). </p> </section> <section id="CD003079-sec-0109"> <h5 class="title">1.2. Behaviours</h5> <p>There was a clear difference with ABS scores in favour of participants allocated to benzodiazepine (n = 101, MD ‐3.61, 95% CI ‐5.92 to ‐1.30, <a href="./references#CD003079-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD003079-sec-0110"> <h5 class="title">1.3 to 1.5 Global state</h5> <p>There was no clear difference in the number of people who had not improved in the short term (n = 102, RR 0.89, 95% CI 0.69 to 1.16) but fewer people receiving benzodiazepines were rated as not improved in the medium term (n = 102, RR 0.62, 95% CI 0.40 to 0.97, <a href="./references#CD003079-fig-0007" title="">Analysis 1.3</a>, <i>very low quality evidence</i>). There was no clear difference between benzodiazepine and placebo in the number of people who needed additional medication (n = 102, RR 1.00, 95% CI 0.69 to 1.44, <a href="./references#CD003079-fig-0008" title="">Analysis 1.4</a>, <i>very low quality evidence</i>). The mean change in CGI scores was also comparable (n = 76, MD 0.07, 95% CI ‐0.46 to 0.60, <a href="./references#CD003079-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD003079-sec-0111"> <h5 class="title">1.6 to 1.7 Mental state</h5> <p>There was no clear difference between groups in the change in PANSS (n = 99, MD ‐2.57, 95% CI ‐6.23 to 1.09, <a href="./references#CD003079-fig-0010" title="">Analysis 1.6</a>) or PANSS excited component scores (n = 101, MD ‐1.91, 95% CI ‐3.83 to 0.01, <a href="./references#CD003079-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD003079-sec-0112"> <h5 class="title">1.8 to 1.10 Adverse effects/events</h5> <p>There was no clear difference between benzodiazepine and placebo in EPS (n = 102, RR 0.33, 95% CI 0.04 to 3.10, <a href="./references#CD003079-fig-0012" title="">Analysis 1.8</a>, <i>very low quality evidence</i>) or receiving medication for EPS (n = 102, RR 0.33, 95% CI 0.04 to 3.10, <a href="./references#CD003079-fig-0013" title="">Analysis 1.9</a>) There was no clear difference in dizziness, nausea and vomiting (<a href="./references#CD003079-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD003079-sec-0113"> <h5 class="title">1.11 Leaving study early</h5> <p>There was no clear difference in leaving the study early for any reason (n = 102, RR 0.60, 95% CI 0.15 to 2.38, <a href="./references#CD003079-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD003079-sec-0114"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, none of the studies reported hospital and service outcomes, satisfaction with treatment or economic outcomes. </p> </section> </section> <section id="CD003079-sec-0115"> <h4 class="title">Comparison 2: Benzodiazepines versus antipsychotics</h4> <p>We included 11 trials comparing benzodiazepines with antipsychotics (<a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a>; <a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a>; <a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>; <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>; <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>). </p> <section id="CD003079-sec-0116"> <h5 class="title">2.1 Tranquillisation or asleep</h5> <p>There was no clear difference in the number of people sedated when benzodiazepines were compared with haloperidol in the short term (n = 44, 1 RCT, RR 1.17, 95% CI 0.53 to 2.59) or medium term (n = 434, 8 RCTs, RR 1.13, 95% CI 0.83 to 1.54, <i>low quality evidence</i>) or olanzapine in the medium term (n = 150, 1 RCT, RR 0.75, 95% CI 0.28 to 1.98). However, people receiving benzodiazepines were more likely to be sedated in the short term when compared with people receiving droperidol (n = 153, 1 RCT, RR 2.71, 95% CI 1.55 to 4.73). The differences between subgroups were significant (Chi<sup>2</sup> = 8.77, P = 0.03, I<sup>2</sup> = 66%, <a href="./references#CD003079-fig-0016" title="">Analysis 2.1</a>. </p> </section> <section id="CD003079-sec-0117"> <h5 class="title">2.2 to 2.3 Behaviours</h5> <p>People receiving olanzapine scored significantly lower on the Agitated Behaviour Scale (ABS) in the medium term (n = 149,1 RCT, MD 2.91, 95% CI 0.80 to 5.02) but there was no difference when haloperidol was compared with lorazepam (n = 66,1 RCT, MD 1.80, 95% CI ‐2.39 to 5.99, <a href="./references#CD003079-fig-0017" title="">Analysis 2.2</a>). There was no significant difference in OAS scores at medium term when clonazepam was compared with haloperidol (n = 46, 1 RCT, MD 0.20, 95% CI ‐0.57 to 0.97, <a href="./references#CD003079-fig-0018" title="">Analysis 2.3</a>). </p> </section> <section id="CD003079-sec-0118"> <h5 class="title">2.4 to 2.7 Global state</h5> <p>More people in the benzodiazepines group were likely to be rated as not improved in the medium term (n = 150, 1 RCT, RR 1.84, 95% CI 1.06 to 3.18, <i>very low quality evidence</i> ) when compared with olanzapine but there was no clear difference in the short term (n = 150, 1 RCT, RR 1.26, 95% CI 0.95 to 1.66) or when benzodiazepines were compared with haloperidol in the medium term (n = 188, 5 RCTs, RR 0.89, 95% CI 0.71 to 1.11, <i>low quality evidence</i>). <a href="./references#CD003079-fig-0019" title="">Analysis 2.4</a> </p> <p>People receiving benzodiazepines were no more likely to need additional medication compared with those receiving droperidol in the short term (n = 153, 1 RCT, RR 1.87, 95% CI 0.83 to 4.19) or haloperidol in the medium term (n = 66, 1 RCT, RR 0.87, 95% CI 0.70 to 1.09, <i>very low quality evidence</i> ). However, participants receiving lorazepam were more likely to require additional medication than those receiving olanzapine in the medium term (n = 150, 1 RCT, RR 2.02, 95% CI 1.33 to 3.07, <i>very low quality evidence</i>); <a href="./references#CD003079-fig-0020" title="">Analysis 2.5</a>. </p> <p>CGI change/endpoint scores for the short term favoured lorazepam when compared with haloperidol (n = 37, 1 RCT, MD ‐0.67, 95% CI ‐1.09 to ‐0.25). Because of the marked heterogeneity of medium‐term data, these were not pooled. Results clearly favoured lorazepam compared with haloperidol (n = 37, 1 RCT, MD ‐0.81, 95% CI ‐1.37 to ‐0.25). There was no clear difference when diazepam was compared with haloperidol (n = 40, 1 RCT, MD 0.60, 95% CI ‐0.17 to 1.37) or when olanzapine was compared with lorazepam (n = 147, 1 RCT, MD 0.14, 95% CI ‐0.15 to 0.43). (All in <a href="./references#CD003079-fig-0021" title="">Analysis 2.6</a>). There was also no clear difference in IMPS scores in the medium term when clonazepam was compared with haloperidol (n = 16, 1 RCT, MD 2.60, 95% CI ‐3.04 to 8.24, <a href="./references#CD003079-fig-0022" title="">Analysis 2.7</a>). </p> </section> <section id="CD003079-sec-0119"> <h5 class="title">2.8 to 2.14 Mental state</h5> <p>When no clinical improvement was defined as the decrease rate of BPRS score less than 30%, there was no clear difference between clonazepam and haloperidol (n = 30, 1 RCT, RR 0.93, 95% CI 0.73 to 1.18, <a href="./references#CD003079-fig-0023" title="">Analysis 2.8</a>). There was no clear difference in BPRS scores in the short term (n = 37, 1 RCT, MD ‐3.26, 95% CI ‐10.65 to 4.13) or medium term (n = 123, 3 RCTs, MD 1.67, 95% CI ‐1.84 to 5.18), <a href="./references#CD003079-fig-0024" title="">Analysis 2.9</a>). As the medium‐term data were heterogenous (Chi<sup>2</sup> = 4.43, P = 0.11, I<sup>2</sup> = 55%), we used a random‐effects model but these results were also equivocal (n = 123, 3 RCTs, MD 1.18, 95% CI ‐4.18 to 6.53). In the medium term, there was no difference between people receiving lorazepam or haloperidol in BPRS psychosis subscale scores (n = 66, 1 RCT, MD = 0.70, 95% CI ‐7.20 to 8.60, <a href="./references#CD003079-fig-0025" title="">Analysis 2.10</a>). For BPRS positive subscale and excited component subscale, there was no clear difference between clonazepam and haloperidol (n = 30, 1 RCT, MD 0.80, 95% CI ‐1.83 to 3.43, <a href="./references#CD003079-fig-0026" title="">Analysis 2.11</a>; n = 30, 1 RCT, MD 1.27, 95% CI ‐0.49 to 3.03, <a href="./references#CD003079-fig-0027" title="">Analysis 2.12</a>). For people receiving antipsychotics, the change in PANSS (n = 146, 1 RCT, MD 5.64, 95% CI 2.20 to 9.08, <a href="./references#CD003079-fig-0028" title="">Analysis 2.13</a>) and PANSS excited component scores were significantly better for people receiving olanzapine compared to those receiving lorazepam (n = 149, 1 RCT, MD 2.85, 95% CI 1.14 to 4.56, <a href="./references#CD003079-fig-0029" title="">Analysis 2.14</a>). </p> </section> <section id="CD003079-sec-0120"> <h5 class="title">2.15 to 2.17 Adverse effects/events</h5> <p>EPS were significantly lower in the group receiving benzodiazepines compared with those receiving haloperidol (n = 233, 6 RCTs, RR 0.13, 95% CI 0.04 to 0.41, <i>low quality evidence</i>) and cumulatively (n = 536, 8 RCTs, RR 0.15, 95% CI 0.06 to 0.39). There was no difference in the single trials where lorazepam was compared with olanzapine (n = 150, 1 RCT, RR 0.24, 95% CI 0.03 to 1.89) and midazolam was compared with droperidol (n = 153, 1 RCT, RR 0.15, 95% CI 0.01 to 2.90), <a href="./references#CD003079-fig-0030" title="">Analysis 2.15</a>. People receiving antipsychotics were no more likely to require medication for EPS (n = 216, 2 RCT, RR 0.40, 95% CI 0.15 to 1.05) or the single trials that compared lorazepam with haloperidol (n = 66, 1 RCT, RR 0.50, 95% CI 0.17 to 1.47) or olanzapine (n = 150, 1 RCT, RR 0.24, 95% CI 0.03 to 1.89). <a href="./references#CD003079-fig-0031" title="">Analysis 2.16</a>. </p> <p>There were no differences in the number of people experiencing specific adverse effects: airway management, akathisia, ataxia, low blood pressure, dizziness, dry mouth, drowsiness, hypoxia, high or low heart rates, nausea or vomiting, seizures, speech disorder or tremor when compared with people receiving antipsychotics. However, these results all came from single trials (<a href="./references#CD003079-fig-0032" title="">Analysis 2.17</a>). </p> </section> <section id="CD003079-sec-0121"> <h5 class="title">2.18 Leaving study early</h5> <p>There was no clear difference between groups at medium term for leaving the study early (n = 339, 3 RCTs, RR 1.48, 95% CI 0.70 to 3.13, <a href="./references#CD003079-fig-0033" title="">Analysis 2.18</a>). </p> </section> <section id="CD003079-sec-0122"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, none of the studies reported hospital and service outcomes, satisfaction with treatment or economic outcomes. </p> </section> </section> <section id="CD003079-sec-0123"> <h4 class="title">Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines</h4> <p>Two trials compared benzodiazepines versus antipsychotics + antihistamines (<a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>). </p> <section id="CD003079-sec-0124"> <h5 class="title">3.1 Tranquillisation or asleep</h5> <p>The two trials presented conflicting results for sedation (<a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>; <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>). People receiving lorazepam were less likely to be sedated compared with haloperidol and promethazine in the immediate term (n = 200, 1 RCT, RR 0.88, 95% CI 0.77 to 0.99), short term (n = 200, 1 RCT, RR 0.85, 95% CI 0.77 to 0.95) and medium term (n = 200, 1 RCT, RR 0.91, 95% CI 0.84 to 0.98, <i>low quality evidence</i>), while people receiving midazolam were more likely to be sedated in the short term (n = 301, 1 RCT, RR 1.32, 95% CI 1.16 to 1.49) and medium term (n = 301, 1 RCT, RR 1.13, 95% CI 1.04 to 1.23, <a href="./references#CD003079-fig-0034" title="">Analysis 3.1</a>, <i>low quality evidence</i>) compared to those receiving combined haloperidol/promethazine mix. Because of the high degree of heterogeneity (short term: Chi<sup>2</sup> = 30.06; I<sup>2</sup> = 97%; medium term: Chi<sup>2</sup> = 14.31; I<sup>2</sup> = 93%), data from these trials were not pooled (see <a href="#CD003079-sec-0163">Summary of main results</a>). </p> </section> <section id="CD003079-sec-0125"> <h5 class="title">3.2 to 3.4 Global state</h5> <p>One study reported most of these outcomes (<a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>). More people receiving lorazepam had not improved compared to those receiving combined haloperidol/promethazine in the immediate term (n = 200, 1 RCT, RR 1.79, 95% CI 1.36 to 2.37), short term (n = 200, 1 RCT, RR 2.47, 95% CI 1.51 to 4.03), and medium term (n = 200, 1 RCT, RR 2.17, 95% CI 1.16 to 4.05, <i>low quality evidence).</i><a href="./references#CD003079-fig-0035" title="">Analysis 3.2</a>. Neither group required additional medication in the immediate term and there was no clear difference between groups in the short term (n = 200, RR 3.00, 95% CI 0.12 to 72.77) and medium term (n = 200, RR 1.33, 95% CI 0.31 to 5.81, <i>low quality evidence).</i><a href="./references#CD003079-fig-0036" title="">Analysis 3.3</a>. </p> <p>One study reported mean CGI scores (<a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>). The scores were higher in participants receiving combined haloperidol/promethazine than participants receiving benzodiazepines alone in the immediate term (n = 200, 1 RCT, MD 0.49, 95% CI 0.23 to 0.75) and short term (n = 200, 1 RCT, MD 0.60, 95% CI 0.34 to 0.86), but not the medium term (n = 200, 1 RCT, MD 0.23, 95% CI ‐0.05 to 0.51). <a href="./references#CD003079-fig-0037" title="">Analysis 3.4</a>. </p> </section> <section id="CD003079-sec-0126"> <h5 class="title">3.5 Adverse effects/events</h5> <p>There were no clear differences in the specific adverse events: airway management (n = 501, 2 RCTs, RR 2.99, 95% CI 0.31 to 28.54), nausea (n = 200, 1 RCT, RR 3.00; 95% CI 0.12 to 72.77) or seizure (n = 301, 1 RCT, RR 0.33, 95% CI 0.01 to 8.06) when midazolam or lorazepam were compared with combined haloperidol/promethazine. <a href="./references#CD003079-fig-0038" title="">Analysis 3.5</a> </p> </section> <section id="CD003079-sec-0127"> <h5 class="title">3.6 Hospital and service outcomes</h5> <p>There was no clear difference in the number of people 'not discharged' in each treatment group (n = 200, medium term RR 1.13, 95% CI 0.86 to 1.48, <a href="./references#CD003079-fig-0039" title="">Analysis 3.6</a>). </p> </section> <section id="CD003079-sec-0128"> <h5 class="title">3.7 Leaving study early</h5> <p>There was no clear difference in people lost to follow‐up when midazolam and lorazepam were compared with combined haloperidol/promethazine (n = 501, 2 RCTs, RR 0.43, 95% CI 0.06 to 2.87, <a href="./references#CD003079-fig-0040" title="">Analysis 3.7</a>). </p> </section> <section id="CD003079-sec-0129"> <h5 class="title">Missing outcomes</h5> <p>For this comparions, non of the studies reported data for mental state, hospital and service outcomes, satisfaction with treatment or economic outcomes. </p> </section> </section> <section id="CD003079-sec-0130"> <h4 class="title">Comparison 4: Benzodiazepines plus antipsychotics versus same benzodiazepines</h4> <p>Five trials reported data comparing benzodiazepines plus antipsychotics versus same benzodiazepines (<a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a>). </p> <section id="CD003079-sec-0131"> <h5 class="title">4.1 Tranquillisation or asleep</h5> <p>Sedation was higher in the combined lorazepam/haloperidol group than the lorazepam only group in the short term (n = 47, 1 RCT, RR 1.92, 95% CI 1.10 to 3.35), although there was no difference in the medium term (n = 110, 2 RCTs, RR 0.84, 95% CI 0.59 to 1.19, <i>low quality evidence</i>). <a href="./references#CD003079-fig-0041" title="">Analysis 4.1</a>. </p> </section> <section id="CD003079-sec-0132"> <h5 class="title">4.2 Behaviours</h5> <p>Medium‐term ABS scores for people receiving lorazepam were similar to those receiving combined lorazepam/haloperidol treatment (n = 63, 1 RCT, RR ‐1.60, 95% CI ‐5.94 to 2.74, <a href="./references#CD003079-fig-0042" title="">Analysis 4.2</a>). </p> </section> <section id="CD003079-sec-0133"> <h5 class="title">4.3 to 4.4 Global state</h5> <p>There was no clear difference in improvement when people who received combined lorazepam/haloperidol were compared to people receiving lorazepam in the short term (n = 20, 1 RCT, RR 0.11, 95% CI 0.01 to 1.74) or medium term (n = 113, 3 RCTs, RR 0.96, 95% CI 0.76 to 1.20, <i>low quality evidence</i> ), or compared to people receiving combined lorazepam/risperidone in the medium term (n = 20, 1 RCT, RR 0.86, 95% CI 0.45 to 1.64, <i>low quality evidence</i>). <a href="./references#CD003079-fig-0043" title="">Analysis 4.3</a>. There was no clear difference in the number of participants requiring additional medication when lorazepam was compared with combined lorazepam/haloperidol in the medium term (n = 103, 3 RCTs, RR 1.02, 95% CI 0.79 to 1.32, <i>low quality evidence)</i>, with no instances reported when comparing combined lorazepam/risperidone with lorazepam alone. <a href="./references#CD003079-fig-0044" title="">Analysis 4.4</a>. </p> </section> <section id="CD003079-sec-0134"> <h5 class="title">4.5 to 4.12 Mental state</h5> <p>When no clinical improvement was defined as the decrease rate of BPRS score less than 30%, there was no clear difference between clonazepam and haloperidol (n = 30, 1 RCT, RR 1.00 CI 0.76 to 1.32, <a href="./references#CD003079-fig-0045" title="">Analysis 4.5</a>). </p> <p>There was no clear difference between people who received combined lorazepam/antipsychotics compared with people who received lorazepam alone for BPRS (short term: n = 20, 1 RCT, MD 1.10, 95% CI ‐23.17 to 25.37; medium term: n = 20, 1 RCT, MD ‐1.70, 95% CI ‐24.26 to 20.86). <a href="./references#CD003079-fig-0046" title="">Analysis 4.6</a>. BPRS psychosis subscale (n = 63, 1 RCT, MD 1.20, 95% CI ‐6.28 to 8.68, <a href="./references#CD003079-fig-0050" title="">Analysis 4.10</a>), BPRS positive subscale (n = 30, 1 RCT, MD 0.06, 95% CI ‐2.73 to 2.85, <a href="./references#CD003079-fig-0051" title="">Analysis 4.11</a>), BPRS excited component scale (n = 30, 1 RCT, MD ‐0.80, 95% CI ‐2.41 to 0.81, <a href="./references#CD003079-fig-0052" title="">Analysis 4.12</a>) and PANSS (short term: n = 20, 1 RCT, MD 6.40, 95% CI ‐36.50 to 49.30; medium term: n = 20, 1 RCT, MD 3.20, 95% CI ‐29.41 to 35.81, <a href="./references#CD003079-fig-0048" title="">Analysis 4.8</a>) . Data from <a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a> could not be added to the meta‐analysis for BPRS (<a href="./references#CD003079-fig-0047" title="">Analysis 4.7</a>) and PANSS scores (<a href="./references#CD003079-fig-0049" title="">Analysis 4.9</a>) because data appeared to be skewed. </p> </section> <section id="CD003079-sec-0135"> <h5 class="title">4.13 to 4.15 Adverse effects/events</h5> <p>There was no clear difference in EPS when comparing combined lorazepam/haloperidol with lorazepam alone (n = 83, 2 RCTs, RR 1.94, 95% CI 0.18 to 20.30, <a href="./references#CD003079-fig-0053" title="">Analysis 4.13</a>, <i>low quality evidence</i>), but <a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a> reported no instances of EPS in their study. There was also no clear difference in the need for medication for EPS (n = 63, 1 RCT, RR 0.73, 95% CI 0.18 to 2.99, <a href="./references#CD003079-fig-0054" title="">Analysis 4.14</a>), or any clear difference in the specific adverse events; akathisia, ataxia, dizziness, drowsiness, dry mouth or speech disorder, <a href="./references#CD003079-fig-0055" title="">Analysis 4.15</a>). </p> </section> <section id="CD003079-sec-0136"> <h5 class="title">4.16 Leaving study early</h5> <p>There was no clear difference in the number of people leaving the study early when lorazepam was compared with combined lorazepam/haloperidol (n = 40, 2 RCTs, RR 0.71, 95% CI 0.34 to 1.50) or combined lorazepam/risperidone (n = 20, 1 RCT, RR 0.86, 95% CI 0.45 to 1.64). <a href="./references#CD003079-fig-0056" title="">Analysis 4.16</a>. </p> </section> <section id="CD003079-sec-0137"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, none of the studies reported hospital and service outcomes, satisfaction with treatment or economic outcomes. </p> </section> </section> <section id="CD003079-sec-0138"> <h4 class="title">Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics</h4> <p>Six trials compared benzodiazepines plus antipsychotics versus same antipsychotics (<a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>; <a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a>; <a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a>; <a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a>; <a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a>; <a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>). All trials compared combined benzodiazepine/haloperidol with haloperidol alone. </p> <section id="CD003079-sec-0139"> <h5 class="title">5.1 Tranquillisation or asleep</h5> <p>Sedation was significantly more likely in the combined benzodiazepines/haloperidol group compared with haloperidol in the short term (n = 45, 1 RCT, RR 2.25, 95% CI 1.18 to 4.30) and medium term (n = 172, 3 RCTs, RR 1.75, 95% CI 1.14 to 2.67, <i>very low quality evidence</i>) when using a fixed‐effect model. However, the medium‐term results were highly heterogeneous (Chi<sup>2</sup> = 6.90, P = 0.03, I<sup>2</sup> = 71%) and no longer significant when a random‐effects model was used (n = 172, 3 RCTs, RR 1.67, 95% CI 0.67 to 4.12). <a href="./references#CD003079-fig-0057" title="">Analysis 5.1</a>. </p> </section> <section id="CD003079-sec-0140"> <h5 class="title">5.2 to 5.4 Behaviours</h5> <p>There was no clear difference in ABS agitation scores when lorazepam plus haloperidol was compared with haloperidol (n = 67, 1 RCT, MD ‐0.20, 95% CI ‐5.05 to 4.65, <a href="./references#CD003079-fig-0058" title="">Analysis 5.2</a>). OAS aggression scores were also not different when combined midazolam/haloperidol was compared with haloperidol in the short term (n = 60, 1 RCT, MD 1.20, 95% CI ‐0.04 to 2.44) but in the medium term favoured the haloperidol only group (n = 60, 1 RCT, MD 2.40, 95% CI 0.59 to 4.21). <a href="./references#CD003079-fig-0059" title="">Analysis 5.3</a>. Agitation scores using the OASS were significantly higher in the midazolam/haloperidol group compared with haloperidol in the short term (n = 60, 1 RCT, MD 8.50, 95% CI 7.07 to 9.93) and medium term (n = 60, 1 RCT, MD 6.70, 95% CI 5.94 to 7.46, <a href="./references#CD003079-fig-0060" title="">Analysis 5.4</a>). </p> </section> <section id="CD003079-sec-0141"> <h5 class="title">5.5 to 5.8 Global state</h5> <p>In the medium term, people who received combined benzodiazepines/haloperidol were no more likely to improve than those receiving haloperidol alone (n = 185, 4 RCTs, RR 1.17, 95% CI 0.93 to 1.46, <a href="./references#CD003079-fig-0061" title="">Analysis 5.5</a>, <i>low quality evidence</i>). These results were heterogeneous (Chi<sup>2</sup> = 11.15, P = 0.01, I<sup>2</sup> = 73%) but this was due to one small study contributing only 2.9% of weight to the analysis. The findings using a random‐effects model were very similar (n = 185, 4 RCTs, RR 1.04 CI 0.67 to 1.62). In the medium term, people receiving haloperidol alone were no more likely to require additional medication than those receiving combined lorazepam/haloperidol (n = 67, 1 RCT, RR 0.95, 95% CI 0.79 to 1.15). <a href="./references#CD003079-fig-0062" title="">Analysis 5.6</a>, <i>low quality evidence</i>). There was also no clear difference in mean doses of additional medication when midazolam plus haloperidol was compared with midazolam (n = 60, 1 RCT, MD 0.20, 95% CI ‐0.33 to 0.73, <a href="./references#CD003079-fig-0063" title="">Analysis 5.7</a>). Mean change scores for the RSS were significantly higher in the combined midazolam/haloperidol group when compared with haloperidol in the short term (n = 60, 1 RCT, MD 0.50, 95% CI ‐0.01 to 1.01) although this was not different in the medium term (n = 60, 1 RCT, MD 0.10, 95% CI ‐0.36 to 0.56). <a href="./references#CD003079-fig-0064" title="">Analysis 5.8</a>. </p> </section> <section id="CD003079-sec-0142"> <h5 class="title">5.9 to 5.13 Mental state</h5> <p>When clinical improvement was defined as the decrease rate of BPRS score less than 30%, there was no clear difference between clonazepam and haloperidol (n = 30, 1 RCT, RR 0.93, 95% CI 0.73 to 1.18, <a href="./references#CD003079-fig-0065" title="">Analysis 5.9</a>). <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> reported medium‐term BPRS scale data, with no significant difference between (n = 28, MD 0.01, 95% CI ‐7.26 to 7.28, <a href="./references#CD003079-fig-0066" title="">Analysis 5.10</a>). There was no different between groups receiving the combined treatment compared to benzodiazepine alone in the medium term for BPRS psychosis subscale scores (n = 95, 2 RCTs, MD ‐1.19, 95% CI ‐4.60 to 2.23, <a href="./references#CD003079-fig-0067" title="">Analysis 5.11</a>), BPRS positive scores (n = 30, 1 RCT, MD 0.86, 95% CI ‐1.62 to 3.34, <a href="./references#CD003079-fig-0068" title="">Analysis 5.12</a>) and BPRS excited component scores (n = 30, 1 RCT, MD 0.47, 95% CI ‐1.32 to 2.26). <a href="./references#CD003079-fig-0069" title="">Analysis 5.13</a>. </p> </section> <section id="CD003079-sec-0143"> <h5 class="title">5.14 to 5.16 Adverse effects/events</h5> <p>There was no clear difference in the rate of EPS (n = 127, 2 RCTs, RR 0.44, 95% CI 0.16 to 1.17, <a href="./references#CD003079-fig-0070" title="">Analysis 5.14</a>, <i>low quality evidence</i>) or medication for EPS (n = 95, 2 RCTs, RR 0.52, 95% CI 0.27 to 1.01, <a href="./references#CD003079-fig-0071" title="">Analysis 5.15</a>) when people receiving combined benzodiazepines/haloperidol were compared with those receiving haloperidol alone. There was no clear difference between groups when assessing specific adverse events (<a href="./references#CD003079-fig-0072" title="">Analysis 5.16</a>). </p> </section> <section id="CD003079-sec-0144"> <h5 class="title">5.17 Hospital and service outcomes</h5> <p>In <a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a>, there was no difference in participants who had not been discharged in the medium term (n = 28, 1 RCT, RR 0.90, 95% CI 0.54 to 1.50, <a href="./references#CD003079-fig-0073" title="">Analysis 5.17</a>). </p> </section> <section id="CD003079-sec-0145"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, none of the studies reported leaving the study early, satisfaction with treatment or economic outcomes. </p> </section> </section> <section id="CD003079-sec-0146"> <h4 class="title">Comparison 6: Benzodiazepines plus antipsychotics versus antipsychotics plus antipsychotics</h4> <p>One study compared benzodiazepines plus antipsychotics versus antipsychotics plus antipsychotics (<a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>). </p> <section id="CD003079-sec-0147"> <h5 class="title">6.1 Behaviour</h5> <p>There was no clear difference in medium‐term OAS scores when combined lorazepam/haloperidol was compared with combined clothiapine/haloperidol (n = 60, 1 RCT, MD ‐5.83, 95% CI ‐27.60 to 15.94, <a href="./references#CD003079-fig-0074" title="">Analysis 6.1</a>). </p> </section> <section id="CD003079-sec-0148"> <h5 class="title">6.2 Leaving the study early</h5> <p>The study reported no participants left the study early (<a href="./references#CD003079-fig-0075" title="">Analysis 6.2</a>). </p> </section> <section id="CD003079-sec-0149"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, none of the studies reported data for tranquilisation or asleep, global state, mental state, adverse effects/events, hospital and service outcomes, satisfaction with treatment or economic outcomes. </p> </section> </section> <section id="CD003079-sec-0150"> <h4 class="title">Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines</h4> <p>One study compared benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines (<a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>). </p> <section id="CD003079-sec-0151"> <h5 class="title">7.1 Tranquillisation or asleep</h5> <p>Medium‐term sedation was higher in the midazolam/haloperidol group (n = 60, 1 RCT, RR 12.00, 95% CI 1.66 to 86.59, <i>very low quality evidence,</i><a href="./references#CD003079-fig-0076" title="">Analysis 7.1</a>). </p> </section> <section id="CD003079-sec-0152"> <h5 class="title">7.2 to 7.3 Behaviours</h5> <p>OAS aggression scores in people receiving combined midazolam/haloperidol were significantly lower than scores in the combined promethazine/haloperidol group in the short term (n = 60, 1 RCT, MD ‐3.30, 95% CI ‐5.25 to ‐1.35), but there was no clear difference in the medium term (n = 60, 1 RCT, MD 1.70, 95% CI ‐0.06 to 3.46). <a href="./references#CD003079-fig-0077" title="">Analysis 7.2</a>. People who received combined midazolam/haloperidol scored lower on the OASS agitation scale in the short term (n = 60, 1 RCT, MD ‐16.00, 95% CI ‐18.98 to ‐13.02) and medium term (n = 60, 1 RCT, MD ‐2.70, 95% CI ‐3.73 to ‐1.67). <a href="./references#CD003079-fig-0078" title="">Analysis 7.3</a>. </p> </section> <section id="CD003079-sec-0153"> <h5 class="title">7.4 to 7.6 Global state</h5> <p>In the medium term, more people receiving combined midazolam/haloperidol had not improved (n = 60, 1 RCT, RR 25.00, 95% CI 1.55 to 403.99, <i>very low quality evidence,</i><a href="./references#CD003079-fig-0079" title="">Analysis 7.4</a>) and were given a higher dose of additional medication compared with the combined promethazine/haloperidol group (n = 60, 1 RCT, MD 0.63, 95% CI 0.15 to 1.11, <a href="./references#CD003079-fig-0080" title="">Analysis 7.5</a>). Short‐term RSS sedation scores (n = 60, 1 RCT, MD short term 0.60, 95% CI 0.07 to 1.13) were higher in the midazolam/haloperidol group, although there was no clear difference in medium‐term RSS scores (n = 60, 1 RCT, MD 0.00, 95% CI ‐0.46 to 0.46). <a href="./references#CD003079-fig-0081" title="">Analysis 7.6</a>. </p> </section> <section id="CD003079-sec-0154"> <h5 class="title">7.7 to 7.8 Adverse events</h5> <p>There was no clear difference between groups in the incidence of EPS in the medium‐term (n = 60, 1 RCT, RR 0.60, 95% CI 0.16 to 2.29, <i>very low quality evidence,</i><a href="./references#CD003079-fig-0082" title="">Analysis 7.7</a>) or hypotension (n = 60, 1 RCT, RR 1.67, 95% CI 0.44 to 6.36, <a href="./references#CD003079-fig-0083" title="">Analysis 7.8</a>). </p> </section> <section id="CD003079-sec-0155"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, none of the studies reported data for leaving the study early, hospital and service outcomes, satisfaction with treatment or economic outcomes. </p> </section> </section> <section id="CD003079-sec-0156"> <h4 class="title">Sensitivity analyses</h4> <p>We conducted sensitivity analyses for Comparison 2 (benzodiazepines versus antipsychotics) for the primary outcome of our primary outcome tranqulisation or asleep (sedation) and additional outcomes of global state 'improvement' and adverse effects 'extrapyramidal symptoms' as these analyses had the most available data. </p> <section id="CD003079-sec-0157"> <h5 class="title">8. Sensitivity analysis ‐ Randomised sequence generation</h5> <p>In trials rated as low risk of bias, people receiving benzodiazepines were significantly more likely to be sedated compared with people receiving antipsychotics (n = 247, 3 RCTs, RR 2.22, 95% CI 1.52 to 3.25) with slight heterogeneity (Chi<sup>2</sup> = 2.26, P = 0.32, I<sup>2</sup> = 11%); there was no clear difference between groups in trials where the method of sequence generation was unclear (n = 340, 6 RCTs, RR 0.84, 95% CI 0.56 to 1.26, <a href="./references#CD003079-fig-0084" title="">Analysis 8.1</a>). The test for differences between subgroups was significant and demonstrated high heterogeneity (Chi<sup>2</sup> = 11.86, P = 0.0006, I<sup>2</sup> = 91.6%). </p> <p>In trials rated as low risk of bias, there was no clear difference between groups in the numbers who had not improved (n = 124, 3 RCTs, RR 1.01, 95% CI 0.80 to 1.28, <a href="./references#CD003079-fig-0085" title="">Analysis 8.2</a>), neither was there any clear difference between groups in trials where the method of sequence generation was unclear (n = 214, 3 RCTs, RR 1.13, 95% CI 0.78 to 1.63); however, heterogeneity was high (Chi<sup>2</sup> = 9.34, P =.009, I<sup>2</sup> = 79%). The test for differences between subgroups was not significant (Chi<sup>2</sup> = 0.06, P = 0.81, I<sup>2</sup> = 0%). </p> <p>The estimates of EPS were similar in trials with a low risk of bias (n = 247, 3 RCTs, RR 0.16, 95% CI 0.03 to 0.85) and for trials that were unclear (n = 285, 5 RCTs, RR 0.15, 95% CI 0.05 to 0.47); both trials demonstrating a clear difference between benzodiazepines and antipsychotics (<a href="./references#CD003079-fig-0086" title="">Analysis 8.3</a>). There was no significant difference between subgroups (Chi<sup>2</sup> = 0.00, P = 0.95, I<sup>2</sup> = 0%). </p> </section> <section id="CD003079-sec-0158"> <h5 class="title">9. Sensitivity analysis ‐ Allocation concealment</h5> <p>People receiving benzodiazepines were more likely to be sedated in the one trial rated at low risk of bias for allocation concealment (n = 153, RR 2.71, 95% CI 1.55 to 4.73), although there was no clear difference between groups for those trials rated as unclear (n = 434, 8 RCTs, RR 1.08, 95% CI 0.79 to 1.48, <a href="./references#CD003079-fig-0087" title="">Analysis 9.1</a>). The difference between subgroups was clear and demonstrated high heterogeneity (Chi<sup>2</sup> = 7.86, P = 0.005, I<sup>2</sup> = 87.3%). </p> <p>All trials reporting improvement/no improvement were rated as having an unclear risk of bias. There was no clear difference in 'no improvement' (n = 338, 6 RCTs, RR 1.07, 95% CI 0.86 to 1.32); however, results displayed high heterogeneity (Chi<sup>2</sup> = 11.33, P = 0.05, I<sup>2</sup> = 56%, <a href="./references#CD003079-fig-0088" title="">Analysis 9.2</a>). </p> <p>The risk of EPS was similar in the benzodiazepine and antipsychotics group in one study at a low risk of bias (n = 153, RR 0.15, 95% CI 0.01 to 2.90) and slightly reduced in the seven trials with an unclear risk of allocation bias (n = 379, 7 RCTs, RR 0.15, 95% CI 0.06 to 0.41, <a href="./references#CD003079-fig-0089" title="">Analysis 9.3</a>). There was no significant difference between subgroups (Chi<sup>2</sup> = 0.00, P = 1.00, I<sup>2</sup> = 0%). </p> </section> <section id="CD003079-sec-0159"> <h5 class="title">10. Sensitivity analysis ‐ Blinded outcome measurement</h5> <p>There was a clear difference in the amount of people who were sedated in the benzodiazepines group in those trials that were rated at low risk of bias (n = 119, 2 RCTs, RR 1.66, 95% CI 1.05 to 2.64), but not in trials rated at unclear risk of bias (n = 424, 6 RCTs, RR 1.34, 95% CI 0.93 to 1.94) for blinded outcome measurement. There was also no clear change in trials exhibiting a high risk (n = 44, 1 RCT, RR 1.14, 95% CI 0.56 to 2.34); however, heterogeneity was high (<a href="./references#CD003079-fig-0090" title="">Analysis 10.1</a>). There was no clear difference between subgroups (Chi<sup>2</sup> = 0.89, P = 0.64, I<sup>2</sup> = 0%). </p> <p>In trials rated as having an unclear risk of bias, the rate of no improvement was similar between people receiving benzodiazepines and people receiving antipsychotics (n = 224, 4 RCTs, RR 1.18, 95% CI 0.88 to 1.59), the heterogeneity was high (Chi<sup>2</sup> = 12.97, P = 0.005; I<sup>2</sup> = 77%) and in trials rated at low risk of bias, there was no clear difference in improvement between groups (n = 114, 2 RCTs, RR 0.80, 95% CI 0.60 to 1.07), but heterogeneity was high (Chi<sup>2</sup> = 3.15, P = 0.08, I<sup>2</sup> = 68%); differences between subgroups were significant with high heterogeneity (Chi<sup>2</sup> = 3.36, P = 0.07, I<sup>2</sup> = 70.2%, <a href="./references#CD003079-fig-0091" title="">Analysis 10.2</a>). </p> <p>There was a clearly decreased risk of EPS in people receiving benzodiazepines, irrespective of whether trials were rated as low risk of bias (n = 106, 2 RCTs, RR 0.12, 95% CI 0.03 to 0.48) or unclear risk of bias (n = 426, 6 RCTs, RR 0.19, 95% CI 0.05 to 0.68) for blinded outcome measurement (<a href="./references#CD003079-fig-0092" title="">Analysis 10.3</a>). There was no significant difference between subgroups (Chi<sup>2</sup> = 0.21, P = 0.64, I<sup>2</sup> = 0%). </p> </section> <section id="CD003079-sec-0160"> <h5 class="title">11. Sensitivity analysis ‐ Incomplete outcome data (attrition bias)</h5> <p>There was no clear difference in sedation whether trials were rated at low risk of bias (n = 260, 4 RCTs, RR 1.30, 95% CI 0.83 to 2.03) or at unclear risk of bias (n = 134, 3 RCTs, RR 1.07, 95% CI 0.62 to 1.83). Where risk of bias was high, there was a difference in favour of antipsychotics, but heterogeneity between trials was high (n = 193, 2 RCTs, RR 1.78, 95% CI 1.15 to 2.75, <a href="./references#CD003079-fig-0093" title="">Analysis 11.1</a>). Apparent differences between subgroups were not significant (Chi<sup>2</sup> = 2.23, P = 0.33, I<sup>2</sup> = 10.1%). </p> <p>Trials rated as a low risk of attrition bias were more likely to find similar rates of no improvement in people receiving benzodiazepines compared with people receiving antipsychotics (n = 290, 5 RCTs, RR 1.23, 95% CI 0.98 to 1.56), whereas, in the one trial rated at unclear risk of bias, there was a lower rate of no improvement in people receiving benzodiazepines identified (n = 48, RR 0.56, 95 % CI 0.32 to 0.97). There was a clear difference between these subgroups (Chi<sup>2</sup> = 6.65, P = 0.01, I<sup>2</sup> = 85.0%, <a href="./references#CD003079-fig-0094" title="">Analysis 11.2</a>). </p> <p>The finding that the incidence of EPS was lower in people receiving benzodiazepines was clearly identified in low risk of bias trials (n = 302, 5 RCTs, RR 0.18, 95% CI 0.06 to 0.60) and in unclear risk of bias trials (n = 77, 2 RCTs, RR 0.09, 95% CI 0.01 to 0.65), but not in high risk of bias trials (n = 153, 1 RCT, RR 0.15, 95% CI 0.01 to 2.90, <a href="./references#CD003079-fig-0095" title="">Analysis 11.3</a>). However, this apparent difference between subgroups was not significant (Chi<sup>2</sup> = 0.44, P = 0.93, I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD003079-sec-0161"> <h4 class="title">Publication bias</h4> <p>Sedation data from the comparison of benzodiazepines versus antipsychotics were used to investigate whether there was evidence of systematic small trial bias in a funnel plot analysis. There was a small number of trials and it was difficult to be sure of any asymmetry (<a href="#CD003079-fig-0001">Figure 1</a>). We think it inadvisable to read too much into this exploratory, low‐powered technique of investigation. What is needed are more trials with a wide spread of findings. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003079-sec-0162" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003079-sec-0162"></div> <section id="CD003079-sec-0163"> <h3 class="title" id="CD003079-sec-0163">Summary of main results</h3> <section id="CD003079-sec-0164"> <h4 class="title">Comparison 1: Benzodiazepines versus placebo</h4> <p>See <a href="./full#CD003079-tbl-0001">summary of findings Table 1</a>. There was some evidence that lorazepam was superior to placebo in terms of improvement and behaviour in the medium but not short term, although these data came from a single small study with very serious risk of bias and were, therefore, graded as very low quality evidence. There was no clear evidence of a difference between groups in tranquillisation, mental state, adverse events or leaving the study early. </p> <p>It is understandable that placebo‐controlled trials in this area are uncommon as withholding treatment from people in such a distressed state can be considered unethical. Therefore, evidence from RCTs that benzodiazepines are superior to placebo is insufficient. </p> </section> <section id="CD003079-sec-0165"> <h4 class="title">Comparison 2: Benzodiazepines versus antipsychotics</h4> <p>See <a href="./full#CD003079-tbl-0002">summary of findings Table 2</a>. Overall, there was very low‐ to low‐quality evidence of no difference between benzodiazepines and antipsychotics in terms of global state (e.g. clinical improvement or need for additional medication) or sedation, or both. However, there as low‐quality evidence from single small studies showing a clear difference between groups, One small study found that olanzapine was superior to lorazepam in terms of clinical improvement (n = 150, <a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a>). One small study with high attrition rates found that midazolam can achieve higher rates of sedation than droperidol (n = 163, <a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a>). On esmall study found lorazepam can reduce the severity of symptoms compared with haloperidol when measured by CGI (n = 37, <a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a>). Due to the high levels of heterogeneity between studies and the very low quality of evidence, it was difficult to make any conclusions from the results on the need of additional medication comparing benzodiazepines and antipsychotics. Moreover, there was no evidence available looking at the short‐term effect of benzodiazepines and haloperidol on various outcomes such as sedation, improvement in global state, adverse effects and need for additional medication. </p> <p>In addition, low‐quality evidence showed that EPS were considerably lower in people receiving benzodiazepines. The data suggest EPS were significantly higher in people receiving antipsychotics and this should be considered in choosing the correct treatment in an emergency situation. In clinical practice, antipsychotics and mainly typical antipsychotics are often accompanied by anticholinergic treatment that may substantially decrease the incidence of EPS particularly in non‐organic psychosis. Therefore, the use of atypical antipsychotics based on the reduced EPS profile may be a suitable potential treatment option. Typical antipsychotics such as haloperidol without accompanying anticholinergics does not seem acceptable and this is consistent with outcomes of other relevant reviews (<a href="./references#CD003079-bbs2-0097" title="HufG , AlexanderJ , AllenMH , RaveedranNS . Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD005146. [DOI: 10.1002/14651858.CD005146.pub2]">Huf 2009</a>). </p> <p>There was no difference between groups for mental state and other adverse events. Considering the above findings, due to the very low or low quality of evidence, the difference between benzodiazepine and antipsychotics for acute agitation remain uncertain. </p> </section> <section id="CD003079-sec-0166"> <h4 class="title">Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines</h4> <p>See <a href="./full#CD003079-tbl-0003">summary of findings Table 3</a>. This comparison included <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a> and <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>, which were larger trials. Results for improvement and global state scores favoured the use of combined haloperidol/promethazine over lorazepam but all these data came from <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; sedation was reported in both <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a> and <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a> trials, but data could not be pooled because of substantial heterogeneity between the two trials. People receiving midazolam were more likely to become sedated compared with combined haloperidol/promethazine in <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>, unlike <a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a> where people receiving combined haloperidol/promethazine were more likely to become sedated. Possible reasons for this dramatic heterogeneity was discussed in depth in another review (<a href="./references#CD003079-bbs2-0097" title="HufG , AlexanderJ , AllenMH , RaveedranNS . Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD005146. [DOI: 10.1002/14651858.CD005146.pub2]">Huf 2009</a>), but the most likely reason is midazolam is a faster‐acting and more potent benzodiazepine than lorazepam (<a href="./references#CD003079-bbs2-0101" title="LarsonJS , LunnJJ . Comparing drugs for short-term sedation. Contemporary Internal Medicine1994;6(12):55-60.">Larson 1994</a>). Clinically, sedation caused by combined haloperidol/promethazine was dose related. </p> <p><a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a> reported the use of physical restraints. Throughout the course of the trial, people receiving lorazepam alone were more likely to be mechanically restrained than people who received combined haloperidol/promethazine. Although restraint was not a stated outcome in our protocol and may be of more relevance to clinicians in countries where the use of mechanical restraints is employed, we feel that it is an important outcome and should be considered in future reviews and trials. </p> <p>In these larger and better‐reported trials, adverse effects were infrequent but important, and included respiratory depression, nausea and seizure. Respiratory depression is a very serious potential adverse effect of all benzodiazepines, and occurred in both trials. One participant in <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a> watdmitted with cocaine‐induced aggression, a potential mitigating factor. </p> <p>The above findings were based on low‐quality evidence, and results from future studies are likely to change the findings. </p> </section> <section id="CD003079-sec-0167"> <h4 class="title">Comparison 4: Benzodiazepines plus antipsychotics versus same benzodiazepines</h4> <p>See <a href="./full#CD003079-tbl-0004">summary of findings Table 4</a>. There was little difference between combined benzodiazepines/antipsychotics compared with benzodiazepines alone but the quality of these data was low. The only significant difference was that sedation was more likely in people receiving the combination in the short term, although these data were from one small trial. Ratings of global state, mental state, behaviour and adverse effects were all equivocal between groups ‐ as could be expected in such low power. A real and important difference could exist, but larger trials are needed before any confident conclusions can be drawn. </p> </section> <section id="CD003079-sec-0168"> <h4 class="title">Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics</h4> <p>See <a href="./full#CD003079-tbl-0005">summary of findings Table 5</a>. There were no apparent advantages in using combined benzodiazepines/antipsychotics compared with antipsychotics alone in terms of our primary outcome of no improvement but there were relatively few data with considerable heterogeneity. In addition, as each of the included trials defined 'improvement' differently, it was difficult to interpret how meaningful these data were. </p> <p>Sedation rates were significantly higher in the combined benzodiazepines/haloperidol group compared with haloperidol alone in the short and medium term although the medium‐term data were heterogeneous. There were no differences between groups in the incidence of EPS or other adverse effects but these were rated as low‐quality evidence. </p> <p>Behaviour scores did seem to favour haloperidol when compared with combined midazolam/haloperidol but these data came from one small trial (n = 60). This finding may be changed by further trials. </p> </section> <section id="CD003079-sec-0169"> <h4 class="title">Comparison 6: Benzodiazepines plus antipsychotics versus antipsychotics plus antipsychotics</h4> <p>See <a href="./full#CD003079-tbl-0006">summary of findings Table 6</a>. The only trial to report data for this comparison provided few data (<a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a>), with no documented instances of people leaving the study early, and no difference in aggression ratings. Therefore, it is difficult to draw any meaningful conclusions from this comparison; larger, more informative trials with clearly defined outcomes are needed before any conclusions can be made. </p> </section> <section id="CD003079-sec-0170"> <h4 class="title">Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines</h4> <p>See <a href="./full#CD003079-tbl-0007">summary of findings Table 7</a>. Only one trial reported two relevant arms (total n = 60), and the quality of evidence was very low (<a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a>). There was very low quality evidence that combined haloperidol/promethazine was significantly better than combined midazolam/haloperidol in terms of improvement, need for additional medication, sedation and behaviour. However, as the quality of the evidence was very low, it was difficult to draw any meaningful conclusions. </p> </section> <section id="CD003079-sec-0171"> <h4 class="title">Sensitivity analysis</h4> <p>Although sensitivity analyses were conducted for the 'Risk of bias' criteria, sequence generation, allocation concealment, blinded outcome measurement and incomplete data, there were few differences between trials at high, low and unclear risk of bias. Trials at low risk of bias for sequence generation, allocation concealment and blinded outcome measurement were more likely to favour benzodiazepines over antipsychotics in terms of sedation and lowering the risk of EPS. However, these findings were based on relatively few data and should at this stage be interpreted with caution. </p> </section> </section> <section id="CD003079-sec-0172"> <h3 class="title" id="CD003079-sec-0172">Overall completeness and applicability of evidence</h3> <section id="CD003079-sec-0173"> <h4 class="title">1. Completeness</h4> <section id="CD003079-sec-0174"> <h5 class="title">1.1. Power</h5> <section id="CD003079-sec-0175"> <h6 class="title">1.1.1. Limited power</h6> <p>We only found one trial (n = 102) comparing benzodiazepines with placebo. Although data were incomplete, we know enough to suggest that randomisation of benzodiazepine versus placebo to be ethical only in the most constrained services of such limited supply that anything but randomisation would be inequitable. </p> <p>Eleven trials compared benzodiazepines directly with antipsychotics, and most of trials had small sample sizes. When a benzodiazepine was compared with combined benzodiazepine/antipsychotic, the five trials had a mean of 50 participants. Even if the outcome reporting had been comprehensive (taking into account views of clinicians and participants as well as researchers), the depth and strength of evidence in this area is very far from complete. Despite an increasing trend to consider atypical antipsychotics as more suitable for rapid tranquillisation than the older antipsychotics, there were inadequate data to compare atypical antipsychotics with benzodiazepines. Such promotion of the antipsychotics is based more on well‐meaning faith combined with an understandable lack of resistance from industry rather than good evidence. </p> <p>The two TREC trials (Tranquilização Rápida‐Ensaio Clínico (Rapid Tranquillisation‐Clinical Trial)) that compared benzodiazepines with combined haloperidol/promethazine were large (n = 200 and 301), high‐powered trials, recognised for high methodological quality in this area of research (<a href="./references#CD003079-bbs2-0109" title="National Institute for Health and Care Excellence. Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments, NG10. www.nice.org.uk/guidance/ng10 (accessed prior to 17 October 2017).">NICE 2015</a>). These trials did not have an emphasis on recording scale‐derived data but did provide useful binary outcomes. </p> <p>The comparison for combined benzodiazepines/haloperidol versus combined haloperidol/promethazine was very limited (1 RCT, n = 60) with few data from a single trial with multiple treatment arms. All outcomes need to be interpreted with great caution. </p> </section> <section id="CD003079-sec-0176"> <h6 class="title">1.1.2. No power</h6> <p>The trial search did not identify trials that compared specific benzodiazepines at a high versus low dose; oral versus IM/intravenous; or low frequency versus high frequency (as defined by each study). Future research could examine these comparisons to highlight any potential benefits/efficacy of specifically named benzodiazepines in the management of psychosis‐induced aggression/agitation. </p> </section> </section> <section id="CD003079-sec-0177"> <h5 class="title">1.2. Outcome measurement</h5> <section id="CD003079-sec-0178"> <h6 class="title">1.2.1. Measures</h6> <p>A major difficulty in synthesising data from trials in this review was the considerable variability in what and how outcomes were measured. Several trials reported outcomes that were not within the specified time period and therefore could not be used. </p> <p>Given the potential for adverse events with benzodiazepines and antipsychotics, future trials should ensure that these data are collected and reported. In addition, as most trials allow for 'as‐needed' repeat doses of these drugs, the number of additional doses or mean dosage is also an important outcome in these trials. </p> <p>The trials used a range of modified versions of validated measures or domain scores, thus, these data could not be synthesised in this review. If scales are to be used, it is important that they, and the individual subscales, are validated. Consistent use of measures of agreed importance is important. </p> </section> <section id="CD003079-sec-0179"> <h6 class="title">1.2.2. Sedation</h6> <p>There is a need to achieve behavioural control without sedation (<a href="./references#CD003079-bbs2-0114" title="RoccaP , VillariV , BogettoF . Managing the aggressive and violent patient in the psychiatric emergency. Progress in Neuro-Psychopharmacology and Biological Psychiatry2006;30(4):586-98.">Rocca 2006</a>). This perspective is reflected by sedation being reported as a positive outcome in earlier trials but as negative in more recent trials. However, sedation remains important and should be recorded and value judgements can be made by those who wish to use the evidence. In future trials, other outcomes such as improvement should be reported, as consensus guidelines have emphasised that calming an agitated/aggressive person is the key goal in an acute setting as opposed to rapid tranquillisation (<a href="./references#CD003079-bbs2-0072" title="AllenMH , CurrierGW , CarpenterD , Ross RW DochertyJP . The expert consensus guideline series. Treatment of behavioural emergencies. Journal of Psychiatric Practice2005;11(Suppl 1):5-108.">Allen 2005</a>). </p> </section> </section> </section> <section id="CD003079-sec-0180"> <h4 class="title">2. Applicability</h4> <p>Despite a relatively broad range of inclusion criteria in regard to participants and settings, results were quite homogenous. Largely, participants, interventions and situations of administration were familiar to the average clinical setting and the data seem to be applicable. Benzodiazepines and antipsychotics were used quite consistently across trials. The majority used lorazepam or haloperidol in consistent clinically applicable doses. Only six trials used atypical antipsychotics. </p> <p>The major sources of heterogeneity were CGI scores when lorazepam and diazepam were compared with haloperidol (<a href="./references#CD003079-fig-0021" title="">Analysis 2.6</a>), OASS scores when combined midazolam/haloperidol was compared with olanzapine and ziprasidone (<a href="./references#CD003079-fig-0062" title="">Analysis 5.6</a>), and sedation when lorazepam and midazolam were compared with combined haloperidol/promethazine (<a href="./references#CD003079-fig-0034" title="">Analysis 3.1</a>). There were several potential reasons for this heterogeneity. The most identifiable of these were differences in the types and doses of benzodiazepines and antipsychotics that were used. </p> </section> </section> <section id="CD003079-sec-0181"> <h3 class="title" id="CD003079-sec-0181">Quality of the evidence</h3> <p>Overall, most quality criteria were poorly reported in the trials included in this review. Large, well‐designed, clinically relevant and clearly reported trials are clearly possible (<a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a>; <a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a>), but these are very much the exceptions to the rule. The randomisation methods and allocation concealment were poorly reported in the included trials. Most trials did not state whether they had concealed the group allocation regimen. Some trials used a double‐blind design, however, did not state who was blinded (e.g. participants, outcome assessor, data analyser). About 30% of trials were supported by pharmaceutical institutes. </p> <p>The quality of evidence was low to very low, the main reasons for downgrading the evidence were very small sample size and serious risk of bias across included studies. </p> </section> <section id="CD003079-sec-0182"> <h3 class="title" id="CD003079-sec-0182">Potential biases in the review process</h3> <p>It is entirely possible that we have not identified small negative trials and would be most interested if readers know of these. </p> </section> <section id="CD003079-sec-0183"> <h3 class="title" id="CD003079-sec-0183">Agreements and disagreements with other studies or reviews</h3> <p>The findings of this review agree with other narrative syntheses of the literature that have concluded that benzodiazepines are at least as effective as antipsychotics in controlling severely agitated behaviour (<a href="http://archie.cochrane.org/sections/documents/view?version=63012133905858853540120326233832&amp;format=REVMAN#REF-Allen-2000" target="_blank">Allen 2000</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=63012133905858853540120326233832&amp;format=REVMAN#REF-NICE-2005" target="_blank">NICE 2005</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=63012133905858853540120326233832&amp;format=REVMAN#REF-Rocca-2006" target="_blank">Rocca 2006</a>); however, because benzodiazepines have the potential to cause respiratory depression, their use should be carefully monitored in an environment suited to manage such cases. The findings are also consistent with other similar and overlapping reviews (see <a href="#CD003079-sec-0185">Implications for practice</a>: 3. for managers and policy‐makers). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003079-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 benzodiazepines versus antipsychotics, outcome: 2.1 Tranquillisation or asleep: 1. sedation." data-id="CD003079-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 benzodiazepines versus antipsychotics, outcome: 2.1 Tranquillisation or asleep: 1. sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003079-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003079-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-FIG-04" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003079-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 1: Tranquillisation or asleep: 1. sedation" data-id="CD003079-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 1: Tranquillisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 2: Behaviour: 1. mean change score (Agitated Behaviour Scale, high = worse)" data-id="CD003079-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 2: Behaviour: 1. mean change score (Agitated Behaviour Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 3: Global state: 1. no improvement (&gt; 40% reduction Positive and Negative Syndrome Scale‐Excited Component (PANSS‐EC))" data-id="CD003079-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 3: Global state: 1. no improvement (&gt; 40% reduction Positive and Negative Syndrome Scale‐Excited Component (PANSS‐EC)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 4: Global state: 2. need for additional medication" data-id="CD003079-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 4: Global state: 2. need for additional medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 5: Global state: 3. mean change score (Clinical Global Impression Severity Scale, high = worse)" data-id="CD003079-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 5: Global state: 3. mean change score (Clinical Global Impression Severity Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 6: Mental state: 1. mean change score (Positive and Negative Syndrome Scale, high = worse)" data-id="CD003079-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 6: Mental state: 1. mean change score (Positive and Negative Syndrome Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 7: Mental state: 2. mean change score (PANSS‐EC, high = worse)" data-id="CD003079-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 7: Mental state: 2. mean change score (PANSS‐EC, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 8: Adverse effects/events: 1. extrapyramidal symptoms (EPS)" data-id="CD003079-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 8: Adverse effects/events: 1. extrapyramidal symptoms (EPS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 9: Adverse effects/events: 2. use of medication for EPS" data-id="CD003079-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 9: Adverse effects/events: 2. use of medication for EPS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 10: Adverse effects/events: 3. specific" data-id="CD003079-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 10: Adverse effects/events: 3. specific </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benzodiazepines versus placebo, Outcome 11: Leaving the study early: 1. any reason" data-id="CD003079-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Benzodiazepines versus placebo, Outcome 11: Leaving the study early: 1. any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 1: Tranquillisation or asleep: 1. sedation" data-id="CD003079-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 1: Tranquillisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 2: Behaviour: 2. mean change/endpoint score (Agitated Behaviour Scale, high = worse)" data-id="CD003079-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 2: Behaviour: 2. mean change/endpoint score (Agitated Behaviour Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 3: Behaviour: 4. mean change score (Overt Aggression Scale, high = worse)" data-id="CD003079-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 3: Behaviour: 4. mean change score (Overt Aggression Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 4: Global state: 1. no improvement (&gt; 40% reduction Positive and Negative Syndrome Scale‐Excited Component (PANSS‐EC))" data-id="CD003079-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 4: Global state: 1. no improvement (&gt; 40% reduction Positive and Negative Syndrome Scale‐Excited Component (PANSS‐EC)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 5: Global state: 2. need for additional medication" data-id="CD003079-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 5: Global state: 2. need for additional medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 6: Global state: 3. mean change/endpoint score (Clinical Global Impression Severity Scale, high = worse)" data-id="CD003079-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 6: Global state: 3. mean change/endpoint score (Clinical Global Impression Severity Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 7: Global state: 4. mean endpoint score (Inpatient Multidimensional Psychiatric Scale, high = worse)" data-id="CD003079-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 7: Global state: 4. mean endpoint score (Inpatient Multidimensional Psychiatric Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 8: Mental state: 1. no improvement (decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%)" data-id="CD003079-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 8: Mental state: 1. no improvement (decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 9: Mental state: 2. mean change/endpoint score (BPRS, high = worse)" data-id="CD003079-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 9: Mental state: 2. mean change/endpoint score (BPRS, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 10: Mental state: 3. mean endpoint score (BPRS psychosis subscale, high = worse)" data-id="CD003079-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 10: Mental state: 3. mean endpoint score (BPRS psychosis subscale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 11: Mental state: 3a. mean endpoint score (BPRS positive subscale, high = worse)" data-id="CD003079-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 11: Mental state: 3a. mean endpoint score (BPRS positive subscale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 12: Mental state: 4a. mean endpoint score (BPRS‐excited component, high = worse)" data-id="CD003079-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 12: Mental state: 4a. mean endpoint score (BPRS‐excited component, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 13: Mental state: 2a. mean change score (Positive and Negative Syndrome Scale, high = worse)" data-id="CD003079-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 13: Mental state: 2a. mean change score (Positive and Negative Syndrome Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 14: Mental state: 4. mean change score (PANSS‐EC, high = worse)" data-id="CD003079-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 14: Mental state: 4. mean change score (PANSS‐EC, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 15: Adverse effects/events: 1. extrapyramidal symptoms (EPS)" data-id="CD003079-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 15: Adverse effects/events: 1. extrapyramidal symptoms (EPS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 16: Adverse effects/events: 2. use of medication for EPS" data-id="CD003079-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 16: Adverse effects/events: 2. use of medication for EPS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 17: Adverse effects/events: 3. specific" data-id="CD003079-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 17: Adverse effects/events: 3. specific </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Benzodiazepines versus antipsychotics, Outcome 18: Leaving the study early: 1. any reason" data-id="CD003079-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Benzodiazepines versus antipsychotics, Outcome 18: Leaving the study early: 1. any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 1: Tranquilisation or asleep: 1. sedation" data-id="CD003079-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 1: Tranquilisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 2: Global state: 1. no improvement (Clinical Global Impression (CGI) ‐ improvement scale dichotomised; much and very much improved)" data-id="CD003079-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 2: Global state: 1. no improvement (Clinical Global Impression (CGI) ‐ improvement scale dichotomised; much and very much improved) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 3: Global state: 2. need for additional medication" data-id="CD003079-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 3: Global state: 2. need for additional medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 4: Global state: 3. mean endpoint score (CGI, high = worse)" data-id="CD003079-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 4: Global state: 3. mean endpoint score (CGI, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 5: Adverse effects/events: 1. specific" data-id="CD003079-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 5: Adverse effects/events: 1. specific </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 6: Hospital and service outcomes: 1. changes in hospital status" data-id="CD003079-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 6: Hospital and service outcomes: 1. changes in hospital status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 7: Leaving the study early: 1. any reason" data-id="CD003079-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Benzodiazepines versus antipsychotics plus antihistamines, Outcome 7: Leaving the study early: 1. any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 1: Tranquillisation or asleep: 1. sedation" data-id="CD003079-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 1: Tranquillisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 2: Behaviour: 1. mean endpoint score (Agitated Behaviour Scale, high = worse)" data-id="CD003079-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 2: Behaviour: 1. mean endpoint score (Agitated Behaviour Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 3: Global state: 1. no improvement mean endpoint change in Clinical Global Impression score)" data-id="CD003079-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 3: Global state: 1. no improvement mean endpoint change in Clinical Global Impression score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 4: Global state: 2. need for additional medication" data-id="CD003079-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 4: Global state: 2. need for additional medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 5: Mental state: 1. no improvement (the decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%)" data-id="CD003079-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 5: Mental state: 1. no improvement (the decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 6: Mental state: 2a. mean endpoint score (BPRS, high = worse)" data-id="CD003079-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 6: Mental state: 2a. mean endpoint score (BPRS, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0047"> <p> <div class="table" id="CD003079-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Mental state: 2b. mean endpoint score (BPRS, high = worse, skew)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>+ haloperidol ‐ short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Lorazepam 2006, USA</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam+haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>+ haloperidol ‐ medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Lorazepam 2006, USA</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam+haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 7: Mental state: 2b. mean endpoint score (BPRS, high = worse, skew) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0047">Navigate to figure in review</a></div> </div> <div class="figure" id="CD003079-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 8: Mental state: 2c. mean endpoint score (Positive and Negative Syndrome Scale (PANSS), high = worse)" data-id="CD003079-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 8: Mental state: 2c. mean endpoint score (Positive and Negative Syndrome Scale (PANSS), high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0049"> <p> <div class="table" id="CD003079-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Mental state: 2d. mean endpoint score (PANSS, high = worse, skew)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>+ haloperidol ‐ short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Lorazepam 2006, USA</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam+haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>+ haloperidol ‐ medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Lorazepam 2006, USA</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam+haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 9: Mental state: 2d. mean endpoint score (PANSS, high = worse, skew) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0049">Navigate to figure in review</a></div> </div> <div class="figure" id="CD003079-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 10: Mental state: 3a. mean endpoint score (BPRS psychosis subscale, high = worse)" data-id="CD003079-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 10: Mental state: 3a. mean endpoint score (BPRS psychosis subscale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 11: Mental state: 3b. mean endpoint score (BPRS positive subscale, high = worse)" data-id="CD003079-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 11: Mental state: 3b. mean endpoint score (BPRS positive subscale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 12: Mental state: 4. mean endpoint score (BPRS‐excited component, high = worse)" data-id="CD003079-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 12: Mental state: 4. mean endpoint score (BPRS‐excited component, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 13: Adverse effects/events: 1. extrapyramidal symptoms (EPS)" data-id="CD003079-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 13: Adverse effects/events: 1. extrapyramidal symptoms (EPS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 14: Adverse effects/events: 2. use of medication for EPS" data-id="CD003079-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 14: Adverse effects/events: 2. use of medication for EPS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 15: Adverse effects/events: 3. specific" data-id="CD003079-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 15: Adverse effects/events: 3. specific </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-004.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 16: Leaving the study early: 1. any reason" data-id="CD003079-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-004.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines plus antipsychotics vs same benzodiazepines, Outcome 16: Leaving the study early: 1. any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-004.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 1: Tranquillisation or asleep: 1. sedation" data-id="CD003079-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 1: Tranquillisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 2: Behaviour: 1. mean endpoint score (Agitated Behaviour Scale, high = worse)" data-id="CD003079-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 2: Behaviour: 1. mean endpoint score (Agitated Behaviour Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 3: Behaviour: 2. mean endpoint score (Overt Aggression Scale (OAS), high = worse)" data-id="CD003079-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 3: Behaviour: 2. mean endpoint score (Overt Aggression Scale (OAS), high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 4: Behaviour: 3. mean endpoint score (Overt Agitation Severity Scale, high = worse)" data-id="CD003079-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 4: Behaviour: 3. mean endpoint score (Overt Agitation Severity Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 5: Global state: 1. no improvement" data-id="CD003079-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 5: Global state: 1. no improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 6: Global state: 2. need for additional medication" data-id="CD003079-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 6: Global state: 2. need for additional medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 7: Global state: 3. need for additional medication (mean dose, high = worse)" data-id="CD003079-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 7: Global state: 3. need for additional medication (mean dose, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 8: Global state: 4. mean change score (Ramsey Sedation Scale, high = worse)" data-id="CD003079-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 8: Global state: 4. mean change score (Ramsey Sedation Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 9: Mental state: 1. no improvement (the decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%)" data-id="CD003079-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 9: Mental state: 1. no improvement (the decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 10: Mental state: 2. mean endpoint score (BPRS, high = worse)" data-id="CD003079-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 10: Mental state: 2. mean endpoint score (BPRS, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 11: Mental state: 3a. mean endpoint score (BPRS psychosis subscale, high = worse)" data-id="CD003079-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 11: Mental state: 3a. mean endpoint score (BPRS psychosis subscale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 12: Mental state: 3b. mean endpoint score (BPRS positive subscale, high = worse)" data-id="CD003079-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 12: Mental state: 3b. mean endpoint score (BPRS positive subscale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 13: Mental state: 4. mean endpoint score (BPRS‐excited component, high = worse)" data-id="CD003079-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 13: Mental state: 4. mean endpoint score (BPRS‐excited component, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 14: Adverse effects/events: 1. extrapyramidal symptoms (EPS)" data-id="CD003079-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 14: Adverse effects/events: 1. extrapyramidal symptoms (EPS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 15: Adverse effects/events: 2. use of medication for EPS" data-id="CD003079-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 15: Adverse effects/events: 2. use of medication for EPS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 16: Adverse effects/events: 3. specific" data-id="CD003079-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 16: Adverse effects/events: 3. specific </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-005.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 17: Hospital and service outcomes: 1. changes in hospital status" data-id="CD003079-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-005.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5: Benzodiazepines plus antipsychotics versus same antipsychotics, Outcome 17: Hospital and service outcomes: 1. changes in hospital status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-005.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Benzodiazepines + antipsychotics versus antipsychotics plus antipsychotics, Outcome 1: Behaviour: 3. mean endpoint score (Overt Aggression Scale, high = worse)" data-id="CD003079-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Benzodiazepines + antipsychotics versus antipsychotics plus antipsychotics, Outcome 1: Behaviour: 3. mean endpoint score (Overt Aggression Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Benzodiazepines + antipsychotics versus antipsychotics plus antipsychotics, Outcome 2: Leaving the study early: 1. any reason" data-id="CD003079-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Benzodiazepines + antipsychotics versus antipsychotics plus antipsychotics, Outcome 2: Leaving the study early: 1. any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 1: Tranquilisation or asleep: 1. sedation" data-id="CD003079-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 1: Tranquilisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 2: Behaviour: 1. mean endpoint score (Overt Aggression Scale (OAS), high = worse)" data-id="CD003079-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 2: Behaviour: 1. mean endpoint score (Overt Aggression Scale (OAS), high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 3: Behaviour: 2. mean endpoint score (Overt Agitation Severity Scale (OASS) agitation scale, high = worse)" data-id="CD003079-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 3: Behaviour: 2. mean endpoint score (Overt Agitation Severity Scale (OASS) agitation scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 4: Global state: 1. no improvement (number of participants with &lt; 10 points on the OAS and OASS after 12 hours)" data-id="CD003079-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 4: Global state: 1. no improvement (number of participants with &lt; 10 points on the OAS and OASS after 12 hours) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 5: Global state: 2. need for additional medication (mean dose, high = worse)" data-id="CD003079-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 5: Global state: 2. need for additional medication (mean dose, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 6: Global state: 3. mean change score (Ramsey Sedation Scale, high = worse)" data-id="CD003079-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 6: Global state: 3. mean change score (Ramsey Sedation Scale, high = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 7: Adverse effects/events: 1. extrapyramidal symptoms" data-id="CD003079-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 7: Adverse effects/events: 1. extrapyramidal symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 8: Adverse effects/events: 2. specific" data-id="CD003079-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines, Outcome 8: Adverse effects/events: 2. specific </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 1. Random sequence generation, Outcome 1: Tranquilisation or asleep: 1. sedation" data-id="CD003079-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 1. Random sequence generation, Outcome 1: Tranquilisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 1. Random sequence generation, Outcome 2: Global state: 1. no improvement" data-id="CD003079-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 1. Random sequence generation, Outcome 2: Global state: 1. no improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 1. Random sequence generation, Outcome 3: Adverse effects/events: 1. extrapyramidal symptoms" data-id="CD003079-fig-0086" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 1. Random sequence generation, Outcome 3: Adverse effects/events: 1. extrapyramidal symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 2. Allocation concealment, Outcome 1: Tranquilisation or asleep: 1. sedation" data-id="CD003079-fig-0087" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 2. Allocation concealment, Outcome 1: Tranquilisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 2. Allocation concealment, Outcome 2: Global state: 1. no improvement" data-id="CD003079-fig-0088" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 2. Allocation concealment, Outcome 2: Global state: 1. no improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 2. Allocation concealment, Outcome 3: Adverse effects/events: 1. extrapyramidal symptoms" data-id="CD003079-fig-0089" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 2. Allocation concealment, Outcome 3: Adverse effects/events: 1. extrapyramidal symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 3. Blinded outcome measurement, Outcome 1: Tranquilisation or asleep: 1. sedation" data-id="CD003079-fig-0090" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 3. Blinded outcome measurement, Outcome 1: Tranquilisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 3. Blinded outcome measurement, Outcome 2: Global state: 1. no improvement" data-id="CD003079-fig-0091" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 3. Blinded outcome measurement, Outcome 2: Global state: 1. no improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 3. Blinded outcome measurement, Outcome 3: Adverse effects/events: 1. extrapyramidal symptoms" data-id="CD003079-fig-0092" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 3. Blinded outcome measurement, Outcome 3: Adverse effects/events: 1. extrapyramidal symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 4. Incomplete outcome data (attrition bias), Outcome 1: Tranquilisation or asleep: 1. sedation" data-id="CD003079-fig-0093" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 4. Incomplete outcome data (attrition bias), Outcome 1: Tranquilisation or asleep: 1. sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 4. Incomplete outcome data (attrition bias), Outcome 2: Global state: 1. no improvement" data-id="CD003079-fig-0094" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 4. Incomplete outcome data (attrition bias), Outcome 2: Global state: 1. no improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003079-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/urn:x-wiley:14651858:media:CD003079:CD003079-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 4. Incomplete outcome data (attrition bias), Outcome 3: Adverse effects/events: 1. extrapyramidal symptoms" data-id="CD003079-fig-0095" src="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_t/tCD003079-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 4. Incomplete outcome data (attrition bias), Outcome 3: Adverse effects/events: 1. extrapyramidal symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/media/CDSR/CD003079/image_n/nCD003079-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD003079-tbl-0012"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Suggested design of future reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Methods</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully described in terms of methods of randomisation and allocation concealment. </p> <p>Blinding: double/single blind, with methods of maintenance of blinding fully described.</p> <p>Setting: psychiatric emergency settings/hospital.</p> <p>Duration: immediate term (0‐15 minutes); short term (15 minutes to 1 hour); medium term (1‐48 hours); long term (≥ 48 hours). </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Participants</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: primary diagnosis of schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder with psychosis‐induced aggression or agitation. </p> <p>Subgroups: dual diagnoses or drug/alcohol use, or both.</p> <p>Age: adults, with age specified in trial.</p> <p>Sex: both.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparisons</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>a. Benzodiazepines ‐ given alone.</b> </p> <p>Including: alprazolam, bretazenil, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clotiazepam, cloxazolam, delorazepam, diazepam, estazolam, flunitrazepam, halazepam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam or triazolam. </p> <p>Any dose, any means of administration.</p> <p>Compared with:</p> <p>1. Other benzodiazepine ‐ given alone.</p> <p>Any dose, any means of administration.</p> <p>2. Antipsychotics.</p> <p>First generation/typical, including: chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, droperidol, flupentixol/flupenthixol, fluphenazine, haloperidol, levomepromazine, loxapine, mesoridazine, molindone, periciazine, perphenazine, pimozide, prochlorperazine, promazine, promethazine, thioridazine, thiothixene, trifluoperazine, triflupromazine or zuclopenthixol. </p> <p>Second generation/atypical, including: amisulpride, aripiprazole, asenapine, clozapine, clothiapine, clotiapine, iloperidone, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, risperidone, sertindole, sulpiride, ziprasidone or zotepine. </p> <p>Any dose, any means of administration.</p> <p>3. Other combinations of drugs.</p> <p>3.1. Benzodiazepines + antipsychotics.</p> <p>3.2. Antipsychotics + antihistamine/anticholinergic drugs.</p> <p>Antihistamines include: azelastine<i>,</i> brompheniramine<i>,</i> buclizine<i>,</i> bromodiphenhydramine<i>,</i> carbinoxamine<i>,</i> cetirizine<i>,</i> cyclizine<i>,</i> chlorpheniramine<i>,</i> chlorodiphenhydramine<i>,</i> clemastine<i>,</i> cyproheptadine<i>,</i> desloratadine<i>,</i> dexbrompheniramine<i>,</i> deschlorpheniramine<i>,</i> dexchlorpheniramine<i>,</i> dimenhydrinate<i>,</i> dimethindene<i>,</i> diphenhydramine<i>,</i> doxylamine<i>,</i> ebastine<i>,</i> embramine<i>,</i> fexofenadine<i>,</i> levocetirizine<i>,</i> loratadine<i>,</i> meclozine<i>,</i> olopatadine<i>,</i> orphenadrine<i>,</i> phenindamine<i>,</i> pheniramine<i>,</i> phenyltoloxamine<i>,</i> promethazine<i>,</i> pyrilamine<i>,</i> rupatadine<i>,</i> tripelennamine or triprolidine. </p> <p>Any dose, any means of administration.</p> <p>4. Non‐pharmacological approaches.</p> <p><b>b. Benzodiazepines plus antipsychotics.</b> </p> <p>Compared with:</p> <p>1. Placebo.</p> <p>2. Antipsychotics.</p> <p>Any dose, any means of administration.</p> <p>3. Other combinations.</p> <p>3.1. Benzodiazepines plus antipsychotics.</p> <p>3.2. Antipsychotics plus antihistamines.</p> <p>4. Non‐pharmacological approaches.</p> <p><b>c. Benzodiazepines (specific named drug) ‐ given alone.</b> </p> <p>1. High dose (as defined by each study).</p> <p>2. Low or standard dose (as defined by each study).</p> <p><b>d. Benzodiazepines (specific named drug) ‐ given alone.</b> </p> <p>1. Oral.</p> <p>2. Intramuscular or intravenous.</p> <p><b>e. Benzodiazepines (specific named drug) ‐ given alone.</b> </p> <p>1. Low frequency (as defined by each study).</p> <p>2. High frequency (as defined by each study).</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes measures</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary outcomes.</b> </p> <p>1. Global impression.</p> <p>1.1. Specific.</p> <p>1.1.1. No improvement: as defined by each study. If more than 1 measure of improvement was reported, then improvement in behaviour is used, followed by improvement in mental state, and then improvement in symptoms. </p> <p>1.1.2. Tranquillisation (feeling of calmness or calm, non‐sedated behaviour (or both)).</p> <p><b>Secondary outcomes.</b> </p> <p>2. Global impression ‐ CGI.</p> <p>2.1. General.</p> <p>2.1.1. No clinically important change in general functioning.<br/>2.1.2. No change in general functioning.<br/>2.1.3. Mean endpoint change in general functioning.<br/>2.1.4. Mean change in general functioning. </p> <p>2.2. Specific.</p> <p>2.2.1. Aggression.<br/>2.2.2. Self‐harm, including suicide.<br/>2.2.3. Injury to others.<br/>2.2.4. Improvement in self‐care or degree of improvement in self‐care.<br/>2.2.5. Sedation (sleepiness and drowsiness).<br/>2.2.6. Compulsory administrations of treatment.<br/>2.2.7. Need for additional medication.<br/>2.2.8. Decrease in medication.<br/>2.2.9. No change in medication dosage.<br/>2.2.10. Mean change/endpoint scores. </p> <p>3. Behaviour.</p> <p>3.1. General.</p> <p>3.1.1. No clinically important change in behaviour.<br/>3.1.2. Mean behaviour score. </p> <p>4. Mental state ‐ BPRS.</p> <p>4.1. General.</p> <p>4.1.1. No clinically important change in general mental state scores.<br/>4.1.2. Mean endpoint general mental state score. </p> <p>5. Adverse effects/events.</p> <p>5.1. General.</p> <p>5.1.1. Incidence of side effects, general or specific.<br/>5.1.2. Severity of symptoms.<br/>5.1.3. Measured acceptance of treatment.<br/>5.1.4. Sudden or unexpected death. </p> <p>5.2. Specific.</p> <p>5.2.1. EPS.<br/>5.2.2. Use of medication for EPS. </p> <p>6. Hospital and service outcomes.</p> <p>6.1. Hospitalisation.</p> <p>6.1.1. Time to hospitalisation.<br/>6.1.2. Hospitalisation of people in the community.<br/>6.1.3. Duration of hospital stay.<br/>6.1.4. Changes in services provided by community teams. </p> <p>6.2. Seclusion.</p> <p>6.2.1. Time in seclusion.<br/>6.2.2. Changes in hospital status (e.g. changes from voluntary to involuntary care, changes in level of observation, use of seclusion). </p> <p>7. Satisfaction with treatment.</p> <p>7.1. Specific.</p> <p>7.1.1. Consumers.<br/>7.1.2. Family and informal carers.<br/>7.1.3. Professionals/carers. </p> <p>8. Economic outcomes.</p> <p>8.1. Cost‐effectiveness.</p> <p>8.2. Direct costs.</p> <p>8.3. Indirect costs.</p> <p>9. Leaving the study early.</p> <p>9.1. For any reason.</p> <p>9.2. For reasons treatment related.</p> <p>9.3. For reasons unrelated to treatment.</p> <p>9.4. Due to relapse.</p> <p>9.5. Due to adverse effects.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression; EPS: extrapyramidal symptoms. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Suggested design of future reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003079-tbl-0013"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Suggested design of future studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Methods</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully described in terms of methods of randomisation and allocation concealment. </p> <p>Blinding: double/single blind, with methods of maintenance of blinding fully described.</p> <p>Setting: psychiatric emergency settings/hospital.</p> <p>Duration: follow‐up 72 hours.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: primary diagnosis of schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder with psychosis‐induced aggression or agitation. </p> <p>Subgroups: dual diagnoses or drug/alcohol use (or both)</p> <p>Number of participants &gt; 400.</p> <p>Age: adults, with age specified in trial.</p> <p>Sex: both.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interventions</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1. Benzodiazepines ‐ given alone.</b> </p> <p>Including: alprazolam, bretazenil, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clotiazepam, cloxazolam, delorazepam, diazepam, estazolam, flunitrazepam, halazepam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam or triazolam. </p> <p>Any dose, any means of administration.</p> <p>Compared with:</p> <p><b>a. Other benzodiazepine ‐ given alone.</b> </p> <p>Any dose, any means of administration.</p> <p><b>b. Antipsychotics.</b> </p> <p>First generation/typical, including: chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, droperidol, flupentixol/flupenthixol, fluphenazine, haloperidol, levomepromazine, loxapine, mesoridazine, molindone, periciazine, perphenazine, pimozide, prochlorperazine, promazine, promethazine, thioridazine, thiothixene, trifluoperazine, triflupromazine or zuclopenthixol. </p> <p>Second generation/atypical, including: amisulpride, aripiprazole, asenapine, clozapine, clothiapine, clotiapine, iloperidone, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, risperidone, sertindole, sulpiride, ziprasidone or zotepine. </p> <p>Any dose, any means of administration.</p> <p><b>c. Other combinations of drugs.</b> </p> <p>i. Benzodiazepines plus antipsychotics.</p> <p>ii. Antipsychotics plus antihistamine/anticholinergic drugs.</p> <p>Antihistamines including: azelastine<i>,</i> brompheniramine<i>,</i> buclizine<i>,</i> bromodiphenhydramine<i>,</i> carbinoxamine<i>,</i> cetirizine<i>,</i> cyclizine<i>,</i> chlorpheniramine<i>,</i> chlorodiphenhydramine<i>,</i> clemastine<i>,</i> cyproheptadine<i>,</i> desloratadine<i>,</i> dexbrompheniramine<i>,</i> deschlorpheniramine<i>,</i> dexchlorpheniramine<i>,</i> dimenhydrinate<i>,</i> dimethindene<i>,</i> diphenhydramine<i>,</i> doxylamine<i>,</i> ebastine<i>,</i> embramine<i>,</i> fexofenadine<i>,</i> levocetirizine<i>,</i> loratadine<i>,</i> meclozine<i>,</i> olopatadine<i>,</i> orphenadrine<i>,</i> phenindamine<i>,</i> pheniramine<i>,</i> phenyltoloxamine<i>,</i> promethazine<i>,</i> pyrilamine<i>,</i> rupatadine<i>,</i> tripelennamine or triprolidine. </p> <p>Any dose, any means of administration.</p> <p><b>d. Non‐pharmacological approaches.</b> </p> <p><b>2. Benzodiazepines plus antipsychotics.</b> </p> <p>Compared with:</p> <p><b>a. Placebo.</b> </p> <p><b>b. Antipsychotics.</b> </p> <p>Any dose, any means of administration.</p> <p><b>c. Other combinations.</b> </p> <p>i. Benzodiazepines plus antipsychotics.</p> <p>ii. Antipsychotics plus antihistamines.</p> <p><b>d. Non‐pharmacological approaches.</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Global impression: no improvement (as defined by each study. If more than 1 measure of improvement was reported, then improvement in behaviour was used, followed by improvement in mental state, and then improvement in symptoms). </p> <p>2. Global impression; general/specific (including tranquillisation/sedation/need for additional medication/decrease in medication/injury to others/self‐harm/aggression or agitation/compulsory administration of treatment). </p> <p>3. Behaviour: no clinically important change in behaviour.</p> <p>4. Mental state: no clinically important change in general mental state scores.</p> <p>5. Adverse effects/events (including incidence of specific adverse effects/severity of symptoms/death/EPS/use of medication for EPS). </p> <p>6. Hospital and service outcomes (including time to hospitalisation/duration of hospital stay/seclusion/time in seclusion/changes in hospital status/use of mechanical restraints). </p> <p>7. Satisfaction with treatment.</p> <p>8. Economic outcomes.</p> <p>9. Leaving the study early.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any outcomes measured using scale‐derived data should be interpreted in such a way as to make clear the real‐life relevance of changes in scale score. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>EPS: extrapyramidal symptoms.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Suggested design of future studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003079-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benzodiazepines compared to placebo for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines compared to placebo for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> hospitals (Romania and US)<br/><b>Intervention:</b> benzodiazepines<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term</b><br/>Number of participants sedated<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b><br/>(25 to 389) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.67</b> <br/>(0.42 to 6.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>V</b> <b>ery low</b><sup>2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ medium term</b><br/>As defined in each study<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>569 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b><br/>(227 to 552) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/>(0.40 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b><br/>Number of participants requiring additional medication<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b><br/>(365 to 762) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/>(0.69 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ medium term</b><br/>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(2 to 182) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/>(0.04 to 3.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes:</b> cost‐effectiveness ‐ clinically important </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed risk: mean baseline risk presented for single study. Equates with that of control group.<br/><sup>2</sup>Risk of bias: 'very serious' ‐ 90% of trial authors and coauthors were employed by trial sponsors at the time of the study ‐ downgraded by 1.<br/><sup>3</sup>Risk of bias: 'serious' ‐ randomisation poorly described ‐ downgraded by 1.<br/><sup>4</sup>Imprecision: 'serious' ‐ small sample size ‐ downgraded by 1. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benzodiazepines compared to placebo for psychosis‐induced aggression or agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003079-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Benzodiazepines compared to antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines compared to antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> hospitals (US, Canada, Israel, China, Australia)<br/><b>Intervention:</b> benzodiazepines<br/><b>Comparison:</b> antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antipsychotics</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term vs haloperidol</b> </p> <p>Number of participants sedated<br/>Follow‐up: mean 16 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.13</b> <br/>(0.83 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>434<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> </p> <p>(83 to 154)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b><br/>(189 to 350) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>565 per 1000</b><br/>(415 to 770) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: no improvement ‐ vs haloperidol ‐ medium term</b> </p> <p>As defined in each study<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.89</b> <br/>(0.71 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>188<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> <p>(55 to 85)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>551 per 1000</b><br/>(439 to 687) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>830 per 1000</b><br/>(662 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ vs olanzapine ‐ medium term</b> </p> <p>As defined in each study<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000</p> <p>(203 to 610)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.84</b> <br/>(1.06 to 3.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>1,2,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b><br/>Number of participants requiring additional medication<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High levels of heterogeneity between included studies (Chi<sup>2</sup> = 16.41; I<sup>2</sup> = 94%) ‐ data not pooled.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ vs haloperidol ‐ medium term</b> </p> <p>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 21 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.13</b> <br/>(0.04 to 0.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>233<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b><br/>(7 to 76) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/>(20 to 205) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal care givers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: 'serious' ‐ most trials received funding from a pharmaceutical institute and there was potential risk of selection bias.<br/><sup>2</sup>Imprecision: 'serious' ‐ confidence intervals for best estimate of effect included both 'no effect' and appreciable benefit/harm. </p> <p><sup>3</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (61.9%). </p> <p><sup>4</sup>Inconsistency: 'serious' ‐ one study indicated significant favour of antipsychotics, while the other study indicated favour for benzodiazepines (non‐significant). </p> <p><sup>5</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (22.7%). </p> <p><sup>6</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (18.6%). </p> <p><sup>7</sup>Only one small study reporting data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Benzodiazepines compared to antipsychotics for psychosis‐induced aggression or agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003079-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Benzodiazepines compared to antihistamines plus antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines compared to antihistamines + antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> psychiatric hospitals (US, Canada, Israel, China, Australia)<br/><b>Intervention:</b> benzodiazepines<br/><b>Comparison:</b> antihistamines + antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antihistaimes +</b> antipsychotics </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tranquillisation or asleep: sedation ‐ medium term ‐ lorazepam vs haloperidol + promethazine</b><br/>Number of participants sedated<br/>Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>970 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>883 per 1000</b><br/>(815 to 951) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b> <br/>(0.84 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tranquillisation or asleep: sedation ‐ medium term ‐ midazolam vs haloperidol + promethazine</b><br/>Number of participants sedated<br/>Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>827 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>934 per 1000</b><br/>(860 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.13</b> <br/>(1.04 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>301<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ medium term</b><br/>As defined in each study<br/>Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b><br/>(139 to 486) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.17</b> <br/>(1.16 to 4.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b><br/>Number of participants requiring additional medication<br/>Follow‐up: 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b><br/>(9 to 174) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b> <br/>(0.31 to 5.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ medium term</b><br/>Number of instances of extrapyramidal symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed risk: mean baseline risk presented for single study. Equates with that of control group.<br/><sup>2</sup>Risk of bias: 'serious' ‐ non‐blind, open‐label study.<br/><sup>3</sup>Imprecision: 'serious' ‐ small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Benzodiazepines compared to antihistamines plus antipsychotics for psychosis‐induced aggression or agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003079-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Benzodiazepines + antipsychotics compared to same enzodiazepines for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines + antipsychotics compared to same benzodiazepines</b> <b>for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> hospitals (USA, China)<br/><b>Intervention:</b> benzodiazepines + antipsychotics<br/><b>Comparison:</b> same benzodiazepines </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Same</b> benzodiazepines </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Benzodiazepines<b>+</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term‐ + haloperidol ‐ medium term</b> </p> <p>Number of participants sedated<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.84</b> <br/>(0.59 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>556 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>467 per 1000</b><br/>(328 to 661) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: no improvement ‐ + haloperidol ‐ medium term</b> </p> <p>As defined in each study<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.96</b> <br/>(0.76 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>113<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>677 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>650 per 1000</b><br/>(515 to 812) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Modertate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>732 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>703 per 1000</b> </p> <p>(556 to 879)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>867 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>832 per 1000</b><br/>(659 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ lorazepam + risperidone vs lorazepam ‐ medium term</b><br/>As defined in each study<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>700 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>602 per 1000</b><br/>(315 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/>(0.45 to 1.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: need for additional medication ‐ + haloperidol ‐ medium term</b> </p> <p>Number of participants requiring additional medication<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.02</b> <br/>(0.79 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>103<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per 1000</b> </p> <p>(395 to 660)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>774 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>789 per 1000</b><br/>(611 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ + haloperidol ‐ medium term</b> </p> <p>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000<sup>6</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> <p>(4 to 483)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.94</b> </p> <p>(0.18 to 20.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: 'serious' ‐ most trials received funding from a pharmaceutical institute and there was potential risk of selection bias.<br/><sup>2</sup>Imprecision: 'serious' ‐ confidence intervals for best estimate of effect included both 'no effect' and appreciable benefit/harm. </p> <p><sup>3</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (73.2%). </p> <p><sup>4</sup>Assumed risk: calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (50%). </p> <p><sup>5</sup>Calculated from the included studies ‐ 'moderate' risk equates with that of control group (55.6%). </p> <p><sup>6</sup>Calculated from the included studies ‐ 'moderate' risk equates with that of control group (2.4%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Benzodiazepines + antipsychotics compared to same enzodiazepines for psychosis‐induced aggression or agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003079-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benzodiazepines + antipsychotics compared to same antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Benzodiazepines + antipsychotics compared to same antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> hospitals (US, China, Brazil)<br/><b>Intervention:</b> benzodiazepines + antipsychotics<br/><b>Comparison:</b> same antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Same</b> antipsychotics </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Benzodiazepines<b>+</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term ‐ +/vs haloperidol</b> </p> <p>Number of participants sedated<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.75</b> <br/>(1.14 to 2.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>172<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b><br/>(292 to 683) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>175 per 1000</b><br/>(114 to 267) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>380 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>665 per 1000</b><br/>(433 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: no improvement ‐ +/vs haloperidol ‐ medium term</b> </p> <p>As defined in each study<br/>Follow‐up: 36 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.17</b> <br/>(0.93 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>185<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>521 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>610 per 1000</b><br/>(485 to 761) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/>(31 to 48) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/>(868 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication</b> </p> <p>Number of participants requiring additional medication<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ +/vs haloperidol ‐ medium term</b> </p> <p>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 18 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.44</b> <br/>(0.16 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b><br/>(30 to 216) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>+/vs</b> <b>:</b> with or versus; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Inconsistency: 'serious' ‐ high levels of heterogeneity.<br/><sup>2</sup>Imprecision: 'serious' ‐ confidence intervals for best estimate of effect included both 'no effect' and appreciable benefit/harm.<br/><sup>3</sup>Risk of bias: 'serious' ‐ funded by pharmaceutical institutes. </p> <p><sup>4</sup>Calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (52.1%). </p> <p><sup>5</sup>Calculated from the included studies ‐ presented three risks based on the control group risks ‐ 'moderate' risk equates with that of control group (25.6%). </p> <p><sup>6</sup>Calculated from the included studies ‐ 'moderate' risk equates with that of control group (18.5%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benzodiazepines + antipsychotics compared to same antipsychotics for psychosis‐induced aggression or agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003079-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Benzodiazepines plus antipsychotics compared to antipsychotics plus antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>B</b> <b>enzodiazepines + antipsychotics compared to antipsychotics + antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> n/a<br/><b>Intervention:</b> benzodiazepines + antipsychotics<br/><b>Comparison:</b> antipsychotics + antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Antipsychotics<b>+</b> antipsychotics </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Benzodiazepines<b>+</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Benzodiazepines plus antipsychotics compared to antipsychotics plus antipsychotics for psychosis‐induced aggression or agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003079-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Benzodiazepines plus antipsychotics compared to antihistamines plus antipsychotics for psychosis‐induced aggression or agitation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>B</b> <b>enzodiazepines + antipsychotics compared to antihistamines + antipsychotics for psychosis‐induced aggression or agitation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with psychosis‐induced aggression or agitation<br/><b>Settings:</b> psychiatric emergency department (Brazil)<br/><b>Intervention:</b> benzodiazepines + antipsychotics<br/><b>Comparison:</b> antihistamines + antipsychotics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Antihistamine +</b> antipsychotics </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Benzodiazepines<b>+</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep: sedation ‐ medium term</b><br/>Number of participants sedated<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b><br/>(55 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 12.00</b> <br/>(1.66 to 86.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no improvement ‐ medium term</b><br/>As defined in each study<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 25.00</b> <br/>(1.55 to 403.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: need for additional medication ‐ medium term</b><br/>Number of participants requiring additional medication<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global impression: need for additional medication ‐ medium term in the intervention groups was<br/><b>0 higher</b><br/>(0 to 0 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed data ‐ see 'data and analysis'.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects/events: extrapyramidal symptoms ‐ medium term</b><br/>Number of instances of extrapyramidal symptoms<br/>Follow‐up: 12 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(27 to 382) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> <br/>(0.16 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment:</b> from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes: cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed risk: mean baseline risk ‐ only one trial reported with 0 events in the control group and 12 events in the intervention group.<br/><sup>2</sup>Corresponding risk: one trial reported 12 events in the intervention group (40%).<br/><sup>3</sup>Risk of bias: 'serious' ‐ study funded by pharmaceutical institutes, potential risk of selection bias, performance bias and attrition bias.<br/><sup>4</sup>Imprecision: 'very serious' ‐ only one study reported data for this outcome, data were skew.<br/><sup>5</sup>Assumed risk: mean baseline risk presented for single study. Equates with that of control group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Benzodiazepines plus antipsychotics compared to antihistamines plus antipsychotics for psychosis‐induced aggression or agitation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003079-tbl-0008"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The benzodiazepine family</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Code</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Chemical name</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐3350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐bromo‐1, 3‐dihydro‐5‐(2‐pyridyl)‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Camazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SB 5833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐3‐hydroxy‐1‐methyl‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one dimethylcarbamate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlordiazepoxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐0690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐2‐methylamino‐5‐phenyl‐3H‐1, 4‐benzodiazepin‐4‐oxide</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cinolazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OX 373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐2, 3‐dihydro‐3‐hydroxy‐2‐oxo‐1H‐1, 4‐benzodiazepine‐1‐ propionitrile</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobaza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 376 H 4723 LM 2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐methyl‐5‐phenyl‐1H‐1, 5‐benzodiazepine‐2, 4‐(3H, 5H)‐dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐4023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐(o‐chlorophenyl)‐1, 3‐dihydro‐7‐nitro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clorazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4306CB A35.616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>dipotassium 7‐chloro‐2, 3‐dihydro‐2, 2‐oxo‐5‐phenyl‐1H‐1, 4‐benzodiazepine‐3‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cp 1414 S</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐amino‐7‐nitro‐5‐phenyl‐3H‐1, 5‐benzodiazepin‐4‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyprazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 3623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐2‐[(cyclopropylmethyl)amino]‐5‐phenyl‐3H‐1, 4‐benzodiazepin‐4‐oxide</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delorazepam chlordemethyldiazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1, 3‐dihydro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐2807 WY 3467 LA III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐1‐methyl‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxefazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAS 643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐3‐hydroxy‐1‐(2‐hydroxyethyl)‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elfazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SKF 72.517)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐[2‐(ethylsulfonyl)ethyl]‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethyl carfluzepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl ester of 7‐chloro‐5‐(o‐fluorophenyl)‐2, 3‐dihydro‐1‐ (methylcarbamoyl)‐2‐oxo‐1H‐1, 4‐benzodiazepine‐3‐carboxylic acid</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethyl dirazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl 7‐chloro‐5‐(o‐chlorophenyl)‐2, 3‐dihydro‐2‐oxo‐1H‐1, 4‐benzodiazepine‐3‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethyl loflazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CM 6912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl 7‐chloro‐5‐(o‐fluorophenyl)‐2, 3‐dihydro‐2‐oxo‐1H‐1, 4‐ benzodiazepine‐3‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fletazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCH 15.698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐2, 3‐dihydro‐1‐(2, 2, 2‐trifluoroethyl)‐1H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fludiazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID 540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐1 methyl‐2H‐1, 4‐benzodiazepine‐2‐0</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flunitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐4200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐(o‐fluorophenyl)‐1, 3‐dihydro‐1‐methyl‐7‐nitro‐2H‐1, 4‐ benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flurazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐6901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐[2‐(diethylamino)ethyl]‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐2H‐1, 4‐benzodiazepin‐2‐one. dihydrochloride</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flutemazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐3‐hydroxy‐1‐methyl‐2H‐1, 4‐benzodiazepine‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flutoprazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KB 509 ID 1937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐(cyclopropylmethyl)‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fosazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐[(dimethylphosphinyl)methyl]‐1, 3‐dihydro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Girisopam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GYKI 51.189 EGIS 5810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1‐(3‐chlorophenyl)‐4‐methyl‐7, 8‐dimethoxy‐5H‐2, 3‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gv 150013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(R)‐N‐[(adamantane‐1‐methyl)‐2, 4‐dioxo‐5‐phenyl‐2, 3, 4, 5‐tetrahydro‐1H‐1, 5‐benzodiazepin‐3‐yl]‐N‐phenylurea</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Halazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCH 12.041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐5‐phenyl‐1‐(2, 2, 2‐trifluoroethyl)‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iclazepam clazepam (formerly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐[2‐(cyclopropylmethoxy)ethyl]‐1, 3‐dihydro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WY 4036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1, 3‐dihydro‐3‐hydroxy‐2‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lormetazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WY 4082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1, 3‐dihydro‐3‐hydroxy‐1‐methyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M ORF8063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WE 352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1‐methyl‐5‐phenyl‐7‐(trifluoromethyl)‐1H‐1, 5‐benzodiazepine‐2, 4(3H, 5H)dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meclonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(3‐methylclonazepam) Ro 11‐3128 (meclonazepam, Roche) Ro 11‐3624 (steric antipode of meclonazepam) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(+)‐(S)‐5‐(o‐chlorophenyl)‐1, 3‐dihydro‐3‐methyl‐7‐nitro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐4556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐2, 3‐dihydro‐1‐methyl‐5‐phenyl‐1H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB 4857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐(1‐cyclohexen‐1‐yl)‐1, 3‐dihydro‐1‐methyl‐7‐nitro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metaclazepam (formerly: Brometazepam)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KC 2547 KC 3755 (normetaclazepam (active metabolite)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐bromo‐5‐(o‐chlorophenyl)‐2, 3‐dihydro‐2‐(methoxymethyl)‐1‐methyl‐1H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nimetazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>S 1530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1, 3‐dihydro‐1‐methyl‐7‐nitro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 4‐5360 Ro 5‐3059 CB 4395 (potassium salt)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1, 3‐dihydro‐7‐nitro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nordazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐2180 A 101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐3‐hydroxy‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normetrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB 4260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(1‐cyclohexen‐1‐yl)‐1, 3‐dilhydro‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WY 3498 8092 CB Ro 5‐6789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐3‐hydroxy‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazepam hemisuccinate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAS 538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐2, 3‐dihydro‐3‐hydroxy‐2‐(1H)‐oxo‐5‐phenyl‐1, 4‐benzodiazepin‐3‐yl hydrogen succinate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pinazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Z 905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐5‐phenyl‐1‐(2‐propynyl)‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Potassium nitrazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB 4335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2, 3‐dihydro‐7‐nitro‐2‐oxo‐5‐phenyl‐1H‐1, 4‐benzodiazepin‐3‐carboxylic acid monopotassium salt</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 4020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1‐(cyclopropylmethyl)‐1, 3‐dihydro‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCH 16.134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐fluorophenyl)‐1, 3‐dihydro‐1‐(2, 2, 2‐trifluoroethyl)‐2H‐1, 4‐benzodiazepine‐2‐thione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reclazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SC 33.963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐[7‐chloro‐5‐(o‐chlorophenyl)‐2, 3‐dihydro‐1H‐1, 4‐benzodiazepin‐1‐yl]‐2‐oxazolin‐4‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sc 32.855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1‐ (4, 5‐dihydro‐2‐oxazolyl)‐2, 3‐dihydro‐1H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W3676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐ dihydro‐1‐methyl‐5‐phenyl‐ 2H‐1, 4‐ benzodiazepin‐ 2‐thione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ER 115 Ro 5‐5345 WY 3917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐1, 3‐dihydro‐3‐hydroxy‐1‐methyl‐5‐phenyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB 4261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(cyclohexen‐1‐yl)‐1, 3‐dihydro‐1‐methyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tofisopam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EGYT 341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐ethyl‐7‐8‐dimethoxy‐1‐(3, 4‐dimethoxyphenyl)‐4‐methyl‐5H‐2, 3‐benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uldazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 31.920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐[(allyloxy)amino]‐7‐chloro‐5‐(o‐chlorophenyl)‐3H‐1, 4‐benzodiazepine</i> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Tricyclic benzodiazepines</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐Hydroxytriazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine‐1‐methanol</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adinazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 41.123 F (mesylate) U 41.123 (base)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐1‐[(dimethylamino)methyl]‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine (mesylate)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 31.889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐1‐methyl‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Climazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐1‐methyl‐4H‐imidazo[1, 5‐a][1, 4]benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cloxazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS 370 MT 14‐411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐chloro‐11b‐(o‐chlorophenyl)‐2, 3, 7, 11b‐tetrahydro‐oxazolo[3, 2‐d][1, 4]benzodiazepin‐6 (5H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estazolam noralprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 40 TA Lu 7426 Abbott 47631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4] benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flutazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MS 4101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐chloro‐11b‐(2‐flurophenyl)‐2, 3, 7, 11b‐tetrahydro‐7‐(2‐hydroxyethyl‐oxazolo[ 3, 2‐d] [1, 4] benzodiazepin‐6(5H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gp 55.129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 40125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine‐1‐methanol</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloxazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS 430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐bromo‐11b‐(o‐fluorophenyl)‐2, 3, 7, 11b‐tetrahydrooxazolo[3, 2‐d][1, 4]benzodiazepin‐6(5H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 28.774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>11‐chloro‐8, 12b‐dihydro‐2, 8‐dimethyl‐12b‐phenyl‐4H‐[1, 3]oxazino[3, 2‐d][1, 4]benzodiazepine‐4, 7(6H)‐ dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU 31.158 HR 158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(Z)‐6‐(o‐chlorophenyl)‐2, 4‐dihydro‐2‐[(4‐methylpiperazin‐1‐yl)methylene]‐8‐nitro‐1H‐ imidazo[1, 2‐a][1,~ 4]benzodiazepin‐1‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mexazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CS 386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐chloro‐11b‐(o‐chlorophenyl)‐2, 3, 7, 11b‐tetrahydro‐3‐methyl‐oxazolo[3, 2‐d][1, 4]benzodiazepin‐6(5)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 21‐3981 (maleate) Ro 21‐3981/003 (HCl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐fluorophenyl)‐1‐methyl‐4H‐imidazo [1, 5‐a][1, 4]benzodiazepine maleate (1: 1)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Noradinazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 42.352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐1‐(methylamino)methyl]‐6‐phenyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>10‐chloro‐2, 3, 7, 11b‐tetrahydro‐2‐methyl‐11b‐phenyloxazolo[3, 2‐d][1, 4]benzodiazepin‐ 6(5H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ru 31.124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐2‐(4‐ethylpiperazin‐1‐yl)methyl]‐2, 4‐dihydro‐1H‐imidazo[1, 2‐a][1, 4]benzodiazepin‐1‐one (methyl bridge or methylene group uncertain)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U 33.030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐1‐methyl‐4H‐s‐triazolo[4, 3‐a][1, 4]benzodiazepine</i> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Benzodiazepines with atypical mode of action</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arfendazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl 7‐chloro‐2, 3, 4, 5‐tetrahydro‐4‐oxo‐5‐phenyl‐1H‐1, 5‐benzodiazepine‐1‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Devazepide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L 364.718 (former designation) MK 329 (Merck and Co., USA) L 365.031(Merck)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(S)‐N‐(2, 3‐dihydro‐1‐methyl‐2‐oxo‐5‐phenyl‐1H‐1, 4‐ benzodiazepin‐3‐yl)‐indole‐2‐carboxamideL 365031 N‐(2, 3‐ dihydro‐1‐methyl‐2‐oxo‐5‐phenyl‐1H‐1, 4‐benzodiazepin‐3‐yl)‐1H‐p‐bromobenzamide</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gyki 52.322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EGIS 6775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1‐(4‐aminophenyl)‐4‐methyl‐7, 8‐dimethoxy‐5H‐2, 3‐benzodiazepine 2, 3‐</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L 365260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(R)‐N‐(2, 3‐dihydro‐1‐methyl‐2‐oxo‐5‐phenyl‐1H‐1, 4‐benzodiazepin‐3‐yl)‐N’‐(3‐methylphenyl)‐urea</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 15‐4513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>ethyl 8‐azido‐5, 6‐dihydro‐6‐oxo‐4H‐imidazo[1, 5‐a][1, 4]benzodiazepine‐3‐carboxylate</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 5‐4864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(p‐chlorophenyl)‐1, 3‐dihydro‐1‐methyl‐2H‐1, 4‐benzodiazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tifluadom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KC 5103 (+)‐tifluadom KC 6128 (Sandoz/Kali‐ Chemie, BRD) (‐)‐tifluadom KC5911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>(+/‐)‐N‐[[5‐(o‐fluorophenyl)‐2, 3‐dihydro‐1‐methyl‐1H‐1, 4‐benzodiazepin‐2‐yl]methyl]‐3‐thiophenecarboxamide</i> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Fused benzodiazepines</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brotizolam Ladormin (provisional name)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We 941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐bromo‐4‐(o‐chlorophenyl)‐9‐methyl‐6H‐thieno [3, 2‐f]‐s‐triazolo[4, 3‐a][1, 4]diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclotizolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We 973‐BS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>2‐bromo‐4‐(o‐chlorophenyl)‐9‐cyclohexyl‐6H‐thieno[3, 2‐f]‐s‐triazolo[4, 3‐a][1, 4]diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotiazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y 6047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐(o‐chlorophenyl)‐7‐ethyl‐1, 3‐dihydro‐1‐methyl‐2H‐thieno[2, 3‐e][1, 4]diazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Etizolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AHR 3219 Y 7131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>4‐(o‐chlorophenyl)‐2‐ethyl‐9‐methyl‐6H‐thieno [3, 2‐f]‐s‐triazolo[4, 3‐a][1, 4]diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lopirazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 12524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7‐chloro‐5‐(o‐chlorophenyl)‐1, 2‐dihydro‐3‐hydroxy‐3H‐pyrido[3, 2‐ e][1, 4]diazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDL 181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>3, 7‐dihydro‐6, 7‐dimethyl‐5‐phenylpyrrolo[3, 4‐e][1, 4]diazepin‐2(1H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Razobazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hoe 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>4, 8‐dihydro‐3, 8‐dimethyl‐4‐phenylpyrazolo[3, 4‐b][1, 4]diazepine‐5, 7(1H, 6H)‐dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ripazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CI 683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1‐ethyl‐4, 6‐dihydro‐3‐methyl‐8‐phenylpyrazolo[4, 3‐e][1, 4]diazepin‐5(1H)‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 11‐7800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>9‐aminomethyl‐2‐chloro‐4‐(o‐chlorophenyl)‐6H‐thieno[3, 2‐f]‐s‐triazolo[4, 3‐a][1, 4] diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiadipone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CI 718 bentazepam QM 6008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>1, 3, 6, 7, 8, 9‐hexahydro‐5‐phenyl‐2H‐[1]benzothieno[2, 3‐e][1, 4]diazepin‐2‐one</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zapizolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>8‐chloro‐6‐(o‐chlorophenyl)‐4H‐pyrido[2, 3‐f]‐s‐triazolo[4, 3‐a][1, 4]diazepine</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zomebazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>4, 8‐dihydro‐1, 3, 8‐trimethyl‐4‐phenylpyrazolo [3, 4‐b][1, 4]diazepine‐5, 7(1H, 6H)‐dione</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zometapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CI 781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>7, 8‐dihydro‐1, 3‐dimethyl‐4‐phenyl‐6H‐pyrazolo[3, 4‐e][1, 4] diazepine</i> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The benzodiazepine family</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003079-tbl-0009"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Half lives of some benzodiazepines</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzodiazepine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Half‐life</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>1. Long</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlordiazepoxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐30 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16‐60 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clorazepate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐2 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20‐40 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flurazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐2 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>~30 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metaclazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7‐23 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>~30 hours</p> </td> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>2. Medium/short</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐15 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐20 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brotizolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐7 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotiazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐15 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loprazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐8 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐24 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lormetazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐14 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐30 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐15 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐14 hours</p> </td> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>3. Extremely short</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐7 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5‐5 hours</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Half lives of some benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003079-tbl-0010"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reviews focusing on similar participant groups</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Focus of review</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Reference</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0111" title="PagadalaB , JayaramMB , MitraL . Aripiprazole for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD008074. [DOI: 10.1002/14651858.CD008074]">Pagadala 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepines for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0122" title="VolzA , KhorsandV , GilliesD , LeuchtS . Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD006391. [DOI: 10.1002/14651858.CD006391]">Volz 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Containment strategies for people with serious mental illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0108" title="MuralidharanS , FentonM . Containment strategies for people with serious mental illness. Cochrane Database of Systematic Reviews2006, Issue 3. Art. No: CD002084. [DOI: 10.1002/14651858.CD002084.pub2]">Muralidharan 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0069" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD007445. [DOI: 10.1002/14651858.CD007445.pub2]">Ahmed 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol (rapid tranquillisation) for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0112" title="PowneyMJ , AdamsCE , JonesH . Haloperidol (rapid tranquilisation) for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD009377. [DOI: 10.1002/14651858.CD009377]">Powney 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol for long‐term aggression in psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0100" title="KhushuA , PowneyMJ , AdamsCE . Haloperidol for long-term aggression in psychosis. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD009830. [DOI: 10.1002/14651858.CD009830]">Khushu 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol plus promethazine for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0097" title="HufG , AlexanderJ , AllenMH , RaveedranNS . Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD005146. [DOI: 10.1002/14651858.CD005146.pub2]">Huf 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loxapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0080" title="ChakrabartiA , BagnallAM , ChueP , FentonM , PalaniswamyV , WongW , et al. Loxapine for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD001943. [DOI: 10.1002/14651858.CD001943.pub2]">Chakrabarti 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loxapine inhaler for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0121" title="VangalaR , AhmedU , AhmedR . Loxapine inhaler for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD010190. [DOI: 10.1002/14651858.CD010190]">Vangala 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0074" title="BelgamwarRB , FentonM . Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD003729. [DOI: 10.1002/14651858.CD003729.pub2]">Belgamwar 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0123" title="WilkieF , FentonM . Quetiapine for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD009801. [DOI: 10.1002/14651858.CD009801]">Wilkie 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone for psychosis‐induced agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0070" title="AhmedU , RehmanF , JonesH , AdamsCE . Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 11. Art. No: CD009412. [DOI: 10.1002/14651858.CD009412]">Ahmed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seclusion and restraint for people with serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0115" title="SailasEES , FentonM . Seclusion and restraint for people with serious mental illnesses. Cochrane Database of Systematic Reviews2000, Issue 1. Art. No: CD001163. [DOI: 10.1002/14651858.CD001163]">Sailas 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0090" title="JayakodyK , GibsonRC , KumarA , GunadasaS . Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD000525. [DOI: 10.1002/14651858.CD000525.pub3]">Gibson 2012</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reviews focusing on similar participant groups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003079-tbl-0011"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">High and low attrition studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% loss</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0001" title="BarbeeJG , MancusoDM , FreedCR , TodorovAA . Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. American Journal of Psychiatry1992;149:506-10. [CSZG: Ref302]">Alprazolam 1992, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0002" title="ChouinardG , AnnableL , TurnierL , HolobowN , SzkrumelakN . A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry1993;38:S114-21. [CSZG: Ref509]">Clonazepam 1993, CA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0019" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006;47(1):61-7. [CSZG: Ref13930]">Midazolam 2006, AU</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0005" title="LernerY , LwowE , LevitinA , BelmakerRH . Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry1979;136:1061-4. [CSZG: Ref1664]">Diazepam 1979, IL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0008" title="SalzmanC , SolomonD , MiyawakiE , GlassmanR . Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry1991;52(4):177-80. [CSZG: Ref2492]SolomonDA , MiyawakiE , SalzmanC . Benzodiazepine augmentation of the treatment of disruptive psychotic behaviour [Review]. Progress in Drug Research1990;35:139-49. [CSZG: Ref14827]">Lorazepam 1991, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33% participants lost to follow‐up for EPS outcome and 12% loss for 'sedation'</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0015" title="VeserF , ZealburgJ , VeserB , ZhuY , GharabawiG . Oral risperidone in the management of agitated behavior in emergency settings. Journal of the European College of Neuropsychopharmacology2002;12(Suppl 3):S313. [CSZG: Ref9090] VeserFH , VeserBD , McMullanJT , ZealbergJ , CurrierGW . Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Practice2006;12(2):103-8. [CSZG: Ref13125]">Lorazepam 2006, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0012" title="BieniekSA , OwnbyRL , PenalverA , DominguezRA . A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy1998;18:57-62. [CSZG: Ref3442]">Lorazepam 1998, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0006" title="DorevitchA , KatzN , ZemishlanyZ , AizenbergD , WeizmanA . Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry1999;156:142-4. [CSZG: Ref3467]">Flunitrazepam 1999, IL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0013" title="BattagliaJ , LindborgSR , AlakaK , MeehanK , WrightP . Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine2003;21(3):192-8. [CSZG: Ref9826]BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441-8. [CSZG: Ref8394] [DOI: 10.1001/archpsyc.59.5.441]DavidSR , BattagliaJ , AlakaK , MeehanK , WrightP . Calming versus sedative effects of IM olanzapine in agitated patients. In: 11th Association of European Psychiatrists Congress; 2002 May 4-8; Stockholm, Sweden. [CSZG: Ref8499]DavidSR , JonesB , AlakaK , MeehanK , WrightP , TaylorCC , et al. The efficacy of intramuscular olanzapine in acutely agitated patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA). [CSZG: Ref8964]MeehanKZ . A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology2001;21(4):389-97. ">Lorazepam 2001, RO and USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0011" title="SubramaneyU , BrookS , BerkM . A prospective randomised double-blind controlled study of the efficacy of lorazepam versus clothiapine in the control of acutely behaviourally disturbed patients. South African Medical Journal1998;88(3):307-10. [CSZG: Ref5270]">Lorazepam 1998, SA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0018" title="HufG , CoutinhoESF , AdamsCE . TREC III. The protocol and progress of TREC. Schizophrenia Research2002;53(3 (Suppl 1)):187. [CSZG: Ref8077] [MEDLINE: 73085373] [PMID 4405388]HufG , CoutinhoESF , AdamsCE . TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):4. [CSZG: Ref8765] [EMBASE 2002383527]HufG , CoutinhoESF , AdamsCE . The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials. In: 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands.  . [CSZG: Ref16746]HufG , CoutinhoESF , Fagundes HM Jr, CarvalhoAL , RamosFA , KeusenAL , et al. TREC II. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro, Brazil. Schizophrenia Research2002;53(3):236-7. [CSZG: Ref8075] [MEDLINE: 73085373] [PMID 4405388]HufG . Haloperidol plus promethazine versus haloperidol for psychosis induced aggression. Data on file2004. [CSZG: Ref16747] [MEDLINE: 18433659]TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708-13. [CSZG: Ref27918] [EMBASE: 2003210869]">Midazolam 2003, BZ</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0014" title="AlexanderJ , JohnT , TharyanP , AdamsCE . TREC-India. A second arm of TREC. Schizophrenia Research2002;53(3 Suppl. 1):236. [CSZG: Ref8047] [MEDLINE: 73085373] [PMID 4405388]AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. British Journal of Psychiatry2004;185:63-9. AlexanderJ . Vellore (India): Christian Medical College, 2003. [CSZG: Ref9199]">Lorazepam 2004, IN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0003" title="QuHF , ZhangZ , XuB . Comparison of the effects of clonazepam and haloperidol in the treatment of psychotic breakdown behavior. Health Psychology Journal1999;7(2):134-5. [CSZG: Ref11939]">Clonazepam 1999, CHN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0004" title="LiC , ZhuS , WangH , ChenH , YuY , LiuD , et al. Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the [氯硝西泮、氟哌啶醇及其联合治疗对精神分裂症激越症状疗效的比较]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2007;19(3):150-2. [CSZG: Ref15960]">Clonazepam 2007a, CHN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0007" title="Garza-TrevinoES , HollisterLE , OverallJE , AlexanderWF . Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry1989;146:1598-601. [CSZG: Ref860]">Lorazepam 1989, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0009" title="BattagliaJ , MossS , RushJ , KangJ , MendozaR , LeedomL . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine1997;15:335-40. [CSZG: Ref3439]">Lorazepam 1997a, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0010" title="FosterS , KesselJ , BermanME , SimpsonGM . Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology1997;12:175-9. [CSZG: Ref1912]">Lorazepam 1997b, USA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0020" title="BaldacaraL , SanchesM , CordeiroDC , JackoswksiAP . Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileire da Psiquiatria2011;33(1):30-9. [CSZG: Ref22900]">Midazolam 2011, BZ</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0016" title="KongBG , ShimJC , LeeSK . Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. European Neuropsychopharmacology2009;19:S525-6. [CSZG: Ref24883]">Lorazepam 2009, SK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only abstract available.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003079-bbs2-0017" title="SrinathG , ShailajaB , SaiPG , ReddyKA . A comparative study of injection haloperidol and promethazine vs. injection lorazepam in controlling acute psychotic agitation. Indian Journal of Psychiatry2010;52:S21. [CSZG: Ref20833]">Lorazepam 2010, IN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only abstract available.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Trials were considered to have a high attrition rates if it was more than 5% within the first two hours or 25% to 50% overall. </p> <p>EPS: extrapyramidal symptoms.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">High and low attrition studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/full#CD003079-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Benzodiazepines versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Tranquillisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.42, 6.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.42, 6.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Behaviour: 1. mean change score (Agitated Behaviour Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Global state: 1. no improvement (&gt; 40% reduction Positive and Negative Syndrome Scale‐Excited Component (PANSS‐EC)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.69, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Global state: 2. need for additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Global state: 3. mean change score (Clinical Global Impression Severity Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mental state: 1. mean change score (Positive and Negative Syndrome Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Mental state: 2. mean change score (PANSS‐EC, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse effects/events: 1. extrapyramidal symptoms (EPS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse effects/events: 2. use of medication for EPS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Adverse effects/events: 3. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 dizziness ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 nausea ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 vomiting ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Leaving the study early: 1. any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Benzodiazepines versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Benzodiazepines versus antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Tranquillisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 vs droperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.55, 4.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.53, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.83, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.28, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Behaviour: 2. mean change/endpoint score (Agitated Behaviour Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐2.39, 5.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [0.80, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Behaviour: 4. mean change score (Overt Aggression Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Global state: 1. no improvement (&gt; 40% reduction Positive and Negative Syndrome Scale‐Excited Component (PANSS‐EC)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 vs olanzapine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.95, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.06, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.71, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Global state: 2. need for additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 vs droperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Global state: 3. mean change/endpoint score (Clinical Global Impression Severity Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.4 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Global state: 4. mean endpoint score (Inpatient Multidimensional Psychiatric Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [‐3.04, 8.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [‐3.04, 8.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Mental state: 1. no improvement (decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Mental state: 2. mean change/endpoint score (BPRS, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.26 [‐10.65, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [‐1.84, 5.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Mental state: 3. mean endpoint score (BPRS psychosis subscale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐7.20, 8.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Mental state: 3a. mean endpoint score (BPRS positive subscale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐1.83, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Mental state: 4a. mean endpoint score (BPRS‐excited component, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [‐0.49, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Mental state: 2a. mean change score (Positive and Negative Syndrome Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.64 [2.20, 9.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Mental state: 4. mean change score (PANSS‐EC, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [1.14, 4.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Adverse effects/events: 1. extrapyramidal symptoms (EPS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.06, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.04, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.3 vs droperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Adverse effects/events: 2. use of medication for EPS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.15, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.17, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Adverse effects/events: 3. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 vs haloperidol ‐ akathisia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 vs droperidol ‐ airway management ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.47 [0.39, 142.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.3 vs haloperidol ‐ ataxia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.22, 23.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.4 vs droperidol ‐ low blood pressure ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.33, 6.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.5 vs haloperidol ‐ dizziness ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.25, 5.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.6 vs olanzapine ‐ dizziness ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.60, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.7 vs haloperidol ‐ drowsiness ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 14.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.8 vs haloperidol ‐ dry mouth ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.49, 7.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.9 vs droperidol ‐ low heart rate ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.01, 8.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.10 vs haloperidol ‐ high heart rate ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 4.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.11 vs droperidol ‐ hypoxia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.33, 6.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.12 vs olanzapine ‐ nausea ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.76 [0.89, 67.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.13 vs droperidol ‐ seizure ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.14 vs haloperidol ‐ speech disorder ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.11, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.15 vs haloperidol ‐ tremor ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.16 vs droperidol ‐ vomiting ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.17 vs olanzapine ‐ vomiting ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.46 [0.71, 255.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Leaving the study early: 1. any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.70, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 vs droperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.60, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.3 vs olanzapine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.82 [0.62, 54.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Benzodiazepines versus antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Benzodiazepines versus antipsychotics plus antihistamines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Tranquilisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 vs haloperidol + promethazine ‐ immediate term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.77, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 vs haloperidol + promethazine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.84, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 vs haloperidol + promethazine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.16, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.04, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Global state: 1. no improvement (Clinical Global Impression (CGI) ‐ improvement scale dichotomised; much and very much improved) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 vs haloperidol + promethazine ‐ immediate term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.36, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 vs haloperidol + promethazine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [1.51, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.16, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Global state: 2. need for additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 vs haloperidol + promethazine ‐ immediate term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 vs haloperidol + promethazine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.31, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Global state: 3. mean endpoint score (CGI, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 vs haloperidol + promethazine ‐ immediate term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.23, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 vs haloperidol + promethazine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.34, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.05, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Adverse effects/events: 1. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 vs haloperidol + promethazine ‐ airway management ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.99 [0.31, 28.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 vs haloperidol + promethazine ‐ nausea ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 vs haloperidol + promethazine ‐ seizure ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Hospital and service outcomes: 1. changes in hospital status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 vs haloperidol + promethazine ‐ not discharged ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.86, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Leaving the study early: 1. any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.06, 2.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Benzodiazepines versus antipsychotics plus antihistamines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Benzodiazepines plus antipsychotics vs same benzodiazepines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Tranquillisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 + haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.10, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.59, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Behaviour: 1. mean endpoint score (Agitated Behaviour Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐5.94, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Global state: 1. no improvement mean endpoint change in Clinical Global Impression score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 + haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.76, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 + risperidone ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.45, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Global state: 2. need for additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 + risperidone ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Mental state: 1. no improvement (the decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.76, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Mental state: 2a. mean endpoint score (BPRS, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 + risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐23.17, 25.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 + risperidone ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐24.26, 20.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Mental state: 2b. mean endpoint score (BPRS, high = worse, skew) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 + haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Mental state: 2c. mean endpoint score (Positive and Negative Syndrome Scale (PANSS), high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 + risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.40 [‐36.50, 49.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 + risperidone ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [‐29.41, 35.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Mental state: 2d. mean endpoint score (PANSS, high = worse, skew) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 + haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.2 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Mental state: 3a. mean endpoint score (BPRS psychosis subscale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐6.28, 8.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Mental state: 3b. mean endpoint score (BPRS positive subscale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐2.73, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Mental state: 4. mean endpoint score (BPRS‐excited component, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.41, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Adverse effects/events: 1. extrapyramidal symptoms (EPS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.1 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.18, 20.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Adverse effects/events: 2. use of medication for EPS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.1 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.18, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Adverse effects/events: 3. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.1 + haloperidol ‐ akathisia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.2 + haloperidol ‐ ataxia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.26, 8.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.3 + haloperidol ‐ dizziness ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.12, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.4 + haloperidol ‐ drowsiness ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 14.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.5 + haloperidol ‐ dry mouth ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.15, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.6 + haloperidol ‐ speech disorder ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.26, 8.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.16 Leaving the study early: 1. any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16.1 + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.34, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16.2 + risperidone ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.45, 1.64]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Benzodiazepines plus antipsychotics vs same benzodiazepines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Benzodiazepines plus antipsychotics versus same antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Tranquillisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 +/vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.18, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.14, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Behaviour: 1. mean endpoint score (Agitated Behaviour Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐5.05, 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Behaviour: 2. mean endpoint score (Overt Aggression Scale (OAS), high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 +/vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐0.04, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [0.59, 4.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Behaviour: 3. mean endpoint score (Overt Agitation Severity Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 +/vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.50 [7.07, 9.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.70 [5.94, 7.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Global state: 1. no improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.93, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Global state: 2. need for additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Global state: 3. need for additional medication (mean dose, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.33, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Global state: 4. mean change score (Ramsey Sedation Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 +/vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.01, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.2 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.36, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Mental state: 1. no improvement (the decrease rate of Brief Psychiatric Rating Scale (BPRS) score &lt; 30%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Mental state: 2. mean endpoint score (BPRS, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐7.26, 7.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Mental state: 3a. mean endpoint score (BPRS psychosis subscale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.19 [‐4.60, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 Mental state: 3b. mean endpoint score (BPRS positive subscale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12.1 vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [‐1.62, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.13 Mental state: 4. mean endpoint score (BPRS‐excited component, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13.1 vs hoperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐1.32, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.14 Adverse effects/events: 1. extrapyramidal symptoms (EPS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.14.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.15 Adverse effects/events: 2. use of medication for EPS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.15.1 +/vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.27, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.16 Adverse effects/events: 3. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.1 +/vs haloperidol ‐ akathisia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.2 +/vs haloperidol ‐ ataxia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.28 [0.36, 29.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.3 +/vs haloperidol ‐ dizziness ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.12, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.4 +/vs haloperidol ‐ drowsiness ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 14.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.5 +/vs haloperidol ‐ dry mouth ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.32, 4.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.6 +/vs haloperidol ‐ hypotension ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.00 [0.64, 190.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.7 +/vs haloperidol ‐ speech disorder ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.20, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.17 Hospital and service outcomes: 1. changes in hospital status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.17.1 +/vs haloperidol ‐ not discharged ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.54, 1.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Benzodiazepines plus antipsychotics versus same antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Benzodiazepines + antipsychotics versus antipsychotics plus antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Behaviour: 3. mean endpoint score (Overt Aggression Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 + haloperidol vs clothiapine + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.83 [‐27.60, 15.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Leaving the study early: 1. any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 + haloperidol vs clothiapine + haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Benzodiazepines + antipsychotics versus antipsychotics plus antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Tranquilisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 + haloperidol vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.00 [1.66, 86.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Behaviour: 1. mean endpoint score (Overt Aggression Scale (OAS), high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 + haloperidol vs haloperidol + promethazine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐5.25, ‐1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 + haloperidol vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐0.06, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Behaviour: 2. mean endpoint score (Overt Agitation Severity Scale (OASS) agitation scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 + haloperidol vs haloperidol + promethazine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.00 [‐18.98, ‐13.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 + haloperidol vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐3.73, ‐1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Global state: 1. no improvement (number of participants with &lt; 10 points on the OAS and OASS after 12 hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 + haloperidol vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.00 [1.55, 403.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Global state: 2. need for additional medication (mean dose, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 + haloperidol vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.15, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Global state: 3. mean change score (Ramsey Sedation Scale, high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 + haloperidol vs haloperidol + promethazine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.07, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.2 + haloperidol vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.46, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Adverse effects/events: 1. extrapyramidal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 + haloperidol vs haloperidol + promethazine ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.16, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Adverse effects/events: 2. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.1 + haloperidol vs haloperidol + promethazine ‐ hypotension ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.44, 6.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 1. Random sequence generation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Tranquilisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.52, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Global state: 1. no improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.78, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Adverse effects/events: 1. extrapyramidal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.05, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.03, 0.85]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 1. Random sequence generation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 2. Allocation concealment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Tranquilisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.79, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.55, 4.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Global state: 1. no improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.86, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Adverse effects/events: 1. extrapyramidal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.06, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 2. Allocation concealment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 3. Blinded outcome measurement</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Tranquilisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.56, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.93, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.3 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.05, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Global state: 1. no improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.88, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.60, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Adverse effects/events: 1. extrapyramidal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.05, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.2 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 3. Blinded outcome measurement</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003079-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 4. Incomplete outcome data (attrition bias)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Tranquilisation or asleep: 1. sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.15, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.62, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.3 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.83, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Global state: 1. no improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.32, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.2 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.98, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Adverse effects/events: 1. extrapyramidal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.3 low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.06, 0.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Sensitivity analysis: benzodiazepines versus antipsychotics ‐ 4. Incomplete outcome data (attrition bias)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003079.pub4/references#CD003079-tbl-0024">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003079.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003079-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003079-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003079-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD003079-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003079-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003079-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003079\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003079\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003079\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003079\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003079\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003079.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003079.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003079.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003079.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003079.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714885786"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003079.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714885790"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003079.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7999dc209368',t:'MTc0MDcxNDg4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 